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Abstract 
 
Bone morphogenetic protein 15 (BMP15) and growth differentiation factor 9 
(GDF9) are both members of the TGF-ß protein superfamily and are known to be 
essential for normal follicular development in mammals. Several studies have 
highlighted the species-specific effects of BMP15 and GDF9, which could be 
attributed, at least in part to the differences in the follicular expression patterns and 
to different forms of the secreted proteins. In the mouse, GDF9 is required for 
follicular development, whereas BMP15 appears to be only required near 
ovulation with contradictory reports as to the timing of BMP15 expression. 
However, mouse BMP15 and GDF9 are known to have the capability of acting 
together synergistically. The aims of this thesis were to characterise in the mouse 
ovary, the expression patterns (localisation and levels) of Bmp15 and Gdf9 mRNA 
throughout follicular development, and to determine the peri-ovulatory expression 
of the corresponding proteins.  
 
In situ hybridisation and quantitative PCR analyses of ovarian samples and 
follicular cells collected from control and superovulated mice confirmed that Gdf9 
and Bmp15 mRNA are expressed exclusively in oocytes from primary and early 
secondary stage follicles respectively. qPCR analysis of denuded oocytes (DO) 
revealed a tight correlation, and therefore co-regulation, between the expression 
levels of Bmp15 and Gdf9 irrespective of follicular developmental stage, with 
steady expression until the preovulatory LH surge when down-regulation of 
Bmp15 and Gdf9 occurred. Throughout the follicular developmental stages 
examined, Gdf9 was expressed in greater abundance relative to Bmp15, with a 
Bmp15:Gdf9 mRNA ratio of 1:4.12.  
 
Western blot analyses of DO, intact cumulus-oocyte complex (COC), and somatic 
follicular cell samples, collected both before and after the preovulatory LH surge, 
showed that prior to the LH surge, BMP15 was present in the DO lysates as 
unprocessed precursor, and processed proregion and mature proteins, as well as 
mature protein dimer and large, potentially multimeric complexes. From the forms 
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of GDF9 able to be identified, it seemed likely that the GDF9 protein expression 
pattern is similar to that of BMP15 in the mouse follicles.  
 
Following the preovulatory LH surge, once the oocyte underwent germinal vesicle 
breakdown (GVBD), the only protein form detected in DO was the unprocessed 
BMP15 precursor, indicating that processing of BMP15, and potentially GDF9 
stops prior to ovulation. In the expanded cumulus cells of GVBD COC and 
granulosa cell lysates, however, all BMP15 protein forms were detected. This 
suggests that posttranslational processing of BMP15 and GDF9 could be taking 
place both inside and outside of the oocyte. 
 
The present study confirmed that in vivo, the mouse oocyte secretes the uncleaved 
promature form of BMP15 as well as the cleaved proregion and mature proteins in 
large complexes, but the biological activities of these different forms are unknown. 
The biological activity of the BMP15 precursor protein was investigated, to 
determine if the precursor form regulates the bioactivity of the growth factor or has 
a separate bioactivity. By transfecting 293 HEK cells with a Bmp15 gene construct 
where the RXXR proprotein convertase cleavage site was modified to QXXQ, 
production of non-cleavable mouse BMP15 promature protein conditioned media 
was achieved. The biological activity of the BMP15 precursor protein was then 
tested in a 3H-thymidine incorporation assay in rat granulosa cells. Mitogenic 
effects were compared with wild-type mouse BMP15 conditioned media, both as 
individual treatments and in combination with ovine GDF9. These data confirmed 
that the BMP15 precursor is biologically active, and while the wild-type mouse 
BMP15 was able to enhance rat granulosa cell proliferation only when combined 
with ovine GDF9, the non-cleavable mouse BMP15 promature protein was weakly 
mitogenic without GDF9.  
 
In conclusion, oocyte-derived Bmp15 and Gdf9 mRNA expression is co-regulated 
throughout follicular development in mice, with Gdf9 being more abundant than 
Bmp15, which might be an important factor in determining high ovulation quota. 
The expression of the target genes is down-regulated as the oocyte reaches 
developmental competence following the preovulatory LH surge. Protein 
expression data provided evidence that in vivo the immature mouse oocyte is 
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capable of secreting all BMP15 protein forms previously detected in vitro. After 
the preovulatory LH surge, all visible protein forms are associated with the 
somatic follicular cells, in particular with the expanded cumulus mass. Of 
particular interest is the presence of the large protein complexes in the cumulus 
cell lysates, which suggests a storage and activation process involving ECM 
proteins, similar to the mechanism reported for other TGF-ß superfamily members, 
such as TGF-ß1 and myostatin. 
 
The finding that the BMP15 precursor protein is biologically active with a 
different activity to that of the processed mature protein form suggests that the 
full-length precursor protein may regulate or provide at least a portion of the 
biological activity of BMP15 in mice. 
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Chapter 1:  Introduction 
 
1.1  General outline  
 
 
The scope of this chapter includes an overview of the female reproductive 
system in mammals starting from the development of the ovaries and the 
formation of follicles during embryonic and early neonatal life and thereafter to 
follicular growth and subsequently ovulation from the onset of puberty. In 
addition, the endocrine, morphological and physiological aspects of these 
processes are discussed.  Since the experimental work presented in this thesis is 
focussed on follicular growth in mice, the introduction will primarily review what 
is currently known about the reproductive system of this species. 
 
At the start of this thesis, it was already known that the oocyte itself plays a 
crucial role in regulating its own development within the growing follicle and in 
determining the number of follicles that will ovulate in each cycle. It was also 
understood that two TGF-β superfamily members, bone morphogenetic protein 15 
(BMP15) and growth differentiation factor 9 (GDF9) play an important role in the 
communication between the oocyte and the surrounding somatic follicular cells 
during follicular development (Dong, Albertini et al. 1996; Galloway, McNatty et 
al. 2000; Shimasaki, Moore et al. 2004; Juengel and McNatty 2005; Gilchrist, 
Lane et al. 2008).  
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1.2   Overview of the female reproductive system 
 
1.2.1  The mammalian ovary 
 
The mammalian ovary forms in early embryonic life, when the primitive 
germ cells (PGCs) and somatic cells migrate to the genital ridge, which is the site 
of the undifferentiated gonad. This early differentiating gonad consists of a 
surface epithelium, enclosing mesenchymal cells and mitotically-active PGC 
(Peters and McNatty 1980). The migration of the PGCs occurs around 8.5-11.5 
days of embryonic life in the mouse (Chiquoine 1954; Spiegelman and Bennett 
1973; Clark and Eddy 1975; Ginsburg, Snow et al. 1990; Edson, Nagaraja et al. 
2009). After gonadal sex differentiation, the PGCs differentiate into oogonia and 
form attachments to adjacent somatic cells (i.e. pre-granulosa cells) (Mork, 
Maatouk et al. 2012). At day 12.5 of embryonic life, the oogonia associated with 
pre-granulosa cells enter into meiosis and are thereafter referred to as oocytes. In 
mice, follicular formation begins around 18.5 days (reviewed in(Edson, Nagaraja 
et al. 2009). Individual oocytes and associated granulosa cells separate from their 
adjacent oocyte-granulosa cell entities by a basement membrane to form a 
primordial follicle. At this time, the follicular-enclosed oocytes have been arrested 
at meiosis I (MI) (Mork, Maatouk et al. 2012). In mice, the process of follicular 
formation normally occurs from shortly before birth until around day 3 of neonatal 
life depending on the strain. In humans, primordial follicle formation begins 
around day 140 of fetal life (Baker 1963; Rabinovici and Jaffe 1990). The 
initiation of follicular growth occurs shortly after ovarian follicles are formed 
(Sawyer, Smith et al. 2002), so that the first follicles that start to grow are among 
the first that are formed (Sawyer, Smith et al. 2002; Mork, Maatouk et al. 2012). 
Once a follicle starts to grow, it continues to grow without rest until it ovulates or 
becomes atretic and dies (Peters, Byskov et al. 1975; Fair 2003). 
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1.2.1.1  The cellular composition of the mammalian ovary 
 
In neonatal life, the ovary is surrounded by the surface epithelium, consisting 
of a single layer of cells with a distinct basal membrane.  The next structure under 
the surface epithelium is the ovarian cortex. The outer layer of the cortex is denser 
and more fibrous then the inner layer, which contains the follicles and interstitial 
tissue. The growing follicles are often observed near the surface of the ovary, with 
large preovulatory follicles visible as protruding structures immediately under the 
surface epithelium (see Figures 1A and 1B). Below the cortical layer lies the 
ovarian medulla, containing the blood supply which branches out into an 
extensive network of capillaries that project into the cortex and cluster around 
growing follicles (Reynolds 1973). The medullary region also contains a 
predominant lymphatic system (Peters and McNatty 1980). 
 
 
 
 
 
           
Figure 1A: Mouse ovary, showing protruding antral follicles (arrows) 
                                                                                                                                                                                                           
 
1mm 
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Figure 1B: Cross section of 3 week old prepubertal mouse ovary, showing 
follicles at various stages of development %%
1.2.2  Follicular development in mammals 
 
Recruitment of follicles from the primordial pool is a continuous process 
throughout life. Follicles leave the primordial pool sequentially and enter the 
primary (growth committed) stage. This sequential departure from the primordial 
pool is uninterrupted by reproductive or hormonal status (Peters, Byskov et al. 
1975; Rabinovici and Jaffe 1990; Sawyer, Smith et al. 2002). This process only 
ceases in some species with age when the pool of primordial follicles is depleted, 
as in some primates including humans (Richardson, Senikas et al. 1987).  
The mechanisms involved in initiating growth from the primordial pool are largely 
unknown. Studies in mice carrying mutations in loci encoding the growth factor kit 
ligand (KL) or its tyrosine kinase receptor, c-kit, point to these factors being 
involved in the activation of primordial follicles, as well as in the later stages of 
follicular growth (Hutt, McLaughlin et al. 2006). 
As mentioned earlier, primordial follicles consist of an oocyte, surrounded by a 
layer of squamous granulosa cells, encapsulated by a fully formed basal 
membrane. Morphologically, the transition from primordial to primary follicles 
can be identified by a change in the shape of the granulosa cells from a squamous 
Oocytes(
Surface(
epithelium(
Follicles(
Blood(
vessels 
200(µm 
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to cuboidal appearance. The secretion of a glycoprotein layer, the zona pellucida, 
separating the oocyte and the granulosa cells also happens at this transitional stage 
(Odor 1960; Zamboni 1974; Wassarman and Josefowicz 1978; Sinowatz, 
Amselgruber et al. 1995; Senbon, Hirao et al. 2003). 
When the oocyte is surrounded by more than one concentric layer of granulosa 
cells, the theca cell layer outside the basal membrane of the follicle becomes 
distinguishable. At this stage of growth, the follicle is commonly referred to as a 
secondary follicle. Thereafter, with increasing granulosa cell proliferation, follicles 
develop a fluid-filled antrum. The composition of follicular fluid in this antral 
cavity changes during follicular maturation. This viscous fluid is composed of 
serum-derived products including proteins, hormones and numerous other 
metabolites (McNatty and Baird 1978) together with secreted materials from cells 
within the follicle. The follicular fluid maintains different microenvironments 
within each follicle (Peters and McNatty 1980). The formation of the antrum 
results in the granulosa cells differentiating into two different phenotypes, namely 
the cumulus cells (the granulosa cells immediately adjacent to the oocyte) and 
mural granulosa cells (the cells lining the follicular wall encased by the basement 
membrane) (Eppig 2001; Senbon, Hirao et al. 2003; Juengel and McNatty 2005). 
As the follicles grow, theca cells on the outer side of a basal membrane form two 
layers (theca interna and theca externa) (see Figure 1C). Unlike the granulosa and 
cumulus cells, the theca cells, and predominantly the theca interna, are in direct 
contact with the ovarian blood supply (Reynolds 1973; Peters and McNatty 1980).   
 
Follicles with a fully-formed antrum are called antral or tertiary follicles. These 
follicles continue to increase in size due to proliferating granulosa and cumulus 
cells and an increase in follicular fluid accumulation until a diameter is reached 
corresponding to the preovulatory stage for that species. At this time, and in 
response to the preovulatory LH surge, the oocyte resumes meiosis shortly before 
ovulation. However, in all species including humans, over 99% of follicles that 
enter the growth-committed stage will degenerate before maturation to the 
preovulatory stage. Most appear to undergo atresia during the early stages of antral 
development since relatively low numbers degenerate before antrum formation 
(Byskov 1978).  
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In mice, the oocyte increases in size from about 12 µm in the non-growing follicle 
to 70 µm by antrum formation (Peters and McNatty 1980). The oocyte remains in 
meiotic arrest throughout these phases of follicular development in response to 
inhibitory signals from the follicular somatic cells (Schultz, Montgomery et al. 
1983; Eppig, Ward-Bailey et al. 1985; Bornslaeger, Mattei et al. 1986), due to 
communication between the oocyte and the cumulus cells mainly via gap 
junctions. During the preovulatory surge and rise in intrafollicular LH, the gap-
junctional connections between the cumulus cells and oocyte break down leading 
to the resumption of meiosis (Dekel, Lawrence et al. 1981). During this time, the 
oocyte resumes meiosis to complete metaphase I, thereby achieving developmental 
competence prior to extrusion of the second polar body and preparation for 
fertilisation following ovulation (reviewed in(Russell and Robker 2007). 
 
 
 
 
   
 
Figure 1C: Cross-section through an antral follicle  
 
The antral follicle is encapsulated in the basal membrane, and surrounded by the fully formed theca 
layer, consisting of the steroidogenically active theca interna and the non-steroidogenic theca 
externa. The somatic cells lining the inside of the follicular wall are called granulosa cells, while 
those surrounding the oocyte are the cumulus cells. Both the granulosa and the cumulus cells 
rapidly proliferate during the growth phase of follicular development 
 
 
 
 
 
Several classification systems for follicles have been proposed, based on 
the morphology through the largest cross-section of the follicle and the oocyte 
nucleolus, noting the shape and number of somatic cells and the presence or 
oocyte 
cumulus cells 
granulosa cells 
basal membrane 
theca cells 
antrum 
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absence of the follicular fluid-filled antrum. These follicular classification systems 
in various species have been summarised elsewhere (Pedersen and Peters 1968; 
Lundy, Smith et al. 1999). 
In mice, the classification system used for different follicular types in this thesis is 
as described by (Pedersen and Peters 1968) (see Figure 1D). Type 1 and type 2 
follicles are small, non-growing primordial follicles. Type 3a-3b follicles are the 
primordial to primary follicle transformation stages. Type 3b-5a follicles refer to 
the secondary or preantral stages. Type 5b-8 follicles refer to the tertiary or antral 
stages of growth. Type 8 follicles are those that proceed to become the ovulatory 
follicles. 
 
 
 
 
 
 
(From Peters and McNatty, 1978, with permission from Professor Ken McNatty) 
 
Figure 1D: The Pedersen and Peters (1968) classification of follicles in the mouse 
ovary  
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The primary and early secondary stages of follicular growth are 
independent of gonadotrophins (reviewed in(Edson, Nagaraja et al. 2009), 
suggesting that the early stages of follicular development are regulated by locally 
produced (i.e. paracrine) growth factors. Follicles develop a responsiveness to 
gonadotrophins at the preantral stage and their continued growth becomes 
increasingly dependent on gonadotrophins during the antral stages (reviewed 
in(Scaramuzzi, Baird et al. 2011). Deficiencies in gonadotrophin [follicle-
stimulating hormone (FSH) and/or luteinising hormone, (LH)] (Kumar, Wang et 
al. 1997; Dierich, Sairam et al. 1998; Abel, Wootton et al. 2000) or gonadotrophin 
releasing hormone (GnRH) (Cattanach, Iddon et al. 1977) lead to impaired antral 
follicular development. In hypophysectomised sheep, follicular growth is arrested 
during antral development, and follicles are unable to develop to the preovulatory 
stage (McNatty, Heath et al. 1990). 
 
1.2.3  Gonadotrophin regulation of ovarian follicular development 
 
A main regulator of mammalian fertility and ovarian follicular growth is 
the hypothalamus-pituitary-ovarian system. The anterior pituitary gland secretes 
LH and FSH into the bloodstream under the influence of GnRH, produced by the 
hypothalamus (Carmel, Araki et al. 1976; Peters and McNatty 1980). The pattern 
of release of gonadotrophins is regulated by the ovarian hormones; oestrogens, 
progestins and inhibin through feedback loops (Knobil 1974; Yen, Lasley et al. 
1975; Nakai, Plant et al. 1978; Plant, Nakai et al. 1978; Peters and McNatty 1980). 
 
  Concentrations of FSH vary across the oestrous cycle characterised by periodic 
and low amplitude fluctuations in serum. FSH, together with higher amplitude 
episodic fluctuations in serum LH concentrations, stimulate the growth of 
enlarging antral follicles and eventually the emergence of the large preovulatory 
follicle(s). The healthy, large antral follicles in the ovary are the primary source of 
the rising concentrations of oestradiol-17β in venous blood. These rising levels of 
oestradiol feed back to regulate the release of both FSH and LH from the pituitary 
gland (Baird, Swanston et al. 1981; Backstrom, McNeilly et al. 1982; Scaramuzzi, 
Adams et al. 1993; McGee and Hsueh 2000). Initially, oestradiol inhibits the 
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release of FSH but increases the frequency of episodic LH secretion (Yen, Lasley 
et al. 1975; Moenter, Caraty et al. 1991). In mice, this leads to insufficient trophic 
support of the smaller growing follicles at late secondary to early antral follicle 
phase of development, causing many to become atretic (Peters and McNatty 1980). 
In general, it seems that the developing follicle is most likely to become atretic 
during the transitional period from preantral to early-mid antral stages of growth 
(Hirshfield 1991; McGee and Hsueh 2000). In hypophysectomised animals, 
follicles do not develop beyond this stage. The granulosa cells become apoptotic, 
the follicles undergo atresia and die (Nahum, Beyth et al. 1996). Both FSH and LH 
are necessary survival factors for antral follicles during the final phases of 
development. With the emergence of dominant follicles capable of being supported 
by LH but not FSH, oestradiol levels reach a critical threshold, leading to the 
stimulation of preovulatory surges of both FSH and LH secretion (Docke and 
Dorner 1965; Moenter, Caraty et al. 1990). The large preovulatory surge of LH, 
together with FSH, triggers a chain of events leading to the rupture of the 
preovulatory follicle(s) and the release of the mature oocyte(s) into the oviduct, 
ready for fertilisation (Scaramuzzi, Adams et al. 1993; Messinis, Messini et al. 
2010). The granulosa cells in the ovulated follicle undergo luteinisation and form 
the major component of the corpus luteum (CL; reviewed in(Hirshfield 1991; 
Knobil 1994). These luteinising cells become the main ovarian source of 
progesterone. After ovulation, progesterone plays an important role with respect to 
implantation of the zygote and in supporting pregnancy (Graham and Clarke 
1997). The highly vascularised CL is normally visible as a protruding body on the 
surface of the ovary. If pregnancy does not occur, then the CL structure slowly 
degrades over the next few cycles, while during pregnancy it remains active, 
providing progesterone to maintain the pregnancy (reviewed in(Peters and 
McNatty 1980).  
 FSH acts specifically on granulosa and cumulus cells within the follicle.  
Granulosa and cumulus cells acquire FSH receptors (FSH-R), thus the ability to 
respond to FSH stimulation, during the early secondary (preantral) stage of 
follicular development (Presl, Pospisil et al. 1974; Nimrod, Erickson et al. 1976; 
Kumar, Wang et al. 1997). FSH receptor (FSH-R) knockout mice are infertile due 
to granulosa cell proliferation being blocked at the antral stage, causing arrested 
follicular development (Burns, Yan et al. 2001). The absence of FSH-R expression 
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by follicular cells during early follicular growth and the ability of follicles to 
develop to the secondary stage in mice, and to the early antral stage in humans, 
with minimal or no FSH in the bloodstream, also highlights the fact that FSH is not 
essential in early follicular development (Halpin, Jones et al. 1986; Hillier 1994; 
Aittomaki, Lucena et al. 1995; Fauser and Van Heusden 1997; Dierich, Sairam et 
al. 1998; McGee and Hsueh 2000). However, in hypophysectomised rats, antral 
follicles developed at a slower rate and in smaller numbers than in the untreated 
prepubertal or mature animals (Hirshfield 1985). This supports the notion that 
FSH, while not essential for early follicular development, may play a regulatory 
role. 
 
 LH acts directly on theca cells during preantral and antral follicle 
development and also on granulosa cells of the presumptive preovulatory follicles 
during the final stages of maturation. LH-R are first detected on the theca cells 
during the early secondary follicular stage whereas they are not expressed in 
granulosa cells until the late antral and preovulatory stages (Webb and England 
1982; Peng, Hsueh et al. 1991; McGee and Hsueh 2000; Russell and Robker 
2007). In FSHβ knockout (KO; FSH-deficient) mice, growth beyond the late 
preantral stage is impaired, granulosa cells don’t accumulate LH-R mRNA and do 
not differentiate in response to the preovulatory LH surge. Theca cell function 
however is unimpaired (Burns, Yan et al. 2001). Nevertheless, ovulation in these 
mice could be achieved by exogenous administration of FSH and LH, showing that 
the ability of granulosa cells to respond to pituitary stimulation remained intact 
(Kumar, Wang et al. 1997). 
 In vitro studies show that administration of FSH, but not LH alone, protects 
granulosa cells from apoptosis (Chun, Eisenhauer et al. 1996). FSH action 
promotes granulosa cell survival and proliferation through activation of 
intracellular signalling pathways, such as PI3K/Akt pathway (Gonzalez-Robayna, 
Falender et al. 2000; Zeleznik, Saxena et al. 2003), recruitment of adaptor proteins, 
such as 14-3-3 (involved in the regulation of FSH induced cAMP accumulation) 
(Cohen, Nechamen et al. 2004), and up-regulating the expression of certain genes, 
such as the ones encoding LH-R and vascular endothelial growth factor (Richards 
1994; Alam, Maizels et al. 2004). LH is necessary to stimulate androgen 
production by theca cells. Androgens are converted to oestrogens by granulosa 
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cells, under the influence of FSH-induced aromatase action (Hsueh, Adashi et al. 
1984; Richards 1994; McGee and Hsueh 2000). 
 
1.2.4  The role of steroids in regulating ovarian follicular development 
 
The ovarian tissues, capable of producing the main ovarian steroid hormones 
progestins, androgens and oestrogens, are the follicle, corpus luteum (CL) and the 
stroma (tissue separating the follicles within the ovary) (McNatty, Makris et al. 
1979; Peters and McNatty 1980). Steroid production by ovarian tissues happens 
sequentially, with each steroid, in turn, acting as a precursor for the next in the 
steroid biosynthetic pathway (see Figure 1E). Each of the ovarian cell types has a 
different ability to produce specific steroids. The primary steroids produced by a 
healthy developing follicle are oestrogens, produced by granulosa cells in a two-
step process known as the ‘two-cell, two-gonadotrophin model’. This model shows 
strict compartmentalisation in ovarian steroid production: in response to LH, theca 
cells produce large amounts of androgens, which are converted to oestrogens by 
granulosa cells, under the influence of FSH (review:(Drummond 2006).  
 
Oestradiol-17β plays an important role in follicular development, by being 
involved in a number of intrafollicular events. Oestradiol-17β, together with FSH, 
is responsible for mediating proliferation of granulosa cells throughout follicular 
growth (Rao, Midgley et al. 1978) by activating cyclinD2 expression. CyclinD2 
protein is involved in the regulation of mitosis and in cyclinD2 deficient mice, 
granulosa cell proliferation is impaired. Despite the gonadotrophin signalling 
pathways remaining intact, follicles of cyclinD2 deficient mice are unable to 
ovulate in response to the preovulatory LH surge. Instead they form luteinised 
structures without releasing the oocyte (Sicinski, Donaher et al. 1996).  
Oestrogens exert their effects through binding to oestrogen receptors (ERα 
and ERß) expressed by the target cells (Drummond, Britt et al. 2002). The relative 
roles of ERα and ERß in ovarian follicular development have been studied using 
KO mouse models. In ERα KO mice, follicles developed to the large antral stage 
unimpaired, but the animals were infertile due to the inability to ovulate (Lubahn, 
Moyer et al. 1993; Elvin and Matzuk 1998).  
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(With permission from the author of the thesis Dr G Shuttleworth) 
 
Figure 1E: Steroid biosynthesis in the ovary (modified from(Shuttleworth 2000) 
 
Simplified illustration of steroid synthesis by somatic follicular cells, showing the 
basic structure of steroids and their precursor molecules, as well as the enzymes 
responsible for each step in the pathway.  
 
 
 
ERß KO mice have smaller ovaries than the wild-type, follicular growth is 
impaired and the ovaries have larger numbers of primordial follicles with fewer in 
the growth phases. The incidence of atresia amongst the growing follicle 
population is also increased, possibly caused by up-regulated androgen receptor 
expression. The ovulatory process appears to be impaired as well, evidenced by 
lower number of corpora lutea and smaller litter size (Krege, Hodgin et al. 1998). 
In vitro, granulosa cells harvested from follicles of ERß knockout mice produce 
less oestrogen and have lower aromatase activity than that of the wild type 
(Emmen, Couse et al. 2005). The FSH-oestradiol synergy seems to be mediated 
through ERß, expressed by granulosa cells and oocytes of growing follicles 
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(Cardenas, Burke et al. 2001; Jansen, West et al. 2001; Juengel, Heath et al. 2006). 
ERß expression is down-regulated in preovulatory follicles, following the 
preovulatory LH surge (Byers, Kuiper et al. 1997). Taken together, these findings 
suggest a role for ERß in gonadotrophin-mediated granulosa cell differentiation 
(Krege, Hodgin et al. 1998; Cheng, Weihua et al. 2002; Emmen, Couse et al. 
2005). The structure of ovaries of double ER KO mice shows signs of significant 
morphological changes with extensive intraovarian epithelial tubules and large 
somatic cells reminiscent of luteal or Sertoli-like cells. If oocytes are present at all, 
they show signs of degeneration (Couse, Hewitt et al. 1999; Dupont, Krust et al. 
2000). Studies on mice lacking the ability to produce oestrogen, through 
inactivation of the aromatase gene, also provide insights to the role of oestrogens 
in ovarian function. Aromatase KO mice had a similar phenotype to those of the 
oestrogen receptor knockout mice. Follicular development was arrested at the 
antral stage and mice were unable to ovulate. The number of primordial follicles 
had decreased and antral follicles were more likely to become atretic or to undergo 
premature luteinisation. As the mice grew older, the number of tubular-like 
structures increased, together with an increased incidence of cysts. The effects of 
oestrogen deficiency were partially eliminated by oestrogen treatment (Fisher, 
Graves et al. 1998; Britt, Drummond et al. 2000; Hillier 2000; Britt, Drummond et 
al. 2001; Findlay, Britt et al. 2001; Britt, Saunders et al. 2004; Britt, Stanton et al. 
2004). The aforementioned mouse models highlight the importance of oestradiol 
and its receptors in normal follicular development in mammals. 
 
 Androgens are also key ovarian steroids produced by the theca and, in some 
species, the stroma (interstitial glands). One of the main roles of androgens in the 
regulation of fertility is as a precursor for oestrogen synthesis by P450 aromatase 
(CYP19A1) in granulosa cells (Dorrington, Moon et al. 1975; Drummond 2006). 
Under the influence of LH, the theca cells produce androgens, namely 
androstenedione and testosterone. Many cell-types in the ovary are receptive to 
androgens. Androgen receptors (AR) are expressed in granulosa cells, stromal 
cells, thecal cells and in some species (rat, pig, mouse) the oocyte (Schreiber and 
Ross 1976; Horie, Takakura et al. 1992; Hirai, Hirata et al. 1994; Tetsuka, 
Whitelaw et al. 1995; Szoltys and Slomczynska 2000). Mice lacking AR remain 
fertile, but have a reduced ovulation rate and smaller litter size (Lyon and Glenister 
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1980; Hu, Wang et al. 2004). Under in vitro conditions, androgens enhanced 
follicular growth by promoting granulosa cell proliferation (Wang, Andoh et al. 
2001). Androgens have also been shown to promote FSH-induced granulosa cell 
differentiation (Hillier, Knazek et al. 1977; Nimrod 1977; Hillier and De Zwart 
1981) and have effects on oocyte maturation (Gill, Jamnongjit et al. 2004; 
Drummond 2006)(review). In contrast however, it has been reported that 
androgens may promote granulosa cell apoptosis during antral follicular growth in 
rats (Billig, Furuta et al. 1993), but not primates (Weil, Vendola et al. 1998). In 
humans, excess production of androgens, thought to be caused by abnormal 
regulation of steroid biosynthesis in the theca (and stromal) cells, is often a 
common feature in the polycystic ovarian syndrome (PCOS) (Gilling-Smith, Willis 
et al. 1994; Abbott, Dumesic et al. 2002; Jonard and Dewailly 2004). 
 
  The main progestin, namely progesterone, is produced by granulosa cells of the 
ovulating follicle following the preovulatory LH surge, and by the corpus luteum. 
Progesterone acts through two different isoforms of progesterone receptors in 
regulating granulosa cell function and ovulation. These isoforms result from the 
generation of two splice variants of a single gene. PR-A has the ability to repress 
the activity of PR-B in target cells, with the balance between the two receptor 
expressions determining the progesterone responsiveness of the target cell 
(Kastner, Krust et al. 1990; Tung, Mohamed et al. 1993; Vegeto, Shahbaz et al. 
1993; Conneely, Mulac-Jericevic et al. 2002; Conneely, Mulac-Jericevic et al. 
2003). Premature increases in granulosa cell progesterone synthesis during the 
earlier stages of follicular growth preceding the preovulatory stages are indicative 
of atretic processes (Fukuda, Katayama et al. 1980). Under in vitro conditions, 
progesterone treatment enhanced FSH responsiveness but also the inhibition of 
oestradiol synthesis, mitosis and apoptosis in granulosa cells (Schreiber, Nakamura 
et al. 1980; Schreiber, Nakamura et al. 1981; Fortune and Vincent 1983; Peluso 
and Pappalardo 1994; Luciano and Peluso 1995; Peluso, Luciano et al. 1995; 
Peluso 2003). In vivo, progesterone treatment of newborn rats caused inhibition of 
the primordial to primary follicle transition (Kezele and Skinner 2003). 
Importantly, progesterone has an essential role during the final stages of ovarian 
follicular development. PR expression is localised to granulosa cells of large antral 
follicles following the preovulatory LH surge. If the LH surge is blocked, PR 
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mRNA expression does not occur, proving that LH is necessary for inducing 
progesterone responsiveness of granulosa cells (Hild-Petito, Stouffer et al. 1988; 
Iwai, Yasuda et al. 1991; Iwai, Fujii et al. 1991; Park and Mayo 1991; Natraj and 
Richards 1993). In PR knockout mice, follicular growth remains unimpaired, but 
follicles are unable to ovulate, and undergo luteinisation without releasing the 
oocyte, pointing to progesterone having an essential role in the ovulation process 
(Lydon, DeMayo et al. 1995; Robker, Russell et al. 2000).  
 
1.2.5  Bidirectional oocyte-somatic cell communication 
 
The oocyte is thought to promote its own development through metabolic 
cooperation with cumulus cells (Eppig, Pendola et al. 2005). Cumulus cells play an 
essential role in oocyte maturation by providing nutrients for the oocyte such as 
amino acids, and substrates such as pyruvate for energy production (Sugiura and 
Eppig 2005), through gap junctions. In mice lacking connexin 37, (i.e. the main 
gap junction protein in oocytes), more than 90% of oocytes do not attain 
developmental competence (Simon, Goodenough et al. 1997). Mouse oocytes were 
shown to up-regulate glycolysis in cumulus cells, by producing growth factors, 
such as bone morphogenetic protein 15 (BMP15) and fibroblast growth factor 8 
(FGF8) (Sugiura, Su et al. 2007). Glycolysis in cumulus cells harvested from 
oocyte-cumulus complexes (COC) of BMP15 KO mice was reduced. In wild-type 
mouse cumulus cells, recombinant BMP15 treatment alone was unable to increase 
glycolysis. However, BMP15 was effective in increasing glycolysis when 
administered in combination with FGF (Sugiura, Su et al. 2007). Mouse oocytes 
also promote the expression of Slc38a3, a gene encoding an amino acid transporter 
protein in cumulus cells. SLC38a3 has an affinity to transport L-glutamine, L-
histidine and L-alanine, all three of which are ineffectively taken up by the oocyte 
directly and are reliant upon cumulus cells for their supply via gap-junctions. By 
increasing the ability of cumulus cells for uptake and transport of these amino 
acids, the oocyte thereby supports its own development (Eppig, Pendola et al. 
2005). Apart from glycolysis and amino acid transport, the oocyte was also shown 
to control cholesterol synthesis by cumulus cells in mice. The oocyte itself 
produces negligible amount of cholesterol. In the oocytectomised (i.e. the ooplasm 
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is surgically removed from the COC) mouse COC model, as well as in cumulus 
cells of BMP15 KO and Bmp15-/- Gdf9+/- double mutant mice, the expression of 
genes encoding enzymes required for cholesterol synthesis were down-regulated, 
providing further evidence for the importance of oocyte-derived factors in 
regulating cooperation between the oocyte and the surrounding somatic cells (Su, 
Sugiura et al. 2008). 
The gene encoding luteinising hormone receptor, Lhcgr and the gene encoding kit 
ligand (KL), Kitl, are both expressed by granulosa cells and regulated in cumulus 
cells by oocyte-secreted factors (Otsuka and Shimasaki 2002; Eppig 2005). The 
granulosa cell-derived KL, and its oocyte-expressed receptor c-kit play an 
important role in oocyte-granulosa cell communication. The cooperation between 
KL and c-kit was shown to up-regulate the oocyte-derived growth factors, growth 
differentiation factor 9 (GDF9) and FGF-8 and down-regulate BMP15, thus 
influencing oestradiol production and proliferation by granulosa cells (Miyoshi, 
Otsuka et al. 2012). Once granulosa cells start expressing luteinising hormone 
receptor (LH-R) at late antral stage of follicular development, they are able to 
respond to LH and differentiate into progesterone-producing luteal cells following 
the preovulatory LH surge. The down-regulation of Lhcgr and Kitl expression in 
cumulus cells is necessary to maintain cumulus phenotype during follicular 
development (Eppig 2005).  
Evidence shows that the oocyte regulates cumulus cell function through the 
synthesis and secretion of paracrine factors, such as GDF9 (Elvin, Clark et al. 
1999; Dragovic, Ritter et al. 2005) and BMP15 (Yan, Wang et al. 2001; Yoshino, 
McMahon et al. 2006), both of which have been identified as important factors 
maintaining the cumulus cell phenotype in mice. Growth factors such as BMP15 
and GDF9 and their roles in ovarian follicular development will be discussed in 
detail in paragraph 1.3. 
As discussed previously, the oocyte orchestrates its own development and 
regulates follicular growth through locally produced growth factors. Moreover, 
even during the gonadotrophin-dependent stage, the oocyte has the ability to 
suppress progesterone production by granulosa cells (Vanderhyden and Tonary 
1995), thus preventing premature luteinisation of the follicle (el-Fouly, Cook et al. 
1970; Nekola and Nalbandov 1971; Buccione, Vanderhyden et al. 1990; Salustri, 
Ulisse et al. 1990; Salustri, Yanagishita et al. 1990; Vanderhyden, Caron et al. 
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1990). The oocyte retains this regulatory capability even after ovulation, but the 
cumulus cells lose the ability to respond to the suppression signal in large 
preovulatory follicles (Vanderhyden and Macdonald 1998).  
Bidirectional communication between the oocyte and the surrounding follicular 
cells ensures optimal follicular development and the ovulation of a 
developmentally competent mature oocyte at the end of each cycle, ready for 
fertilisation.   
 
1.2.6  Ovulation 
 
The ovulatory process is controlled by both paracrine and endocrine factors. 
The gonadotrophin surge induces morphological changes within the preovulatory 
follicle leading to follicular rupture. These morphological changes include 
breakdown of the follicular basement membrane, disrupted angiogenesis and 
vascular haemorrhage, infiltration of the follicular antrum by thecal cells as well as 
transformation of granulosa cells into luteal cells (reviewed in(Russell and Robker 
2007). After the expulsion of the oocyte with its associated mucified cumulus cell 
complex during ovulation, the luteinised granulosa cells together, in varying 
degrees, with theca cells form the corpus luteum (Peters and McNatty 1980; Eppig 
2001). 
 
The preovulatory gonadotrophin surge initiates major changes within the cumulus 
oocyte complex. The cumulus cells undergo expansion due, in part, to the 
increased production of hyaluronic acid, a glycosaminoglycan that holds the 
separated cells and oocyte in a mucified, jelly-like matrix (Eppig 1979a; Eppig 
1979b; Salustri, Yanagishita et al. 1989; Vanderhyden, Caron et al. 1990; Chen, 
Russell et al. 1993; Eppig, Wigglesworth et al. 1993; Singh, Zhang et al. 1993; 
Elvin, Yan et al. 1999; Matzuk 2000; Di Pasquale, Beck-Peccoz et al. 2004; 
Gilchrist, Ritter et al. 2004; Dragovic, Ritter et al. 2005). In vitro, LH alone does 
not induce cumulus expansion, indicating that the effect of the preovulatory LH 
surge on the cumulus mass is indirect (Eppig 1979a; Eppig 1979b). Cumulus 
expansion, one of the key events before ovulation, is regulated by the oocyte 
(Eppig 2001; Dragovic, Ritter et al. 2005). An oocyte-derived factor that enables 
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cumulus expansion was shown to be produced by developmentally competent 
oocytes from mice (Vanderhyden, Caron et al. 1990; Eppig, Wigglesworth et al. 
1993), pigs (Singh, Zhang et al. 1993) and cows (Gilchrist, Ritter et al. 2004). In 
vitro, recombinant mouse GDF9, was shown to up-regulate hyaluronan synthase 2 
(HAS2), cyclooxygenase 2 (COX-2) and the steroidogenic acute regulator protein 
(StAR) mRNA expression, whilst LH-R and urokinase plasminogen activator 
(uPA) were down-regulated. The up-regulation of HAS2 and down-regulation of 
uPA are necessary for hyaluronic acid production during cumulus expansion, thus 
GDF9 was implicated as one of the important paracrine factors regulating cumulus 
expansion (Elvin, Clark et al. 1999; Matzuk 2000). Neutralisation of oocyte-
derived GDF9 using specific antibodies did not fully block cumulus expansion 
(Dragovic, Ritter et al. 2005), suggesting that other factors, potentially another 
TGF-β superfamily member such as BMP15, may play a role in the regulation of 
this important preovulatory event. It is also likely that the regulation of cumulus 
expansion is species specific (Elvin, Yan et al. 1999; Di Pasquale, Beck-Peccoz et 
al. 2004). 
 
Cumulus cells supply the oocyte with high levels of cyclic AMP (cAMP) through 
gap junctions during follicular growth, keeping the oocyte in meiotic arrest. After 
the preovulatory LH surge, the gap junctions maintaining the bidirectional 
communication between the oocyte and the surrounding somatic cells stop 
functioning, causing a decrease in cAMP levels in the oocyte (Dekel, Lawrence et 
al. 1981), which leads to germinal vesicle (nucleolus) breakdown (GVBD), 
followed by the completion of metaphase I to achieve developmental competence 
(Schultz, Montgomery et al. 1983; Eppig, Ward-Bailey et al. 1985; Bornslaeger, 
Mattei et al. 1986; Webb, Marshall et al. 2002). Termination of gap junction 
communication leads to physical separation of oocyte and cumulus cells after 
cumulus expansion (Larsen, Chen et al. 1996), down-regulation of connexins, 
which are the building blocks of gap junctions (Granot and Dekel 1994; Kalma, 
Granot et al. 2004; Sela-Abramovich, Chorev et al. 2005) and phosphorylation of 
gap junction proteins (reviewed in(Russell and Robker 2007). 
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1.2.6.1  Artificially-induced ovulation  
 
Experiments characterising follicles in sheep, bovine and human ovaries 
provided evidence that, at any given time, the microenvironment within each 
follicle is unique, supporting the hypothesis that follicular growth in mammals is a 
hierarchical process (McNatty 1978; McNatty, Gibb et al. 1981; McNatty, Heath 
et al. 1984; McNatty, Heath et al. 2010). Moreover, at any moment in time, the 
individual follicles demonstrate different levels of responsiveness to 
gonadotrophins (McNatty, Heath et al. 1990; McNatty, Heath et al. 1999). During 
natural cycles (i.e. when no exogenous hormones are administered to stimulate 
growth of the follicles), there are always follicles in the ovary with granulosa cells 
responsive to LH and having the potential to become preovulatory follicles if 
provided with the appropriate gonadotrophic stimuli (Webb and England 1982; 
Webb, Baxter et al. 1992).   
During fertility treatment, the growth of large numbers of LH-responsive follicles 
followed by ovulation induction is achieved by using exogenous gonadotrophins. 
This superovulation treatment is aimed at increasing the numbers of LH-
responsive follicles in experimental animals and in humans undergoing IVF with 
the objective of increasing the number of oocytes available for fertilization. The 
effectiveness of the treatment however is highly variable, does not lead to 
synchronisation of preovulatory follicular maturation and does not necessarily 
lead to increased ovulation, yield of fertilizable oocytes or pregnancy rates (Hafez, 
Sugie et al. 1963; Hahn 1992; Patrizio and Sakkas 2009). 
 
A number of studies have demonstrated that the size of the follicle is not 
indicative of its ability to respond to LH (Souza, Campbell et al. 1996; McNatty, 
Heath et al. 2010). Moreover, successful ovulation and fertilisation requires not 
only LH-responsive granulosa cells in the follicle, but also the presence of a 
healthy, mature cumulus-oocyte complex (Moor, Dai et al. 1998; Sugiura and 
Eppig 2005; Gilchrist, Lane et al. 2008). 
 
Exogenous gonadotrophin treatment leads to the maturation of the somatic cells 
within the follicle, but does not necessarily ensure the maturation of the oocyte-
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cumulus complex or the synchronisation of the microenvironment of each follicle. 
Even though greater numbers of follicles becomes responsive to LH following 
superovulation treatment, the oocyte-cumulus complexes may each remain at 
different developmental stages within these follicles: this may explain the 
discrepancies between ovulation rates and pregnancy outcomes. The 
superovulation treatments do not appear to override the hierarchical nature of 
follicular development (McNatty, Heath et al. 2010). Even though the event of 
ovulation is dependent on gonadotrophins, other follicle-derived factors must play 
a part in the ovulation process, as well as in the process of follicular growth and 
oocyte maturation. 
 
1.3  Overview of the TGF-β Protein Superfamily 
 
The proteins of interest in this study, BMP15 and GDF9, are members of the 
TGF-β protein superfamily. Therefore it is important to understand general 
concepts of TGF-β superfamily functions, such as structure, receptors and 
signalling. Furthermore, given that multiple members of this family have 
regulatory roles in mammalian fertility, a brief overview of the actions of other 
TGF-β superfamily members with well-established roles in fertility is provided in 
this section. 
 
1.3.1  Structure of the TGF- ß superfamily 
 
 
The TGF-ß superfamily consists of over 40 structurally related proteins 
(reviewed in(Juengel and McNatty 2005). Depending on the extent of sequence 
homology, the family members can be classified into subgroups (McPherron and 
Lee 1993), including the TGF-ß, BMP/GDF and activin/inhibin subgroups. 
 
TGF-ß superfamily proteins are expressed as a preproprotein, consisting of a 
signal peptide, and a proregion and mature protein. After the removal of the N-
terminal signal peptide, the proprotein undergoes dimerisation, followed by 
enzymatic cleavage (Figure 1F) (Massague 1990; McPherron and Lee 1993; 
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Chang, Brown et al. 2002;)reviewed in(Juengel and McNatty 2005). After 
cleavage, the proregion remains in non-covalent interaction with the mature 
protein for several of the TGF-ß family members (Wilson, di Clemente et al. 
1993; Bottinger, Factor et al. 1996; Wolfman, McPherron et al. 2003; Jiang, Liang 
et al. 2004; Le Good, Joubin et al. 2005; McIntosh, Lun et al. 2008). 
The cleavage site that separates the proregion and the mature region is a basic 
RXXR amino acid motif, enzymatically recognised by members of the proprotein 
convertase family, including furin protease (Thomas 2002; Taylor, Van De Ven et 
al. 2003; Rockwell and Thorner 2004; Juengel and McNatty 2005). 
 
 
 
 
Figure 1F: Posttranslational modifications of TGF-ß superfamily proteins, 
indicating the molecular weights of the different mouse BMP15 and GDF9 protein 
forms as examples 
 
 
 
TGF-ß superfamily proteins are structurally similar, consisting of 
conserved cysteine molecules, forming a cysteine knot and allowing dimerisation 
by forming disulphide bonds (see reviews by(Kingsley 1994; Drummond 2005; 
Knight and Glister 2006). For most TGF-ß family proteins, the active form of the 
proregion mature region 
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Proteolytic cleavage 
Dimerisation 
proregion mature region 
proregion mature region 
proregion mature region 
mature region 
mature region 
BMP15 promature protein: 52-55 kDa 
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BMP15 and GDF9 proregion 
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protein appears to be the disulphide-linked mature protein homodimer. In some 
cases, such as for the inhibins and certain TGF-ßs, mature protein heterodimers 
have also been reported. Heterodimers appear to have different biological 
properties than homodimers (McPherron and Lee 1993). 
 
1.3.2  Signalling by TGF- ß family members 
 
TGF-ß family members appear to exert their effects through binding 
to membrane-bound serine-threonine kinase receptor complexes and 
activating intracellular signalling molecules. Many TGF-ß family members 
bind first to a type II receptor (ActRII, ActRIIB, BMPRII, TGFßRII, 
AMHRII) which then enables binding to a type I receptor (ALK1-7). 
However, it has also been reported that some BMP proteins might bind the 
type I receptor first, followed by the mobilization of a type II receptor to 
form a receptor-ligand oligomeric complex (ten Dijke and Hill 2004; 
Drummond 2005). After formation of the receptor-ligand complex, 
phosphorylation of the type I receptor activates intracellular signalling Smad 
molecules. The phosphorylation of the type I receptor is followed by the 
ligand-specific activation of a receptor type Smad molecule (rSmad). The 
activated rSmad forms a complex with Smad4, also known as common Smad 
(cSmad). The rSmad-cSmad complex is capable of regulating gene 
transcription upon translocation to the nucleus (reviews by(Miyazawa, 
Shinozaki et al. 2002; ten Dijke, Korchynskyi et al. 2003; de Caestecker 
2004; Shimasaki, Moore et al. 2004; ten Dijke and Hill 2004; Juengel and 
McNatty 2005). Inhibitory Smads (Smad6 and Smad7) can prevent the 
phosphorylation of the type I BMP receptor, blocking the recruitment of 
rSmads and the activation of the Smad signalling pathway, outlined in Figure 
1G. Studies have shown that TGF-ß superfamily proteins can also signal 
through alternative pathways, such as MAPK (mitogen-activated protein 
kinase) pathway (Derynck and Zhang 2003; Reader, Heath et al. 2011). 
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Figure 1G: TGF-ß signalling through the Smad pathway in mice  
 
 
1.3.3  Roles of the proregion and proprotein in regulating activity  
 
  Until recently, the proregion was thought only to play a part in the folding 
of the precursor protein, and the dimerisation process, before enzymatic cleavage 
releases the biologically active mature dimer (reviews:(Shimasaki, Moore et al. 
2004; Juengel and McNatty 2005). However, in some species, such as mice 
(McIntosh, Lun et al. 2008), sheep (McNatty, Lawrence et al. 2006) and humans 
(Saito, Yano et al. 2008), BMP15 and GDF9 are also secreted in vitro as 
uncleaved promature and proregion proteins, but the biological activities of these 
forms are unknown. There is increasing evidence to support the importance of the 
proregion (prodomain) of TGF-ß superfamily proteins in regulating the activity of 
the growth factors. The non-covalent interaction between the cleaved proregion 
and the mature dimer in some TGF-ß superfamily members is thought to keep the 
growth factor inactive, while in others the interaction is necessary to store the 
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protein in the extracellular matrix (ECM) (Annes, Chen et al. 2004; Ramirez and 
Sakai 2010). Shi et al, (2011) describes a structure for TGF-ß1 protein, where two 
TGF-ß1 monomers create a complex with a single ECM linked binding protein, 
which prevents disulphide bridge formation between the TGF-ß molecules, 
keeping them inactive. Integrin molecules, recognising a binding site in the 
proregion of TGF-ß1, release and activate the growth factors by applying tactile 
force (Shi, Zhu et al. 2011). Following posttranslational modification, continued 
interaction between the pro- and mature regions of TGF-ß1 (McMahon, Dignam 
et al. 1996) or GDF8 (Thies, Chen et al. 2001) was shown to be inhibitory to the 
bioactivities of these proteins, but had no effect on BMP9 bioactivity (Brown, 
Zhao et al. 2005). 
 
In humans, mutations of the gene encoding the prodomain of BMP15 are 
associated with hypergonadotrophic ovarian failure (Di Pasquale, Beck-Peccoz et 
al. 2004; Di Pasquale, Rossetti et al. 2006; Dixit, Rao et al. 2006), while 
mutations affecting the GDF9 proregion led to dizygotic twinning (Palmer, Zhao 
et al. 2006). In mice, the non-covalently associated pro- and mature regions of the 
TGF-ß1, TGF-ß2 and TGF-ß3 proteins have been shown to have an inhibitory 
effect on the mitogenic activity of the mature protein forms both in vitro and in 
vivo (Bottinger, Factor et al. 1996). Immunoneutralisation of the proregions of 
mouse BMP15 and GDF9 led to inhibition of the synergistic mitogenetic effect of 
these growth factors in granulosa cell cultures (McIntosh, Lun et al. 2008). 
Immunisation against these protein forms resulted in different ovulation rates and 
reduced litter sizes in mice (McIntosh, Lawrence et al. 2012), emphasising the 
importance of the proregions of BMP15 and GDF9. 
In zebrafish embryos, TGF-ß proteins belonging to the nodal family were shown 
to have different bioactivity and stability when associated with the proregion 
protein (Le Good, Joubin et al. 2005).  
 
There is little information available about the biological activity of the precursor 
(proprotein) forms of TGF-ß superfamily proteins. The uncleaved precursor form 
of the Nodal protein was shown to enhance nodal expression during mouse 
embryonic development, by up-regulating Bmp4 expression. The Nodal precursor 
protein also maintains proprotein convertase enzyme (furin and PACE4) activity 
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in the mouse embryo, thus promoting its own processing (Ben-Haim, Lu et al. 
2006). Another TGF-ß superfamily protein, anti-Mullerian hormone, reportedly 
requires intact proregion-mature interaction for enhanced bioactivity (Wilson, di 
Clemente et al. 1993).  
 
1.3.4  TGF-β superfamily proteins in mammalian reproduction 
 
TGF-β1, TGF-β2 and TGF-β3 belong to the TGF-β subgroup and were 
shown to be expressed by theca and granulosa cells, and the oocyte (Skinner, 
Keski-Oja et al. 1987; Chegini and Flanders 1992; Teerds and Dorrington 1992; 
Schmid, Cox et al. 1994; Nilsson, Doraiswamy et al. 2003; Bristol and Woodruff 
2004). The effect of these proteins on granulosa cell function is species specific. 
Overall they seem to have a stimulatory effect on granulosa cell proliferation 
(Dorrington, Chuma et al. 1988; Roy 1993; Saragueta, Lanuza et al. 2002), 
progesterone production (Dodson and Schomberg 1987; Hutchinson, Findlay et al. 
1987; Knecht, Feng et al. 1987) and FSH-induced oestradiol production (Adashi, 
Resnick et al. 1989; Zachow, Weitsman et al. 1999) in rodents, but have no effect 
or even inhibitory effect on ovine (Fabre, Pierre et al. 2003; Juengel, Bibby et al. 
2004), bovine (Skinner, Keski-Oja et al. 1987; Gilchrist, Morrissey et al. 2003), 
porcine (May, Frost et al. 1988; Mondschein, Canning et al. 1988; Gangrade and 
May 1990; Kubota, Kamada et al. 1994) and human (McAllister, Byrd et al. 1994) 
granulosa cells. 
 
Activin, inhibin and follistatin are produced by the granulosa cells of the 
growing follicles as well as by the pituitary, and are necessary for the regulation 
of the hypothalamus-pituitary-ovarian system during follicular development. 
Activin increases the responsiveness of the pituitary gland to the hypothalamic 
hormone, GnRH, thus enhancing FSH production by the pituitary gland 
(Bilezikjian, Blount et al. 2006). The effect of activin is regulated by inhibin and 
follistatin (Knight 1996; Fraser, Groome et al. 1999; Welt, Sidis et al. 2002; 
Bilezikjian, Blount et al. 2006). Inhibin, produced by the growing follicle, acts as 
an activin antagonist, providing negative feedback to the pituitary gland and 
suppressing FSH production (Welt, Sidis et al. 2002; Bilezikjian, Blount et al. 
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2006). Follistatin, which binds activin, also has the ability to inhibit activin 
binding to its type 2 BMP receptor, ActRII/B (Teerds and Dorrington 1992; Sidis, 
Schneyer et al. 2001; Welt, Sidis et al. 2002). 
Activin has been shown to stimulate proliferation (Miro and Hillier 1996) and 
FSHR expression (Hutchinson, Findlay et al. 1987; Xiao, Robertson et al. 1992; 
Nakamura, Minegishi et al. 1993) of rat granulosa cells in vitro and oestradiol 
production by bovine granulosa cells (Hutchinson, Findlay et al. 1987). In vivo, 
inhibin and follistatin are likely to act as activin antagonists in the follicle to 
modulate the growth-promoting effects of activin. For example, small growing 
follicles have high activin expression, whereas in antral and preovulatory follicles, 
higher expression levels of inhibin and follistatin are evident (Knight and Glister 
2001). In short, activin, inhibin and follistatin together act to co-ordinate the 
differentiation of granulosa cells from FSH-responsive towards LH-responsive 
during follicular development.  
 
Anti-Mullerian hormone (AMH) is produced by granulosa cells throughout 
follicular growth to preovulatory development, although the expression levels are 
much lower during the later stages of growth as well as in atretic follicles 
(Gruijters, Visser et al. 2003). AMH has been implicated in the recruitment of 
follicles from the primordial pool to the growth-committed follicular population, 
since ovaries in AMH knockout mice (AMHKO) presented with lower number of 
primordial and larger numbers of growing follicles when compared to wild type 
(Durlinger, Kramer et al. 1999). Studies of AMHKO mice (Durlinger, Kramer et 
al. 1999) and AMH treated preantral mouse follicle cultures confirmed that AMH 
also has an inhibitory effect on FSH-induced proliferation (Durlinger, Gruijters et 
al. 2001) as well as aromatase and LHR expression by granulosa cells (di 
Clemente, Wilson et al. 1994). 
The roles of other TGF-ß family members remains to be elucidated (see(Gilchrist, 
Lane et al. 2008)for review). 
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1.4  BMP15 and GDF9  
 
BMP15 and GDF9 belong to a unique subset of the TGF-ß superfamily, 
which has only six of the seven conserved cysteines that are characteristic of other 
TGF-ß family members (McPherron and Lee 1993; Laitinen, Vuojolainen et al. 
1998). It was proposed that these proteins might exist as monomers or non-
covalently bound homodimers and/or heterodimers (McPherron and Lee 1993; 
Shimasaki, Moore et al. 2004). Indeed, recent studies in mice (Liao, Moore et al. 
2003; McIntosh, Lun et al. 2008) showed that BMP15 and GDF9 can form 
heterodimers in vitro. The mature region of mouse GDF9 was shown to interact, 
either directly or indirectly, with the proregion of mouse BMP15, forming 
heteromeric complexes. Multimers containing both mouse BMP15 and GDF9 pro-
and mature region proteins were also observed (McIntosh, Lun et al. 2008). 
Phosphorylation has been shown to be essential for the bioactivity of BMP15 and 
GDF9, as well as other TGF-β protein family members (McMahon, Sharma et al. 
2008). Both proteins appear to have only one phosphorylation site, Ser6, in the 
mature region (Tibaldi, Arrigoni et al. 2010). No phosphorylation site has been 
identified in the proregion of either protein. Golgi apparatus casein kinase has 
been identified as the enzyme responsible for the phosphorylation of both BMP15 
and GDF9 (Tibaldi, Arrigoni et al. 2010). 
Following post-translational modifications, the biologically active form of GDF9 
was shown to bind to BMPRII (Vitt, Mazerbourg et al. 2002) and ALK5 
(Mazerbourg, Klein et al. 2004; Kaivo-Oja, Mottershead et al. 2005) and to signal 
via Smad 2 and 3 (Kaivo-Oja, Bondestam et al. 2003; Roh, Bondestam et al. 
2003), while BMP15 binds to BMPRII and ALK6 to signal via Smad 1, 5, and 8 
(Moore, Otsuka et al. 2003;)reviews by(Shimasaki, Moore et al. 2004; Juengel 
and McNatty 2005). In vitro studies however provided evidence that, in some 
species, BMP15 and GDF9 can also act, directly or indirectly, through pathways 
other than those involving Smad signalling, such as the mitogen-activated protein 
kinase (MAPK), c-Jun N-terminal kinase (JNK), or nuclear factor-κB (NFKB) 
pathways (Moore, Otsuka et al. 2003; Reader, Heath et al. 2011; Mottershead, 
Ritter et al. 2012).  
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1.4.1  The roles of BMP15 and GDF9 in mammalian reproduction 
 
In most species studied, BMP15 and GDF9 are produced by the oocyte of 
the growing follicle. These key oocyte-secreted factors play crucial roles in 
regulating the growth and maturation of follicles and ovulation quota (the number 
of follicles ovulating at each cycle) (Eppig 2001; McNatty, Juengel et al. 2003; 
McNatty, Hudson et al. 2007). 
Development of primary and secondary follicles is independent of 
gonadotrophins, suggesting that the process is regulated by locally produced 
paracrine factors. Inactivation of GDF9, either through targeted disruptions of the 
gene in mice or through naturally occurring mutations in sheep and humans, 
provides strong evidence that GDF9 is a key factor regulating growth of small 
follicles.  In GDF9 null mice, follicular development stops at the primary stage 
causing infertility in these animals (Dong, Albertini et al. 1996; Elvin, Yan et al. 
2000). GDF9 homozygous mutant ewes (Hanrahan, Gregan et al. 2004; Nicol, 
Bishop et al. 2009; Silva, Castro et al. 2011) (Table 1A) or ewes immunised 
against GDF9 (Juengel, Hudson et al. 2002) are also infertile due to arrested 
development at the primary follicle stage whereas ewes heterozygous for the 
mutation have increased ovulation rates (McNatty, Juengel et al. 2003; Hanrahan, 
Gregan et al. 2004; Nicol, Bishop et al. 2009; Silva, Castro et al. 2011). Similarly, 
mutations in GDF9 in humans (Table 1A) have been linked to premature ovarian 
failure (Dixit, Rao et al. 2005; Laissue, Christin-Maitre et al. 2006; Zhao, Qin et 
al. 2007). The role of BMP15 in regulating the development of primary and 
secondary follicles is species-dependent. BMP15 null mice undergo normal 
follicular development, but have a reduced fertilization rate and decreased litter 
size (Yan, Wang et al. 2001). However, an inactivating mutation of the BMP15 
gene in sheep leads to increased ovulation rate and fertility in heterozygous 
animals, but infertility in homozygous carriers (Galloway, McNatty et al. 2000). 
The homozygous mutant BMP15 phenotype is very similar to ewes with 
homozygous mutations in GDF9.  Similarly, a dominant negative mutation in 
human BMP15 lead to primary ovarian failure (Dixit, Rao et al. 2006) (Table 1A). 
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Table 1A: Identified mutations of BMP15, GDF9 and their receptors, affecting 
fertility in sheep and humans 
 
Mutation 
Site 
Protein 
affected 
Species 
(Sheep 
lines) 
Phenotype Reference 
FecXI BMP15 Sheep 
(Inverdale) 
 
FecXH 
 
BMP15 
 
Sheep 
(Hanna) 
Homozygotes: sterile 
due to follicular 
development blocked at 
primary stage 
Heterozygotes: increased 
ovulation rate 
(Galloway, McNatty et al. 
2000) 
 
(Galloway, McNatty et al. 
2000) 
FecGH 
FecXG 
GDF9 
BMP15 
Sheep 
(Belclare, 
Cambridge) 
(Hanrahan, Gregan et al. 
2004) 
FecXL BMP15 Sheep 
(Lacaune) 
(Bodin, Di Pasquale et al. 
2007) 
FecXR BMP15 Sheep 
(Rasa, 
Aragonesa) 
(Martinez-Royo, Dervishi 
et al. 2009; Monteagudo, 
Ponz et al. 2009) 
FecTT GDF9 Sheep 
(Thoka) 
 
 
 
 
Homozygotes: sterile 
Heterozygotes: increased 
fertility 
 
(Nicol, Bishop et al. 2009) 
FecGE GDF9 Sheep 
(Santa Ines) 
Homozygotes have 
increased ovulation rate 
 
(Silva, Castro et al. 2011) 
 
FecXB 
 
ALK6 
 
Sheep 
(Booroola) 
Homozygotes: 
superfertile 
Heterozygotes: increased 
fertility 
(Mulsant, Lecerf et al. 
2001; Souza, MacDougall 
et al. 2001; Wilson, Wu et 
al. 2001) 
Y235C BMP15 Human Impaired granulosa cell 
proliferation in vitro 
(Di Pasquale, Beck-Peccoz 
et al. 2004) 
K67E GDF9 
V216M GDF9 
(Dixit, Rao et al. 2005) 
 
T238A GDF9 (Zhao, Qin et al. 2007) 
S186Y 
L148P 
GDF9 
BMP15 
(Laissue, Christin-Maitre 
et al. 2006) 
R61W BMP15 
R61E BMP15 
R76C BMP15 
R76H BMP15 
A180T BMP15 
A180F BMP15 
N196K BMP15 
R206H BMP15 
E211X BMP15 
W221R BMP15 
I243G BMP15 
 
 
 
 
 
 
 
    Human 
 
 
 
 
 
 
 
Potential role in 
premature ovarian failure 
(POF) 
 
 
 
 
 
(Dixit, Rao et al. 2006) 
 
P103S GDF9 
T121L GDF9 
P374L GDF9 
R454C GDF9 
 
Human 
 
 
Potential role in 
dizygotic twinning 
 
(Palmer, Zhao et al. 2006) 
 
 
 
Several studies of women with premature ovarian failure (POF) have identified 
BMP15 and GDF9 as possible factors in causing this condition. A higher 
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incidence of BMP15 and GDF9 mutations have been identified in women with 
POF, compared to control populations. Some of these mutations have also been 
found in mothers of dizygotic twins, but not in controls (Di Pasquale, Beck-
Peccoz et al. 2004; Dixit, Rao et al. 2005; Dixit, Rao et al. 2006; Zhao, Qin et al. 
2007; Zhao, Painter et al. 2008; Rossetti, Di Pasquale et al. 2009). Most of these 
mutations occur in the proregion of the protein, causing impaired mature protein 
production and potentially disrupting normal biological functions. 
It has been hypothesised that women carrying certain mutations experience an 
enhanced fertility with potential for dizygotic twinning early in their reproductive 
life, which mostly goes undetected due to the trend in the western world of 
women having children later in life. This early enhanced fertility period can cause 
POF due to the earlier exhaustion of the primordial follicular pool (Inagaki and 
Shimasaki 2010). However, studies in ewes that carry either homozygous or 
heterozygous BMP15 or GDF9 mutations showed that the number of follicles 
growing in the ovaries of mutant ewes at any given time is no different from 
normal ewes (Smith, O et al. 1997).  
One possible reason given for higher ovulation rates in women with certain 
mutations in BMP15 or GDF9 genes is that the follicles gain an earlier 
responsiveness to gonadotrophins, especially FSH, than in women without these 
mutations. A study carried out on the effects of BMP15 on the FSH receptor 
expression in rat granulosa cells seems to support this hypothesis (Otsuka, 
Yamamoto et al. 2001; Inagaki and Shimasaki), but is contradicted by a study that 
shows no change in the FSH responsiveness of follicles of BMP15 mutant ewes at 
any stage of follicular development. In this study more follicles showed 
responsiveness to LH at an earlier stage of follicular growth, which could account 
for the higher ovulation rate in ewes carrying the mutation (McNatty, Heath et al. 
2009).  
 
1.4.2  Expression patterns of BMP15 and GDF9 and their receptors 
 
In mice, Bmp15 mRNA expression is detected exclusively in the oocyte 
from primary stage follicles and the expression is maintained until after ovulation 
(Dube, Wang et al. 1998). However, there is some data suggesting that BMP15 
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protein expression in mouse oocytes may not happen until just before ovulation 
(Yoshino, McMahon et al. 2006), while another report shows mouse BMP15 
protein expressed in oocytes at all follicular developmental stages, and in the 
follicular fluid and the cumulus mass following the preovulatory LH surge 
(Gueripel, Brun et al. 2006). Gdf9 mRNA expression is first observed also in 
primary follicles (Dube, Wang et al. 1998) and has been shown to be expressed 
until after ovulation and up to 1.5 days after fertilisation (McGrath, Esquela et al. 
1995). 
GDF9 mRNA and protein in sheep is expressed by the oocyte throughout follicular 
development from the primordial stage of growth (Bodensteiner, Clay et al. 1999; 
Juengel, Bodensteiner et al. 2004) and BMP15 is present from the primary stage 
(Galloway, McNatty et al. 2000; McNatty, Lawrence et al. 2006). 
In humans, both BMP15 and GDF9 mRNA and protein are first observed in 
primary follicles (Dube, Wang et al. 1998; Aaltonen, Laitinen et al. 1999). 
 
It has been reported that, in some species, BMP15 and/or GDF9 expression occurs 
not only in the oocyte, but in other follicular cell types as well. GDF9 mRNA was 
detected in pig somatic follicular cells (Prochazka, Nemcova et al. 2004) and in 
primate granulosa cells adjoining the oocytes (Sidis, Fujiwara et al. 1998; Duffy 
2003). However, there are other reports suggesting the GDF9 and BMP15 
expression is exclusive to the oocyte (Crawford and McNatty 2012). 
In some species, GDF9 and BMP15 mRNA are expressed in tissues other than the 
ovary, such as the pituitary and the testis, which means that the actions of these 
proteins might not be ovary specific in all mammals (Fitzpatrick, Sindoni et al. 
1998; Aaltonen, Laitinen et al. 1999; Galloway, McNatty et al. 2000; Eckery, 
Whale et al. 2002; Otsuka and Shimasaki 2002).  
 
The receptors for GDF9 were shown to be BMPRII and ALK5 (Vitt, Mazerbourg 
et al. 2002; Mazerbourg, Klein et al. 2004; Mottershead, Pulkki et al. 2008), while 
BMP15 preferentially binds to BMPRII and ALK6 (Moore, Otsuka et al. 2003). 
BMPRII is expressed in rat granulosa cells from primary stage follicles onwards, 
with no BMPRII mRNA expression in oocytes or theca cells (Erickson and 
Shimasaki 2003). In sheep however, oocytes and granulosa cells from primordial 
to antral and theca cells from preantral to antral follicular stages expressed 
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BMPRII (Wilson, Wu et al. 2001). The type I BMP receptor ALK6 is expressed in 
oocytes and granulosa cells from the primordial to antral stages in both rats and 
sheep, as well as in theca cells from preantral follicles onwards (Wilson, Wu et al. 
2001; Souza, Campbell et al. 2002; Erickson and Shimasaki 2003).  ALK5 mRNA 
and protein are expressed in oocytes of mouse, sheep and human at all 
developmental stages (Juneja, Chegini et al. 1996; Roy and Kole 1998; Qu, Godin 
et al. 2000; Juengel, Bibby et al. 2004). ALK5 expression was also observed in 
mouse granulosa cells from primordial to preantral stages of growth (Juneja, 
Chegini et al. 1996), in human granulosa cell from primary to preantral stages and 
theca cells of small antral follicles (Roy and Kole 1998; Qu, Godin et al. 2000). In 
sheep, granulosa and theca cells of preantral and antral follicles showed ALK5 
expression (Juengel, Bibby et al. 2004).  
The expression patterns of BMP15, GDF9 and their receptors suggests that these 
growth factors ascertain their effects in a species-specific manner, affecting 
different somatic follicular cell types at different developmental stages during 
follicular growth in mammals. 
 
1.4.3  Effects of GDF9 and BMP15 protein in vitro 
 
In vivo, BMP15 and GDF9 have proven mitogenic effects on somatic 
follicular cells, promoting follicular growth during the gonadotrophin independent 
stage (Hayashi, McGee et al. 1999; Otsuka, Yao et al. 2000; Vitt, Hayashi et al. 
2000; Hreinsson, Scott et al. 2002; Nilsson and Skinner 2002; McNatty, Juengel 
et al. 2005a; McNatty, Juengel et al. 2005b).  
In vitro, ovine granulosa cell proliferation rate was not affected by treatment with 
GDF9 alone, but BMP15 alone stimulated a modest increase (McNatty, Lawrence 
et al. 2006). Proliferation of rat granulosa cells increased when treated with 
BMP15 and GDF9 together in vitro, and this mitogenic effect was reduced by 
treatment with an immunoneutralising BMP15 antibody (McIntosh, Lun et al. 
2008). Rat granulosa cells treated with mouse but not ovine GDF9 showed 
increased proliferation rate (McNatty, Juengel et al. 2005b), suggesting that the 
actions of these growth factors are species specific. 
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The treatment of mouse oocyte-cumulus cell co-cultures with an antibody to 
neutralise the effects GDF9, halved the proliferation rate of cumulus cells 
(Gilchrist, Ritter et al. 2004), and inhibited gonadotrophin-induced expansion of 
the cumulus mass (Dragovic, Ritter et al. 2005), highlighting the importance of 
GDF9 in regulating cumulus cell functions. Co-culturing mouse cumulus cells 
with oocytes from GDF9 or BMP15 KO mice supports the role of GDF9, but not 
BMP15 in cumulus expansion (Gui and Joyce 2005), although treating cumulus 
cell cultures with GDF9 alone failed to induce cumulus expansion (Dragovic, 
Ritter et al. 2005). Likewise, immunoneutralising with GDF9 but not BMP15 
antibodies inhibited the proliferating effects of rat oocytes on rat granulosa cells 
(Lin, Pitman-Crawford et al. 2012). Immunoneutralising BMP15 in mouse 
oocyte-cumulus cultures, however, reduced cumulus expansion (Yoshino, 
McMahon et al. 2006), therefore it is likely that both growth factors play a role in 
regulating cumulus function in mice. BMP15 treatment prevented apoptosis of 
cultured bovine cumulus cells, but GDF9 had no anti-apoptotic effect (Hussein, 
Froiland et al. 2005). 
 
Theca cells collected from bovine follicles at the early stages of follicular 
development showed increased proliferation in response to GDF9 treatment but 
decreased LH-R expression and steroidogenic activity, suggesting that GDF9 or a 
related TGF-ß factor prevents gonadotrophin-induced differentiation of the theca 
layer at early stages of follicle growth (Spicer, Aad et al. 2008). An increase in 
thecal cell proliferation following GDF9 treatment has also been observed in 
human theca cell cultures (Yamamoto, Christenson et al. 2002). 
 
Both GDF9 and BMP15 appear to block gonadotrophin-induced progesterone 
production by granulosa cells, thus preventing premature luteinisation (Otsuka, 
Yao et al. 2000; Vitt, Hayashi et al. 2000; Yamamoto, Christenson et al. 2002; 
McNatty, Juengel et al. 2005b). The anti-luteinisation effect of BMP15 and GDF9 
could potentially be attributed to their role in regulating the gonadotrophin-
responsiveness of somatic follicular cells through mitigating the expression of 
FSH-R and LH-R. GDF9 suppresses LH-R mRNA and BMP15 was shown to 
suppress FSH-R mRNA expression by granulosa cells (Elvin, Clark et al. 1999; 
Vitt, Hayashi et al. 2000; Otsuka, Yamamoto et al. 2001).   
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In both human theca and granulosa cells, recombinant GDF9 treatment reduced 
steroidogenic acute regulatory protein (StAR) mRNA and protein expression, 
P450 aromatase (CYP19A1) and P450 side chain cleavage (CYP11A1) 
expression. All three proteins are involved in the ovarian steroid biosynthesis 
pathway, suggesting that GDF9 regulates steroid hormone synthesis in somatic 
follicular cells (Yamamoto, Christenson et al. 2002). 
 
The addition of recombinant GDF9 to cultured ovarian follicles from mice 
(Hayashi, McGee et al. 1999) and humans (Hreinsson, Scott et al. 2002) induced 
follicular growth in vitro. BMP15 treatment of mice follicle cultures however 
supported follicular growth only in the first 24 h, after which it induced apoptosis 
in granulosa cells, unless GDF9 treatment was also administered (Fenwick, Mora 
et al. 2013). Supplementing IVM oocyte culture media with GDF9 (Yeo, Gilchrist 
et al. 2008) or BMP15 (Hussein, Thompson et al. 2006) led to improved embryo 
development in mice. A study analysing the GDF9 and BMP15 content of human 
follicular fluid from IVF patients also found positive correlation between GDF9 
level, oocyte nuclear maturation and subsequent embryo quality (Gode, Gulekli et 
al. 2011), adding to the evidence supporting GDF9 and BMP15 as potentially 
valuable IVM culture media supplements to improve fertility outcomes. 
 
A potential role of BMP15 and GDF9 has been demonstrated during 
embryonic development as well. For example, BMP15 was shown to be necessary 
for the specification of dorso-anterior structures of Xenopus embryos. Without the 
inhibitory effect of BMP15 on the Smad1/5/8 and the Wnt pathways, the embryos 
developed secondary ectopic heads (Di Pasquale and Brivanlou 2009).  
 
In several species, combining BMP15 and GDF9 has more effect than 
administering either growth factor alone, suggesting that these proteins cooperate 
to promote follicular somatic cell proliferation and regulate gonadotrophin induced 
differentiation (Su, Wu et al. 2004; McNatty, Juengel et al. 2005a; McNatty, 
Juengel et al. 2005b; Edwards, Reader et al. 2008; McIntosh, Lun et al. 2008; 
Mottershead, Ritter et al. 2012; Peng, Li et al. 2013).  
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1.5   Aims of the Study 
 
As highlighted in the literature review, there are conflicting reports as to the 
timing and expression of both Bmp15 and Gdf9 mRNA and protein in mice, 
especially in relation to the preovulatory LH surge (McGrath, Esquela et al. 1995; 
Dong, Albertini et al. 1996; Dube, Wang et al. 1998; Laitinen, Vuojolainen et al. 
1998; Gueripel, Brun et al. 2006; Yoshino, McMahon et al. 2006). The first aim of 
this thesis was to investigate and confirm that Bmp15 and Gdf9 mRNA are 
expressed only in the mouse oocyte, both before and after hCG-induced oocyte 
maturation.  A second aim was to quantify the level of expression of Bmp15 and 
Gdf9 mRNA in relation to cumulus expansion and nuclear maturation of the 
oocyte with particular emphasis on determining if the co-ordinated expression of 
Bmp15 and Gdf9 mRNA observed in growing antral follicles (Crawford and 
McNatty 2012) is maintained during the final stages of maturation prior to 
ovulation. Thirdly, by mapping the protein expression pattern of BMP15 and 
GDF9 in the mouse ovary, this project aimed to determine the secreted forms of 
the target proteins and gain further understanding of the posttranslational 
processing of BMP15 and GDF9 at different stages of follicular development. 
 
In addition to the effects of the mature proteins, recent studies have also 
highlighted a potential role for other forms of BMP15 and GDF9 protein. 
Therefore, to better understand the potential role of the proregion of the protein, 
the final aim of this thesis was to test the mitogenic effect of a non-cleavable 
promature (precursor) form of mouse BMP15 generated by mutating the cleavage 
site between the proregion and mature domains to inhibit enzymatic cleavage.  
 
The hypothesis tested was that BMP15 and GDF9 are produced exclusively by 
the oocyte during follicular development in mice and that the BMP15:GDF9 ratio 
influences follicular development in a species specific manner. Moreover, 
cumulus and granulosa cells are the major targets for the secreted forms of 
BMP15 and GDF9 proteins. 
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Chapter 2: Materials and methods 
 
Detailed instructions on preparing stock solutions and reagents described 
in this chapter can be found in Appendix I. 
 
2.1  Animals, treatments and tissue collection 
 
2.1.1  Animals  
 
 All experiments were performed with the approval of the Animal Ethics 
Committee of Victoria University of Wellington (2008/R2) in accordance with the 
New Zealand Animal Welfare Act 1999. 
 
The animal models for this study were chosen on the basis of ovulation 
rate and predominance in the literature with respect to their reproductive 
physiology. The animals selected were mice (C57BL/6 wild type strain) and rats 
(Sprague-Dawley) and both were species with a high ovulation rate phenotype. 
The mice were purchased from the Malaghan Institute of Medical Research 
(Wellington, NZ) and the rats were obtained from the Psychology Department, 
Victoria University of Wellington, NZ. Mice were used in all experiments, except 
for the methyl-3H-thymidine uptake assays when rat granulosa cells were used. 
The animals were housed in a purpose built animal facility at Victoria University 
of Wellington, NZ, and had access to food and water ad libidum.  
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2.1.2  Treatments and tissue collection %
2.1.2.1  Gonadotrophin injection protocol  
 
For all studies using mice, three week old prepubertal female mice were 
separated into three experimental groups for gonadotrophin priming and 
appropriate controls (Figure 2A). These treatments represented the developmental 
changes that the follicles undergo during the follicular phase of development and 
in response to preovulatory gonadotrophin surges.  
Group 1 received intraperitoneal (IP) saline (100 µl) injections twice, 48 h apart as 
a control group. 
Group 2 was injected IP with 5 IU Pregnant mare serum gonadotrophin (PMSG, 
Folligon, Intervet, Upper Hutt, NZ). A second injection of saline (100µl) was 
given 48 h later. PMSG, containing follicle stimulating hormone (FSH)-like 
activity, promotes preantral and antral follicular growth. It was anticipated that 
this treatment would result in the development of more Type 8 ovarian follicles 
(Pedersen and Peters 1968) (Figure 2B). This was expected to be in contrast to 
controls, where fewer large follicles would be present. The ovarian phenotype in 
this PMSG-treatment group represented the follicular developmental stage before 
the preovulatory luteinising hormone (LH) surge.  
Group 3 received a traditional superovulation treatment applied to mice (Gates 
1956; Luo, Zuniga et al. 2011) consisting of a 5 IU PMSG injection followed by 
5IU hCG (Chorulon®, Intervet, Upper Hutt, NZ) injected 48 h later. The ovarian 
phenotype in this group represented the follicular developmental stage 
immediately after the preovulatory LH surge. Human chorionic gonadotrophin 
(hCG), used as a surrogate of LH, was likely to ensure the presence of large 
preovulatory follicles in the ovaries, with an expanded cumulus cell mass and 
oocytes undergoing germinal vesicle breakdown (GVBD): these represent a chain 
of events necessary to achieve ovulation and subsequent fertilisation (Eppig 
1979a; Salustri, Yanagishita et al. 1989; Chen, Russell et al. 1993; Handel and 
Eppig 1998). 
Mice from all three treatment groups were sacrificed 9 h after the second injection 
using asphyxiation by CO2 inhalation, followed by cervical dislocation. The 
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ovaries were harvested and prepared as described below, depending on the 
experimental protocol.  
 
 
 
 
 
Figure 2A: Timeline of mouse treatments 
 
 
 
 
 
 
 
 
Figure 2B: Mouse ovarian follicle classification chart based on the Petersen and 
                   Peters (1968) classification system   
 
 
  3a  
Follicular Type 
  3b    1    2    4a    4b    5b    6    5a    7  8 
Primordial Primary Secondary Preantral Antral 
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2.1.2.2  Ovarian collections for in situ hybridisation (ISH)  
 
All animals (n=36; 12 animals per treatment group over three separate 
experiments) were euthanised 9 h after the hCG/saline injection. The ovaries were 
dissected free of excess tissue, washed in cold PBS and collected into individual 
20 ml glass vials containing freshly made 4% (w/v) paraformaldehyde fixative.  
Each vial containing an ovary was labelled with the experimental number and 
animal ID. One ovary from each animal was processed for ISH (n=36 ovaries) and 
the other ovary (n=36 ovaries) for confocal immunohistochemistry. 
 
2.1.2.3  Ovarian collection and dissection for Western blotting 
 
For the Western blot sample collection, another three treatment groups of 
mice were set up, as described in section 2.1.2.1. It was established in a pilot 
study that the maximum amount of time between harvesting of ovaries and 
freezing the samples should not be more than 2 h, to ensure the quality/viability of 
the collected ovarian cells. The ovaries collected for ISH hybridisation were fixed 
immediately after euthanasia, so sample degradation was not an issue.  
To be able to adhere to the timeline for these studies, the superovulation treatment 
plan was modified slightly. One animal from each of the 3 treatment groups were 
injected every 2 hours. The first injection was administered at 10 pm on day 1 to 
one Group 1 (control), one Group 2 (PMSG only) and one Group 3 (PMSG+hCG) 
animal. The second animal from each treatment group received the first injection 
2 hours after this at 1 am. The third animal per group was injected at 3 am and the 
fourth animal at 5 am. The second injection followed 48 h later, where animals 
received their second treatment in the same order. All animals were euthanised 9 h 
after the second treatment, i.e. 57 h after the treatments commenced.  
 
The ovaries from each animal were washed and collected into PBS in labelled 1.7 
ml eppendorf tubes and transferred to the tissue culture laboratory on ice. On 
arrival they were dissected free of excess tissue under a dissecting microscope 
(Leica MZ95) and placed in clean 35x10 mm Petri dishes, containing PBS with 
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0.1% bovine serum albumin (BSA, ICPbio, Cat. No. ABRE-010). BSA was added 
to the PBS to prevent cells sticking to the plastic tube, thus leading to loss of 
sample. The ovaries were dissected individually, but the resulting samples were 
pooled for each individual animal and labelled accordingly. 
 
Each ovary was cut in half horizontally to facilitate the visualisation of follicles. 
All visible follicles were punctured with a 20G needle attached to a 3 ml syringe. 
A new needle was fitted for each ovary to minimise cross contamination and to 
ensure optimal sharpness of the needle to prevent tissue maceration. The somatic 
follicular cells and the oocyte were released from the follicles by gentle scraping 
with the needle and forceps. The depleted ovaries were discarded and the 
cumulus-enclosed oocytes were identified and separated from the somatic cells 
using a pulled glass pipette, attached to a mouthpiece through a 0.22 µm filter.  
Cumulus-oocyte complexes (COC) were then separated into denuded oocyte (DO) 
and cumulus cell (CC) fractions by gentle pipetting. Granulosa cells (GC) and CC 
were then pooled to give the somatic cell fraction. COC from large preovulatory 
follicles with expanded cumulus mass were incubated in hyaluronidase 
(HYASE™-10X, Vitrolife, Goteborg, Sweden) solution (10 IU in PBS), for up to 
2 min to dissociate the CC from the DO. The cells were washed once to remove 
the hyaluronidase before either being added to the somatic cell pool, or frozen 
down separately as a CC sample, depending on the planned experiment. The DO 
were rinsed and added to the DO sample pool. 
 
The somatic cells (i.e. the mixture of GC and CC) were transferred into 15 ml 
Falcon tubes, centrifuged at 453g for 5 min at 4°C, washed once in fresh 
PBS+0.1% BSA, pelleted again and then snap frozen on dry ice. The DO were 
counted, moved into sterile 1.7 ml eppendorf tubes and gently centrifuged at 200g 
for 5 min at 4°C. The supernatant was discarded and the DO were snap frozen on 
dry ice. The dissections resulted in 2 groups of samples: i) follicular somatic cells 
(pooled granulosa and cumulus cells) and a pool of denuded oocytes from each 
animal; and ii) an individual pool of CC and a DO from the same COC. All 
samples were stored at -80°C until analysis. 
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2.1.2.4  Ovarian collection and dissection for qPCR analysis 
 
The superovulation injection timetable was further modified for the qPCR 
sample collection experiments to allow for longer time intervals between 
individual animal treatments and dissections. The longer time allowance needed to 
accommodate the extended sample collection times was found to be necessary to 
ensure the purity of the samples collected for qPCR analyses. Group 1 and 2 
animals could be injected at the same time, but only one animal per group per day. 
Group 3 animals had to be treated and dissected individually, because of even 
longer sample collection time requirements, due to some of the oocytes having 
undergone germinal vesicle breakdown (GVBD) and cumulus mass expansion.  
 
The ovaries (n=6 from each treatment group) were collected, transported and 
prepared for dissection the same way as for the Western blot sample collection. 
The qPCR sample collection protocol described here was that described 
previously (Crawford and McNatty 2012). Follicles were punctured under a 
dissecting microscope (Leica MZ95) using a 20G needle. Intact, healthy-looking 
COC were pipetted one by one into individual wells of a 96 well plate, containing 
100 µl PBS/0.01% BSA. The COC were washed twice by moving them through 
two wells of the same 96 well plate, containing 100 µl fresh PBS/0.01% BSA. 
After washing, COC were placed in wells containing 10 µl PBS/0.01% BSA and 
photographed individually, using a DFK 41AF02 camera on a Leica DMI 4000B 
inverted fluorescent microscope, to assess the health of the COC. 
 
The oocytes were denuded of cumulus cells in the same well by pipetting them up 
and down gently, using a 2-10 µl Gilson pipette. The DO were put through two 
more wash wells, then pipetted into a new well and photographed again in 10 µl 
PBS/0.01% BSA to ensure that the oocyte remained undamaged during the 
denuding and wash steps. To avoid cross contamination between samples, a new 
sterile 10 µl pipette tip was used for each transfer. The 96 well plate was sealed 
and snap frozen on dry ice, then stored at -80°C until RNA extraction.  
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Some oocytes from large, preovulatory follicles collected from animals in Group 
3 (PMSG+hCG treated) had undergone germinal vesicle breakdown (GVBD) with 
expanded cumulus cell mass where others were GV oocytes with non-expanded 
cumulus mass. The COC containing GVBD oocytes were subjected to a brief 
enzymatic digestion step before the CC could be removed. Expanded COC were 
washed in PBS/0.01% BSA, then placed into wells of a 96 well plate containing 
10 µl PBS/0.01% BSA and photographed. Hyaluronidase solution (100 µl, 
HYASE™-10X, Vitrolife, Goteborg, Sweden) was added to the COC to aid the 
removal of the outer layer of CC. COC were incubated for up to 2 min in the 
solution, during which the outer cumulus layer was removed by gentle pipetting. 
The oocyte, surrounded by the corona radiata, was moved through two wash wells 
and then photographed before the oocyte was completely denuded in 10 µl 
PBS/0.01% BSA. After a further two wash steps, the DO was placed in a fresh 
well with 10 µl PBS/0.01% BSA and photographed. 
The used hyaluronidase solution, containing the cells from the outer cumulus 
layer, was transferred to sterile 0.65 ml eppendorf tubes. The cells were 
centrifuged at 150g and the pellet was resuspended in fresh PBS + BSA to remove 
the hyaluronidase. All samples were placed on dry ice to freeze down instantly. 
Thereafter the samples were stored at -80°C until RNA extraction.  
 
2.1.2.5  Collection of rat granulosa cells for methyl-3H-thymidine bioassay 
   
Granulosa cells (GC) and COC required for the methyl-3H-thymidine 
uptake assays were collected from 3 week-old (prepubertal) Sprague-Dawley rats. 
Animals (n=1 per experiment) were euthanised by asphyxiation, followed by 
cervical dislocation. Ovaries were removed and transported to the laboratory in 
PBS at room temperature. On arrival at the laboratory, the eppendorf tube 
containing the ovaries was incubated in a 37°C waterbath until dissection (< 1 
hour).  
The dissection medium, M199 (Sigma-Aldrich, Cat. No. M4530) supplemented 
with 100 IU Penicillin and 100 µg streptomycin (Pen Strep, Gibco by Life 
Technologies, Cat. No. 15070-063) per ml and 15 mM HEPES (Sigma-Aldrich, 
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Cat. No. H4034-100G), and cell culture medium (M199 with 1% PenStrep and no 
HEPES buffer) were also kept at 37°C to ensure the viability of the collected GC. 
 
Ovaries (n=2 per experiment) were washed in the dissection medium and 
dissected free of excess tissue under a dissection microscope (Leica MZ95). They 
were then placed in a new 35x10 mm petri dish (Biofil®, Cat. No. TCD000035) 
with the dissection medium, cut in half horizontally and all visible follicles were 
punctured with a 20G needle attached to a 3 ml syringe. GC and COC were 
released from the follicles by gentle scraping with the needle and forceps. The 
depleted ovaries were discarded and all visible COC were transferred into a new 
petri dish with fresh, warm dissection media, using a hand-pulled glass pipette, 
attached to a mouthpiece through a 0.22 µm filter. The COC were placed in the 
incubator until the GC were processed. 
 
All GC were pooled into a 15 ml Falcon tube and pelleted by centrifugation, using 
an Eppendorf 5810R centrifuge at 150g for 5 min at room temperature. The cells 
were washed once with culture medium, and resuspended in 1 ml of fresh media. 
An aliquot of 50 µl cell suspension was removed for cell counting and viability 
assessments, using a haemocytometer and Trypan blue exclusion. Cell 
concentration was established using the following formula: 
 
N = X * 25/Y * 104* V 
  
Where N = total cell number 
 X = number of cells counted under the haemocytometer 
 Y = number of squares counted on the haemocytometer 
 V= total volume of cell suspension (in this case 1 ml) 
 
Non-viable cells turn blue when adding Trypan blue to the suspension (5 µl 0.4% 
dye to 50 µl cell suspension), due to a compromised cell membrane being 
permeable to the dye. Live and dead (blue) cells were counted separately to 
calculate the viability percentage, to assess cell quality and the success of the 
dissection method. The cell suspension was diluted to a concentration of 1000 
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cells/µl and plated at 20,000 cells per well in 96 well plates (NUNC, Cat. No. 
167008). 
 
The COC were mechanically denuded en mass in the petri dish by manual 
pipetting repeatedly using a 50-200 µl Gilson pipette. The DO were used as one of 
the positive controls, by adding 32 DO to the GC culture wells. DO are known to 
stimulate methyl-3H-thymidine uptake by GC (Lin, Pitman-Crawford et al. 2012), 
thus providing positive proliferation measurements for the assay. 
 
2.2  Histology %
2.2.1  Fixation, tissue processing and sectioning 
 
Mouse ovaries collected for ISH and confocal microscopy were placed 
individually into fresh 4% paraformaldehyde fixative as described in section 
2.1.2.2, and processed in batches of 24 ovaries per experiment, 8 ovaries per 
treatment group.  The individually labelled vials were kept at 4°C for 24 h on a 
rotator (Stuart SB2 Rotator, Barloworld Scientific Limited, Stone, Staffordshire, 
UK). After 24 h in fixative, the paraformaldehyde was replaced with 70% ethanol 
in all vials and vials were rotated for 24 h at 4°C before replacing with fresh 70% 
ethanol for storage until processing. 
 
For processing, each ovary was placed into individual embedding cassettes 
(ProSciTech Pty Ltd, Cat. No. CASHD-05) and processed using the Leica TP1020 
automated tissue processor on Routine program consisting of 2 h in 70% ethanol, 
1.3 h in 80% ethanol, 2x 1 h in 95% ethanol, followed by 1.3 h in absolute ethanol 
and another 2x 1.15 h in absolute ethanol. Cassettes were placed in absolute 
ethanol/xylol for 1.3 h, and xylol for 2x 1 h. The program finished with 1.3 h in 
wax, then another 2 h in wax under vacuum. The processing was followed by 
paraffin embedding, using the Leica EG1160 embedder, and sectioning using a 
Leica RM2235 microtome. Each ovary was fully cut into 5 µm serial sections, 
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placing 2 sections onto each slide. The slides were stored at 4°C for either ISH or 
confocal microscopy. 
 
2.2.2  Haematoxylin and eosin (H&E) Staining 
 
Haematoxylin and eosin staining was carried out on every 10th slide of 
each ovary as a quality control for the tissue processing and sectioning, and to 
help identify suitable slides to use in ISH experiments (Fischer, Jacobson et al. 
2008; Gill 2010).  
The slides chosen for H&E staining were placed into staining racks and washed in 
xylol for 5 min to remove the paraffin from the sections. This was followed by 
two 5 min 100% and one 5 min 70% ethanol wash, and 5 min under running tap 
water to rehydrate the sections. 
 
The staining rack was transferred to a staining dish containing Gills haematoxylin 
stain (Sigma-Aldrich, Cat. No. GHS332-1L) for 5 min, followed by a quick wash 
in running tap water, 10 dips in acid alcohol reagent (see Appendix I.) and then 10 
min in running tap water. The slides were then placed in eosin stain (Sigma-
Aldrich, Cat. No. HT110132-1L) for 2 min, followed by ten quick dips in water, 
10 dips in 70% ethanol, a quick pass through 100% ethanol and 2 min in fresh 
100% ethanol to dehydrate the sections again. The process was finished with two 
5 min washes in xylol. After cover-slipping and sealing the sections with clear 
nail polish, they were viewed and photographed on a Leica DM6000B 
microscope, equipped with a Leica DFC490 camera.  
 
2.3  In Situ Hybridisation (ISH) 
 
The ISH method described here was modified from a protocol described 
previously (Tisdall, Hudson et al. 1994). 
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2.3.1  Mouse Bmp15 and Gdf9 DNA template preparation 
  
The DNA templates used to create riboprobes for the mouse Bmp15 
mature region and mouse Gdf9 mature region for the ISH experiments were full 
length mouse Bmp15 (accession number: AF082348.1) and mouse Gdf9 
(accession number: NH_008110.2) DNA samples, amplified from mouse ovarian 
cDNA, supplied by Adrian Bibby (VUW, Reproduction Group). The templates 
were diluted 1:10 with nuclease free water (UltraPure, Invitrogen, Cat. No. 10977-
015).  PCR amplification was performed using primers described in Table 2A.  
 
Initially samples were heated to 95°C for 2 min. This was followed by 35 cycles 
of denaturation (95°C, 20 s), annealing (60°C, 15 s) and elongation (72°C, 50 s), 
then an additional elongation step at the end of 35 cycles (72°C, 7 min).  Mouse 
Bmp15 and Gdf9 mature region size products were identified by electrophoresis of 
the PCR products on 1.5% agarose gel, using SYBR Green dye for detection. 
 
The correct size products encoding the mouse Bmp15 mature region and mouse 
Gdf9 mature region (374 and 404 bp respectively) were excised from the gel 
under a UV lamp and purified using the QIAQuick Gel Extraction kit (QIAGEN, 
Cat. No. 28704), according to the manufacturer’s instructions. The gel extracted 
DNA was ligated into pGEM-Teasy plasmid vector (Promega, Cat. No.A1360) by 
mixing 5 µl of 2x Ligase 10x buffer, 50 ng pGEM-Teasy plasmid vector, 3 µl gel 
extracted DNA and 1 µl T4 DNA Ligase, followed by 2 h incubation at room 
temperature. The ligation mix was used to transform TOP10 DH5α competent 
cells (Life Technologies, C4040-10) to amplify the available inserted DNA. DH5α 
cells were transformed with the DNA ligation mix for 30 min on ice, 2 min at 
37°C, followed by 2 min on ice. The transformed cells were left to recover in LB 
broth for 1 hour, then spread on ampicillin-LB agar plates (50 µg/ml), pre-soaked 
with 200 µl of 2% X-Gal in N, N dimethylformamide. The colonies containing the 
inserts were chosen using blue-white screening. White colonies containing the 
insert were picked and grown overnight in LB broth, then purified using QIAPrep 
Spin Miniprep kit (QIAGEN, Cat. No. 29106), as per the manufacturer’s 
instructions. The resulting products were verified by automated sequence analysis 
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(Waikato DNA Sequencing Facility, University of Waikato, Hamilton, New 
Zealand).   
 
 
Table 2A: Primers used in ISH probe DNA template generation 
 
Target gene Primer name Oligonucleotide 
sequence 
Nucleotide 
positions 
Predicted 
Annealing 
temperature 
(°C) 
Mouse Bmp15 
Forward primer 
mBMP15 mat CAAGCATGCA
GCATTGAATCT 
1045 - 1065 58.8 
Mouse Bmp15 
Reverse primer 
3’Xbal o15 mat GCTCTAGATTA
TCTACATGTAC
AGGACTG 
1402 - 1428 59.4 
Mouse Gdf9 
Forward primer 
mGDF9 mat GCAGAAAGCC
ATCCGCTC 
1041 - 1058 58.7 
Mouse Gdf9 
Reverse primer 
3’EcoRI m9 
mat 
GGAATTCCTAA
CGACAGGTGC
ACCTCGTAG 
1424 - 1451 64 
mat = mature sequence 
 
2.3.2  Riboprobe preparation 
 
The pGEM-Teasy plasmid vector contains RNA polymerase promoters T7 
and SP6, adjacent to multiple restriction enzyme cut sites (see Figure 2C). The 
miniprep-purified plasmid containing the inserted foreign DNA was linearised by 
digestion at 37 °C for 2 h, followed by 5 min at 65 °C with restriction enzymes 
SalI or NcoI for the mouse Bmp15 mature region sample and SalI or SphI for the 
mouse Gdf9 mature region sample. All linearised DNA samples were separated by 
electrophoresis on a 1.5% agarose gel with SYBR Green dye added for detection. 
The correct size bands were cut out under a UV lamp, followed by gel extraction 
(QIAquick® Gel Extraction kit, QIAGEN, Cat. No. 28704), before an aliquot of 
each sample was sent away for sequencing. Sequencing results confirmed that the 
Bmp15 mature insert was cloned into the pGEM-Teasy plasmid vector in reverse 
orientation, while the Gdf9 mature insert was in the forward orientation. This 
resulted in the Bmp15 sense probe being generated by linearising with digestion 
by NcoI and the use of a SP6 promoter, while linearisation with SalI and a T7 
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promoter generated an anti-sense probe using the Riboprobe combination system 
(Promega, PMP1460). The Gdf9 sense probe was generated by linearisation with 
SalI digestion enzyme and transcription from the T7 promoter, whilst the 
antisense probe was linearised with SphI and the SP6 promoter used to transcribe 
the DNA in RNA in the same system. The sense probes were used as negative 
controls to detect the extent of non-specific binding, whilst the antisense probes 
would bind specifically to the target messenger RNA on the tissue sections. The 
amount of DNA used to create each probe was 9-11 µg. 
 
The digestion enzyme SphI, used to linearise the Gdf9 antisense probe, is known 
to create 3’overhangs, which would inhibit the probe from being generated by 
preventing the reverse transcriptase from transcribing the RNA probe. For this 
reason the Gdf9 antisense probe had to be prepared using the Klenow procedure, 
whereas the rest of the probes were prepared using the standard procedure. For 
both procedures, the Promega Riboprobe in vitro Transcription Systems kit (Cat. 
No. P1460) was used. 
 
For probes prepared using the standard procedure, 4 µl 5xTranscription Buffer, 2 
µl 0.1 M DTT, 1 µl RNasin, 1 µl of each of 10 mM rATP, rCTP, rGTP and 0.8 µl 
rUTP (1:100) were mixed with 3.3 µl template linearised DNA, followed by 5 µl 
of [33P]-UTP (Perkin Elmer, Cat. No. NEG607H250UC) and 2 µl of either SP6 or 
T7 RNA polymerase (Promega). 
The Klenow procedure, used to prepare Gdf9 antisense probe, included a 15 min 
pre-incubation step at 22°C with the 5xTranscription Buffer, 0.1 M DTT, RNasin, 
1 µl Klenow enzyme (Promega, M220A) and the template linearised DNA, before 
adding the rATP, rCTP, rGTP, rUTP, the [33P]-UTP, and the RNA polymerase. 
From here on, all probes were treated the same way. After 1 h incubation at 37°C, 
1 µl of RQ1 Dnase was added, followed by a further 15 min incubation at 37°C, 
after which 4 µl 10 mg/ml tRNA, 12 µl 7.5 M ammonium acetate (pH7.0) and 80 
µl ice cold 100% ethanol were mixed into the probes. At this point, the probes 
were either placed on dry ice for 1 h, or left at -20°C overnight. 
Following this, the probes were centrifuged at 10000g for 20 min at 4°C and the 
resulting pellet was resuspended in 30 µl DEPC treated water. The probes then 
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received 15 µl of 7.5 M ammonium acetate and 90 µl ice cold 100% ethanol and 
placed on dry ice for 1 h. All samples were pelleted by centrifugation, dried and 
resuspended in 30 µl autoclaved DEPC treated water. 
Each probe (1µl) was mixed with 200 µl scintillation fluid (Beta Scint, Perkin 
Elmer, Cat. No. SC/9200.21) to determine the CPM (counts per minute), using a 
Wallac 1409 Liquid Scintillation Counter. 
 
 
 
   
 
Figure 2C: pGEM-Teasy plasmid vector map, showing restriction enzyme cut 
sites and RNA polymerase promoters utilised in generating ISH riboprobes  
 
 
 
2.3.3  Preparing tissue sections for ISH 
 
 The sections used for ISH were chosen from the paraffin embedded and 
sectioned (5 µm) mouse ovaries collected and processed as described in section 
2.1.2.2. Care was taken to choose sections where all ovarian cell types were 
represented in a wide range of follicle sizes. 
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The slides underwent deparaffinisation using xylol, rehydration in a series of 
ethanol (100%, 95% and 70%) washes, followed by DEPC-water treatment. 
After rehydration, a pretreatment was carried out to remove all positive protein 
charges that could affect probe binding. The pretreatment included a 20 min 0.2 
M HCl wash, two 30 min washes in 2xSSC buffer, and Proteinase K digestion 
for 5 min at 37ºC.  
 
The pretreatment was followed by acetylation to reduce non-specific binding of 
the probes. This was achieved by pipetting 250 µl of acetic anhydride onto the 
sections and incubating the slides for 5 min in 0.1 M triethanolamine. This 
process was repeated once more, and the slides were then washed in 2xSSC 
buffer for 5 min. 
 
Following acetylation, the sections were dehydrated in a series of 5 min ethanol 
washes, starting with 70% ethanol, followed by 95% and two 100% ethanol 
washes. The slides were then air dried before ISH. 
 
2.3.4  ISH and post hybridisation treatment 
 
The probes were diluted with hybridisation mix to give 45000 cpm/µl. 
 
Diluting the probes to the required volume was calculated by the formula: 
 
X =  45000 x V 
              M 
 
where  X = total volume of probe 
            V = Volume required (number of small sections x 40 µl + number of           
large sections x 70µl) 
            M = measured cpm/µl probe 
Either 40 or 70µl of diluted probes (45000 cpm/µm2) were added to each section, 
depending on the size of the coverslip needed to cover the section. The pretreated 
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5 µm tissue sections were incubated overnight at 55°C with the 33P-labelled 
antisense/sense riboprobes in a humidified chamber, to prevent evaporation.  
Following incubation, the slides were washed 2x 15 min in 5xSSC/DEPC solution 
at 50°C during which the coverslips were removed. This was followed by a 30 
min wash in 2xSSC/50% formamide/DEPC at 65°C and 4x 5 min washes in 2x 
SSC/DEPC at 37°C. Non-hybridised RNA was removed by RNaseA digestion at 
37°C for 30 min, and a series of washes (2×SSC/50% formamide at 65°C for 30 
min, 2 × SSC/MQ water at 37°C for 15 min and 0.2xSSC/MQ water at 37°C for 
15 min). Sections were then dehydrated, air dried and coated with 
autoradiographic silver emulsion (LM-1 emulsion; GE biosciences) in the 
darkroom. The emulsion coated slides were dried overnight and then incubated at 
4°C for 1 week. 
 
2.3.5  Development 
 
After the week-long exposure, the slides were developed in the dark room 
for 3.5 min in Ilford developer solution (Ilford Ltd). Development was stopped by 
1 min incubation in 1% acetic acid and slides were fixed after 10 min incubation 
in Ilfofix II (Ilford Ltd) and washed for 1 h under running tap water.  
The sections were stained with Gills haematoxylin and exposed for 1 min to 
Scott’s tap water (see Appendix I.) before being dehydrated as described 
previously in section 2.3.3. Subsequently, the sections were coverslipped, viewed 
and photographed using both light and dark field illumination on a Leica 
DM6000B microscope, equipped with a Leica DFC490 camera. 
 
2.4  Western blotting procedure 
2.4.1  SDS-PAGE gel preparation 
 
The polyacrylamide gels were prepared in various concentrations, depending on 
the size of the protein(s) of interest to be detected. The exact reagent amounts for 
2 separating and 4 stacking gels are listed in Tables 2B and 2C. Gels were 
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prepared using the Mini-Protean Tetra Cell apparatus (Bio-Rad Laboratories (New 
Zealand) Pty Ltd,Albany, Auckland, NZ, Cat. No. 165-8000).  
The separating gel ingredients were combined and gently layered in glass casts 
secured on stands. They were left to polymerase for 2-4 h, with water layered on 
top to prevent the gel from drying out. After polymerisation was complete, the 
water was removed from the top of the gel and a stacking gel was layered on top. 
A gel comb (10 or 15 well depending on the sample volume to be loaded onto the 
gel) was inserted into the stacking gel layer. Once the stacking gel was 
polymerised, the SDS-PAGE gels were removed from the stand and either stored 
wrapped in wet paper towels in a zip lock bag at 4˚C, or used straight away. 
 
 
Table 2B: Separating gel reagents (see Appendix I. for recipes of stock solutions 
and suppliers of reagents) 
 
Reagents 7.5% 
Separating gel 
10% 
Separating gel 
13.5% 
Separating gel 
Distilled water 4.88 ml 4 ml 2.88 ml 
0.5M Tris-HCl pH6.8 2.5 ml 2.5 ml 2.5 ml 
Bis-acrylamide (30%) 2.5 ml 3.35 ml 4.5 ml 
10% (w/v) SDS 100 µl 100 µl 100 µl 
10%(w/v) ammonium 
persulphate 
50 µl 50 µl 50 µl 
TEMED 5 µl 5 µl 5 µl 
 
 
 
Table 2C: Stacking gel reagents (see Appendix I. for recipes of stock solutions 
and suppliers of reagents) 
 
Reagents 4% 
Stacking gel 
Distilled water 3.0 ml 
0.5M Tris-HCl pH6.8 1.25 ml 
Bis-acrylamide (30%) 0.65 ml 
10% (w/v) SDS 50 µl 
10%(w/v) ammonium 
persulphate 
25 µl 
TEMED 5 µl 
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2.4.2  Sample preparation 
 
The amount of sample able to be loaded onto the gel depended on the well 
size. The 10 well gels held up to 25 µl sample per well, the 15 well gels held up to 
15 µl sample per well. In experiments where HEK 293 cell-derived media 
samples were tested, the sample amount was kept constant between all wells 
within each Western blot. Equal amounts of samples were mixed with 5x loading 
dye (see Appendix I) and incubated at 95°C for 5 min before being loaded onto 
the gel. All Western blot assays were run under reducing conditions, with the 
loading dye containing 1.08% w/v DTT. 
When testing cell lysates, it was important to be able to load the entire sample 
from the individual animals or from groups of animals within a treatment group 
into individual wells. The ovarian somatic cell (GC/CC) or oocyte pellets 
collected in various experiments were stored frozen at -80°C in eppendorf tubes. 
On the day of the analysis, samples were quickly thawed and 15 µl RIPA lysis 
buffer (see Appendix I.) was added. The samples were mixed by vortexing, briefly 
spun down and snap-frozen on dry ice. The freeze/thawing was repeated 3 times 
in quick succession to aid sample lysis. Sample aliquots (5 µl) were then removed 
from all GC/CC cell lysates for BCA protein quantification assay (see paragraph 
2.4.8) to measure the exact amount of protein loaded per well. This information 
was used only to ensure that samples with similar protein content were analysed 
on the same gel, not for standardisation of loaded sample amounts. The sample 
portion not used for BCA assay (10 µl) received the 5x loading dye, was mixed 
and incubated at 95°C for 5 min, then loaded onto the gel. The oocyte lysate 
samples were prepared the same way as the GC/CC samples, but without protein 
quantification due to very limited sample amounts. Instead, the number of oocytes 
loaded per well was recorded at collection and was kept as similar as possible 
between the wells.  
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2.4.3  Protein separation by electrophoresis 
 
The prepared samples and the molecular ladder (BioRad, Cat. No. 161-
0305) were loaded onto the SDS-PAGE gels, secured in a Mini-Protean Tetra Cell 
running cassette. The cassette was filled with SDS-PAGE running buffer (see 
Appendix I.) according to the manufacturer’s instructions, and gel electrophoresis 
carried out at 150 V for 1-1.5 h, depending on the size of the proteins separated 
out on the gels. 
 
2.4.4  Protein transfer to nitrocellulose membrane 
 
After the different-sized protein bands in the samples were separated out 
on the gel by electrophoresis, the protein bands were transferred to nitrocellulose 
membranes (Amersham Biosciences, Hybond™–C Extra, Cat. No. RPN303E). 
 
For preparation of the protein transfer cassette, a tray filled with transfer buffer 
(see Appendix I) was used to prevent the gel and the nitrocellulose membrane 
from drying out. The black (negative charge) side of the transfer cassette was 
placed onto the bottom of the tray and a scotch pad and a piece of blotting paper 
was layered onto it. Care was taken that no air bubbles remained trapped between 
the layers.   
At the completion of the electrophoresis step, the gel was removed from the 
running cassette. The top glass plate (cover) was removed and the stacking gel 
was scraped off the top of the separating gel. The separating gel was carefully 
removed from the bottom glass plate and placed on top of the transfer blotting 
paper.  
A piece of nitrocellulose membrane pre-wetted in transfer buffer was placed on 
top of the gel and once again air bubbles were pressed out gently from between 
the layers using a roller. Another piece of blotting paper was placed on top of the 
membrane, followed by a scotch pad. Air bubbles were removed, and the transfer 
cassette was locked tightly with the white (positive charge) side of the transfer 
cassette, creating a ‘sandwich’. The ‘transfer sandwich’ was placed in a transfer 
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stand with an ice pack and magnetic stirbar, and filled with transfer buffer. The 
protein transfer was carried out at 4°C for 1 h at 100 V.  
 
To prove the transfer had been successful, the nitrocellulose membrane was 
stained with Ponceau S stain (see Appendix I.) for 1 min, and then rinsed briefly 
with distilled water until only the protein bands and the molecular ladder was 
visible. The molecular ladder bands were marked with pencil, along with the 
positions of the wells on the membrane. The stain was then fully washed out of 
the membrane by repeatedly rinsing with distilled water. 
 
2.4.5  Detection by immunoblotting 
 
The nitrocellulose membrane was placed in a plastic 100 x 100 mm square 
Petri dish (ThermoFisher Scientific, LabServe Cat. No. LBS60020) containing 5% 
milk powder blotto solution (5% blotto, see Appendix I) and incubated for 1 h at 
room temperature on a mixing platform (Labnet ORBIT LS, Total Lab Systems 
Ltd, Cat. No. S 2030-L S-230V) set at 60 rpm, to prevent non-specific binding of 
the antibody. 
After 1 h, the blocking solution was replaced with the primary antibody, diluted to 
1 µg/ml in 12 ml of 5% blotto, and the membrane was incubated overnight at 
room temperature with continuous agitation. 
The following day, the membrane was washed 3x 10 min in a low salt Tris wash 
buffer (see Appendix I) and then the secondary antibody solution was diluted 
1:3000 with 5% blotto and added to the membranes. Following a 2 h incubation at 
room temperature with the secondary antibody, the membranes were washed 3x 
10 min in low salt Tris wash buffer and developed. The primary and secondary 
antibody combinations used to detect different forms of mouse BMP15 and GDF9 
proteins are listed in Table 2D. 
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Table 2D: Primary and secondary antibodies used in Western blot experiments 
and target protein sizes  
 
Target protein 
(size) 
Primary antibody Secondary antibody 
mBMP15 mature 
region 
(17-20 kDa) 
A20 – anti-human BMP15 mature goat 
polyclonal IgG 
[Santa Cruz, Cat. No. sc-18337] 
Rabbit anti-goat IgG-HRP 
[Santa Cruz, Cat. No. sc-2768] 
mBMP15 
proregion 
(40 kDa) 
8f – anti-mouse BMP15 proregion 
mouse polyclonal ab 
[in house,(McIntosh, Lun et al. 2008)] 
Rabbit anti-mouse-HRP 
[Abacus, Cat. No. 315-035-045] 
mBMP15 
promature 
(55-60 kDa) 
8f – anti-mouse BMP15 proregion 
mouse polyclonal ab 
[in house] 
Rabbit anti-mouse-HRP 
[Abacus] 
mGDF9 mature 
region 
(19-22 kDa) 
47b – anti-sheep/mouse GDF9 mature 
mouse monoclonal ab [provided by Dr 
Nigel Groome, Oxford Brookes 
University, Oxford, U.K.] 
Rabbit anti-mouse-HRP 
[Abacus] 
mGDF9 proregion 
(40 kDa) 
4e – anti mouse GDF9 proregion mouse 
polyclonal ab 
[in house,(McIntosh, Lun et al. 2008)] 
Rabbit anti-mouse-HRP 
[Abacus] 
mGDF9 promature 
(55-60 kDa) 
4e – anti-mouse GDF9 proregion mouse 
polyclonal ab 
[in house] 
Rabbit anti-mouse-HRP 
[Abacus] 
 
 
2.4.6  Visualisation with Enhanced Chemiluminescence 
 
The immunoblot membrane was transported to the dark room in the low 
salt Tris wash buffer. Enhanced chemiluminesence (ECL) solutions were prepared 
fresh (see Appendix I) and mixed immediately before pipetting onto the 
membrane. After 1 min incubation with the ECL solution, the membrane was 
wrapped in clear plastic film, secured onto a developing cassette with masking 
tape and X-ray film (Kodak) was placed on top of it. A series of exposures using 
different pieces of film were carried out during each development, ranging from 
10 s to 10 min. The X-ray films were developed for 3 min in Kodak GBX 
developer and replenisher (Cat. No. 403 7180), followed by 1 min in water, 3 min 
in Kodak GBX fixer and replenisher (Cat. No. 403 7214) and then another 1 min 
wash in water. The dried film was aligned onto the membrane to mark the 
positions of the ladder bands and the wells. 
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Membranes were stored in sealed plastic boxes containing PBS with 0.05% (w/v) 
sodium-azide at 4°C, until being used for preadsorption experiments to measure 
specificity of the protein bands. 
 
2.4.7  Antibody preadsorption 
 
To validate the results of Western blot experiments, immunoblotted 
antibodies were stripped from the membranes after development and the 
immunoblotting detection repeated using a preadsorbed primary antibody 
solution.  
For stripping, the membrane was first placed into pre-warmed 62.5 mM Tris-HCl 
/2% SDS stripping buffer, containing 0.7% ß-mercaptoethanol (see Appendix I.) 
and incubated at 50°C for 30 min. Following incubation, the membrane was 
rinsed three times with large amounts of PBS to remove all traces of the stripping 
buffer. The membrane was then placed in a clean plastic dish and washed 3x 10 
min in the low salt Tris wash buffer. 
The preadsorbed primary antibody solution was prepared the day before by 
incubating the same amount of antibody as used in the original Western blot with 
10 times as much blocking peptide or protein in 1 ml PBS rotating at 4°C. 
Following the wash steps, the membrane was blocked for 1 h at room temperature 
with 5% blotto solution. The preadsorbed primary antibody was centrifuged for 10 
m at 13000g, the cleared supernatant diluted to 12 ml with 5% blotto, poured onto 
the membrane and left to incubate overnight at room temperature with continuous 
agitation. The following day, membrane washing, incubation with the secondary 
antibody and the ECL development was carried out as in the original Western blot 
assay, described in sections 2.4.5 and 2.4.6. Protein bands were regarded as 
specific if they were detected in the original Western blot experiment but were not 
present on the X-ray film following incubation with the preadsorbed primary 
antibody. 
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2.4.8  Bicinchononic (BCA) Protein Quantification assay     
 
The Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Cat. No. 
23227) was used as per the manufacturer’s protocol, to quantify the amount of 
protein loaded onto the SDS-PAGE gels when analysing somatic follicular cell 
(GC/CC) lysates.  
This assay utilizes the reduction of Cu2+ to Cu+ by proteins in an alkaline solution, 
then detecting Cu+ by bicinchononic acid (BCA) in a colorimetric reaction at 562 
nm. The colour change was measured by a VICTOR3 PerkinElmer 1420 
Multilabel Counter. The unknown protein concentrations were estimated from a 
standard curve, created by plotting the net absorbance of BSA protein standards, 
prepared from stock solutions contained in the kit. 
 
2.5  Quantitative PCR (qPCR) %
2.5.1  RNA extraction and cDNA synthesis 
 
Cumulus cell (CC) and denuded oocyte (DO) samples were collected for 
qPCR analyses as described in section 2.1.2.4. The samples were stored frozen at  
-80°C in 96 well plates and 0.65 ml eppendorf tubes. RNA extraction was carried 
out on individual DO and on the corresponding CC using the ArrayPure™ Nano-
scale RNA purification kit (EPICENTRE Biotechnologies, MPS04050, 
Wisconsin, USA). The procedure involved mixing the samples with 30 µl nano-
scale lysis buffer containing 1 µl Proteinase K. After mixing thoroughly by 
pipetting or vortexing, the samples stored in 96 well plates were transferred into 
sterile eppendorf tubes and all samples were incubated for 15 min at 65°C, 
followed by 5 min on ice. After the incubation period, all samples received 18 µl 
of 5 M ammonium acetate solution (MPC Protein Precipitation Reagent, 
ArrayPure kit). The samples were mixed and centrifuged at 12,000g for 7 min at 
4°C. The supernatants were transferred into sterile eppendorf tubes and pellets 
were discarded. Total RNA was precipitated from the supernatant by mixing in 50 
µl of isopropanol (Global Science, Cat. No. APPA39281000PE) and 
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centrifugation at 12,000g for 5 min at 4°C. The supernatants were discarded and 
the RNA pellets were air dried for 5 min before resuspended in DNase solution 
(0.5 µl RNase free DNase I in 20 µl of 1xDNase buffer per sample, ArrayPure 
kit), used to remove DNA contamination. The samples were incubated with the 
DNase solution at 37°C for 30 min. Following the incubation, 20 µl of 2x nano-
scale lysis solution (ArrayPure kit) was added to the samples and mixed by 
vortexing. Any remaining protein contaminant was removed by the addition of 20 
µl of MPC Protein Precipitation Reagent. The samples were vortexed vigorously, 
and cooled down for 5 min on ice before centrifuging for 5 min at 12,000g at 4°C. 
The supernatants were then transferred to sterile eppendorf tubes and total RNA 
was precipitated with 50 µl of isopropanol and centrifugation for 5 min at 12,000g 
at 4°C. The supernatants were discarded and the RNA pellets were washed once 
with 50 µl of 70% ethanol diluted from 100% analytical grade ethanol (Sigma-
Aldrich, Cat. No. 24106) with DEPC (Sigma-Aldrich, Cat. No. 40718) treated 
water. The samples were once more centrifuged for 3 min at 12,000g at 4°C, and 
then the ethanol was aspirated from the pellets. The RNA pellets were air dried for 
5 min and resuspended in 10 µl of ultra-pure water. Incubation at 55°C for 2 min 
helped to dissolve the RNA. The samples were either used for cDNA synthesis 
immediately or stored at -80°C. 
 
Synthesis of cDNA was carried out using the Superscript® VILO™ cDNA 
synthesis kit (Cat. No. 11754-050, Invitrogen, CA, USA). Each tube of 10 µl 
RNA sample, to be reverse-transcribed to cDNA, was mixed with 4 µl of VILO™ 
reaction mix, 2 µl of 10x Superscript® Enzyme Mix and 4 µl of ultra-pure water. 
After mixing the samples thoroughly, the cDNA synthesis was carried out using a 
Rotor-Gene™ 6000 Rotary Analyser (Corbett Research Ltd). The program used 
incubated the samples at 25°C for 10 min, followed by 1 h at 42°C and 5 min at 
85°C. In each cDNA synthesis run, one No-RT PCR control sample was included: 
this sample did not receive the 10x Superscript® Enzyme Mix and was included 
in the qPCR to monitor potential genomic DNA contamination in the samples. All 
cDNA samples were stored at -20°C until qPCR analyses. 
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2.5.2  Quantitative PCR %
2.5.2.1  Primer and TaqMan Probe optimisation 
 
The methods used to optimise conditions for quantitative PCR analysis 
were described by(Crawford and McNatty 2012.)The primers and TaqMan 
probes, listed in Table 2E, were designed using the ‘Beacon Designer’ computer 
software package (Premier Biosoft International, Palo Alto, CA, USA) and were 
based on sequences obtained from NCBI (National Center for Biotechnology 
Information). 
 
A range of cDNA template and primer concentrations were tested in singleplex 
(measuring mRNA expression of a single gene) reactions, using the SYBR® 
Green system (Agilent Technologies, USA, Cat. No. 600548). SYBR® Green I is 
a DNA binding dye, emitting strong green (~520nm) fluorescence when bound to 
double-stranded (ds), rather than single-stranded DNA. During the annealing step 
of the qPCR reaction when dsDNA is synthesised with the aid of the primers, 
SYBR® Green I fluorescence intensity increases in a linear fashion as the PCR 
product is amplified over a number of cycles. The cycle number where the 
fluorescence intensity becomes significant above the background is the cycle 
threshold (CT). The CT value depends on the initial concentration of the target 
DNA in the sample and is inversely proportional to the log concentration of the 
original template. This means that the higher the original template concentration 
the lower the CT value. The CT values are measured in the exponential part of the 
PCR amplification curve, before the limited reagent amounts could influence the 
efficiency of the amplification (Brilliant SYBR® Green qPCR, Instruction 
Manual, Agilent Technologies). 
 
The optimal template concentration was deemed to be 1.56 µl cDNA per reaction, 
since this resulted in CT values within the measurable range (15-26). The optimal 
primer concentrations are listed in Table 2E. 
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Briefly, cDNA template and forward and reverse primers were pipetted into 0.2 
ml microtubes as a singleplex reaction for each gene. They were mixed with 26 µl 
of 2x Brilliant® Green qPCR Master Mix (Agilent Technologies, Cat. No. 
600548). Ultra-pure water was used to bring the final volume to 52 µl. After 
mixing the samples thoroughly, they were split into two 25 µl aliquots and 
transferred into capped 0.1 ml strip-tubes (Corbett Research, Mortlake, NSW, 
Australia). The Rotor-Gene™ 6000 Rotary Analyser (Corbett Research Ltd) was 
used to amplify the DNA using a program set to heat samples to 95°C for 10 min, 
followed by 40 cycles of 15 s at 95°C and 60 s at 58°C. Results were analysed 
using the Corbett Rotor-Gene 6000 Series Software 1.7. 
 
Multiplex PCR reactions, capable of measuring mRNA expression levels of 
multiple genes at the same time, utilised TaqMan probes labelled with spectrally 
distant fluorescent molecules (fluorophores) and quenchers. During the annealing 
step, when the probe attaches to the target, the DNA polymerase separates the 
quencher from the fluorophore. This results in the fluorophore emitting a 
fluorescence signal, which is monitored in real time in a linear fashion. The 
resulting CT value can be used to calculate the original concentration of the target 
gene in the sample. Using fluorophores with spectrally distant emission peaks 
allows the detection of multiple genes in a single reaction (Brilliant Multiplex 
qPCR Master Mix, Instruction Manual, Agilent Technologies). The reagents used 
in the TaqMan multiplex reactions were supplied as part of the Brilliant Multiplex 
qPCR Master kit (Stratagene, La Jolla, CA, USA). 
The primers and Taqman probes for mouse Bmp15 (accession number: 
AF082348.1), mouse Gdf9 (accession number: NH_008110.2) and the reference 
gene mouse Rpl19 (accession number: BC092539.1) were purchased from 
Invitrogen and Sigma-Proligo respectively (Invitrogen™ NZ Ltd., Auckland 
1006, New Zealand; Proligo-France SAS 1, Paris, France and Proligo-Singapore 
Pte Ltd, Helios, Singapore). Rpl19, encoding ribosomal protein 19, was shown to 
be a suitable reference gene in quantifying ovarian gene expression (Crawford and 
McNatty 2012). 
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Table 2E: Primers, Taqman probes and final concentrations for use in multiplex  
                 qPCR reactions  
 
Gene Primers (forward and reverse) and Taqman probes (P, 5’-3’) Conc. 
(nM) 
mBmp15 
(proregion 
577-676) 
Fwd:  GTACAGACCCTGGACTTTCCTC  (577-598) 
Rev:  GGTAATTAACTAGATGAAGTTGATGGC  (650-676)       (607-640) 
P:   (HEX)AACCAGGTAGCATACGAACTAATCAGAGCCACTG(BHQ1) 
200 
300 
50 
mGdf9 
(proregion 
585-713) 
Fwd:  ATCGGTCTTGCTATACACTCTGAA (585-608) 
Rev:  GTGAATGAGTACGGTGCTCTTG  (692-713) 
P:   (6FAM)TCTGCCTCTTCCTCCTCCACTGTGACCT(BHQ1) (613-640) 
300 
200 
50 
mRpl19 
(141-281) 
Fwd:  CAGGAAGCTGATCAAGGATGGG (141-162) 
Rev:  CGAGCATTGGCAGTACCCTTC (261-281) 
P:   (Cy5)CATCCGCAAGCCTGTGACTGTCCATTCC(BHQ3) (168-195) 
200 
200 
50 
HEX, 6FAM and Cy5 are fluorophores and BHQ1 and BHQ3 are quenchers. Numbers in brackets 
refer to the nucleotide positions. 
   
2.5.2.2  Multiplex qPCR reaction efficiencies 
 
Before the samples were analysed in the multiplex qPCR, it was of 
importance to determine the PCR reaction efficiency for each gene.  
Serial dilutions of mouse COC-derived cDNA samples were prepared with ultra-
pure water, ranging from undiluted to 1:128 and these were tested first in 
singleplex, then duplex and finally in triplex reactions.  
Briefly, the reaction mixes were prepared in 0.2 ml microtubes by mixing the 
primers and TaqMan probes in the optimal concentrations, followed by the 
addition of 26 µl of 2x Brilliant® Multiplex qPCR Master Mix (Agilent 
Technologies), 3.12 µl (2x 1.56 µl) of cDNA and ultra-pure water to bring the 
final sample volume 52 µl. After thorough mixing, the samples were split into two 
25 µl duplicates in 0.1 ml strip-tubes (Corbett Research) and capped. The PCR 
amplification was carried out using the Rotor-Gene™ 6000 Rotary Analyser 
(Corbett Research Ltd) running the program described in paragraph 2.5.2.1. 
 
The amplification efficiencies were calculated by determining the line of best fit 
(slope ±0.1) for each gene, when CT values were plotted against the log 
concentration of total input RNA. The amplification efficiencies in the triplex 
reaction were 93%, 91% and 95% for the mGdf9, mBmp15 and mRpl19 genes 
respectively. 
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2.5.2.3  Quantification of gene expression by multiplex qPCR  
 
  All denuded oocyte (DO) and cumulus cell (CC) samples collected for 
qPCR analyses were tested for the expression levels of mBmp15, mGdf9 and the 
housekeeping gene mRpl19. 
The reaction mixes were prepared in 0.2 ml microtubes, by mixing the 3 sets of 
primers and the probes at the optimal concentration with 26 µl of 2x Brilliant® 
Multiplex qPCR Master Mix (Agilent Technologies), 3.12 µl of cDNA template 
and ultra-pure water to make a final sample volume of 52 µl. The reaction mixes 
were split into two 25 µl aliquots in 0.1 ml strip-tubes (Corbett Research). The 
PCR amplification was carried out using the Rotor-Gene™ 6000 Rotary Analyser 
using the same program settings described in paragraph 2.1.2.1.  
Each sample was analysed twice in separate qPCR runs and the CT value for each 
sample was calculated as the mean of the two technical repeats. 
In each qPCR run, the No-RT PCR controls were included to show the 
effectiveness of the DNase treatment during RNA extraction. Calibrator controls 
were also used at the beginning and end of each run. These samples were aliquots 
of the same cDNA sample used throughout the entire experiment, with known CT 
values, to show the reproducibility and the stability of the multiplex qPCR runs.  
 
The CT values of the target genes mBmp15 and mGdf9 were normalised to the CT 
values of the reference gene mRpl19. The CT values for the reference gene 
mRpl19 were also used to determine whether the sample had enough RNA for the 
quantification of gene expression levels. Samples with an mRpl19 CT value >30 
were excluded from further analysis. Moreover, in cases where photographic 
evidence showed damage to the oocyte during sample collection, both the isolated 
CC and associated oocytes were excluded from analyses. 
Expression levels of the target genes were calculated using a method described by 
Livak et al, 2001 (Livak and Schmittgen 2001), namely the 2(-Delta Delta C(T)) 
method. This method calculates relative changes in the target gene expression 
during qPCR analysis. The CT values of the target genes were normalised to the 
CT value of the reference gene, resulting in ∆CT values for each sample. ∆∆CT 
were calculated by normalising ∆CT values to the mean ∆CT value measured in 
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samples collected from control animals (Group 1 - see section 2.1.2.1. for 
treatment details). These values were converted to linear values for statistical 
analysis, using the formula 2-(∆∆CT). Standard errors of mean (SEM) were 
calculated by formula 2-(mean∆∆CT±StDev), where StDev stands for standard deviation. 
 
The ratio of mRNA expression levels of the two target genes mBmp15 and mGdf9 
were established using the formula 2-(mGdf9CT –mBmp15 CT). The line of best fit was 
generated from the plot of linear regression of the CT values of the two target 
genes, to calculate the correlation coefficients (R2). The closer the R2 value is to 1, 
the stronger the correlation between the two genes. 
 
2.6  Generating non-cleavable forms of mouse BMP15 and GDF9 proproteins 
 
Human embryonic kidney (HEK) cells (originally gifted by Professor Olli 
Ritvos, Helsinki, Finland) were stably transfected with plasmid constructs 
containing full-length sequences of mouse Bmp15 and Gdf9 mutated at the 
proregion-mature region cleavage site with the aim of expression of non-cleavable 
precursor forms of mouse BMP15 and mouse GDF9 proteins.  
 
2.6.1  Designing the non-cleavable gene constructs 
 
The non-cleavable forms of the target proteins were designed with mutated 
putative furin cleavage sites, in order to prevent the enzyme from recognising and 
releasing the mature protein from the full-length precursor promature protein. 
The mBMP15 protein cleavage site, RSVR and the mGDF9 cleavage site, RRRR 
were both modified to QXXQ, where X was kept to the original amino acid in the 
wild-type sequence. A protein and base substitution table was used to design the 
mutated mBmp15 and mGdf9 cleavage site sequences (see Table 2F). The guanine 
to adenine base substitution in the coding sequences of both gene cleavage sites 
was chosen because of its perceived minimal impact on protein structure. In both 
cases the base substitution caused peptide change from arginine to glutamine, thus 
keeping the same charge and polarity.  
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Table 2F:  mBmp15 and mGdf9 sequences, with mutated cleavage sites  
       highlighted in bold, and base substitutions highlighted in red 
 
mBmp15  
(1209 bp) 
sequence: 
 
GAGCTCCCGCTCGAGCTTTGCAAGATGGCCCTTCTCACAATTCTTAGAAT
TCTTTTGTGGGGAGTGGTGCTTTTTATGGAACAGAGGGTCCAAATGGCA
AAGCCAGGGTGGCCCTCCACCGCCCTCCTTGCTGACGACCCTACATTGC
CCTCAATTTTGGATCTGGCCAAAGAAGCCCCTGGCAAGGAGATGAAGCA
ATGGCCCCAAGGCTATCCCCTGAGGTACATGCTCAAGTTATACCATCGT
TCGGCTGACCCGCATGGCCATCCAAGGGAGAACCGCACGATTGGAGCG
AAAATGGTGAGGCTGGTAAAGCCGTCGGCCAACACAGTAAGGCCTCCC
AGAGGTTCCTGGCATGTACAGACCCTGGACTTTCCTCTAGCATCAAACC
AGGTAGCATACGAACTAATCAGAGCCACTGTGGTTTACCGCCATCAACT
TCATCTAGTTAATTACCATCTCTCCTGCCATGTGGAAACTTGGGTTCCTA
AATGCCGGACCAAGCACTTACCTTCTTCTAAATCGGGTTCCTCAAAGCCT
TCTCCCATGTCTAAAGCCTGGACAGAGATAGATATTACACATTGTATTC
AGCAGAAGCTCTGGAATCGCAAGGGACGGAGTGTTCTTCGCCTCCGCTT
CATGTGTCAGCAGCAAAAAGGCAATGAGACTCGTGAGTTCCGGTGGCAT
GGCATGACATCCTTGGATGTTGCCTTCTTGCTACTCTATTTCAATGACAC
CGATGACAGAGTTCAGGGTAAACTTCTTGCAAGAGGCCAAGAGGAGTT
AACTGATAGGGAATCTTCTTTTCTCATGCAGAGTGTCCAGCAAGCATGC
AGCATTGAATCTGATGCCTCTTGTCCTTCTCAGGAACATGATGGGTCTGT
AAATAACCAGTGTTCCCTCCATCCTTACAAGGTCAGCTTCCACCAACTA
GGCTGGGATCACTGGATCATTGCTCCTCGTCTCTATACCCCAAATTACTG
TAAAGGAATCTGTACTCGGGTATTACCCTATGGTCTCAATTCACCCAACC
ATGCCATCATTCAGAGCCTTGTCAATGAACTAGTGAATCACAGTGTACC
TCAGCCTTCCTGTGTCCCTTATAATTTTCTTCCTATGAGCATCCTCCTGAT
TGAGACCAACGGGAGTATCTTGTACAAGGAGTATGAGGGTATGATTGCC
CAGTCCTGTACATGTAGATAATCTAGA 
mGdf9 
(1350 bp) 
sequence: 
 
CCGCTCGAGTCCCAAGTCATGGCACTTCCCAGCAACTTCCTGTTGGGGG
TTTGCTGCTTTGCCTGGCTGTGTTTTCTTAGTAGCCTTAGCTCTCAGGCTT
CTACTGAAGAATCCCAGAGTGGAGCCAGTGAAAATGTGGAGTCTGAGG
CAGACCCCTGGTCCTTGCTGCTGCCTGTAGATGGGACTGACAGGTCTGG
CCTCTTGCCCCCCCTCTTTAAGGTTCTATCTGATAGGCGAGGTGAGACCC
CTAAGCTGCAGCCTGACTCCAGAGCACTCTACTACATGAAAAAGCTCTA
TAAGACGTATGCTACCAAAGAGGGGGTTCCCAAACCCAGCAGAAGTCA
CCTCTACAATACCGTCCGGCTCTTCAGTCCCTGTGCCCAGCAAGAGCAG
GCACCCAGCAACCAGGTGACAGGACCGCTGCCGATGGTGGACCTGCTGT
TTAACCTGGACCGGGTGACTGCCATGGAACACTTGCTCAAATCGGTCTT
GCTATACACTCTGAACAACTCTGCCTCTTCCTCCTCCACTGTGACCTGTA
TGTGTGACCTTGTGGTAAAGGAGGCCATGTCTTCTGGCAGGGCACCCCC
AAGAGCACCGTACTCATTCACCCTGAAGAAACACAGATGGATTGAGATT
GATGTGACCTCCCTCCTTCAGCCCCTAGTGACCTCCAGCGAGAGGAGCA
TTCACCTGTCTGTCAATTTTACATGCACAAAAGACCAGGTGCCAGAGGA
CGGAGTGTTTAGCATGCCTCTCTCAGTGCCTCCTTCCCTCATCTTGTATCT
CAACGACACAAGCACCCAGGCCTACCACTCTTGGCAGTCTCTTCAGTCC
ACCTGGAGGCCTTTACAGCATCCCGGCCAGGCCGGTGTGGCTGCCCGTC
CCGTGAAAGAGGAAGCTATTGAGGTGGAAAGATCTCCCCAGCGCCGTC
AAGGGCAGAAAGCCATCCGCTCCGAAGCGAAGGGGCCACTTCTTACAG
CATCCTTCAACCTCAGCGAATACTTCAAACAGTTTCTTTTCCCCCAAAAC
GAGTGTGAACTCCATGACTTCAGACTGAGTTTTAGTCAGCTCAAATGGG
ACAACTGGATCGTGGCCCCGCACAGGTACAACCCTAGGTACTGTAAAGG
GGACTGTCCTAGGGCGGTCAGGCATCGGTACGGCTCTCCTGTGCACACC
ATGGTCCAGAATATAATCTATGAGAAGCTGGACCCTTCAGTGCCAAGGC
CTTCGTGTGTGCCGGGCAAGTACAGCCCCCTGAGTGTGTTGACCATTGA
ACCCGACGGCTCCATCGCTTACAAAGAGTACGAAGACATGATAGCTACG
AGGTGCACCTGTCGTTAGTCTAGA 
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The gene constructs were designed to be flanked by artificial cut sites. The 
mBmp15 construct had been cloned into pUC57 vector between the SacI and XbaI 
cut sites. The mGdf9 sequence was cloned into pUC57 in the more commonly 
used EcoRV site (see Figure 2D). The gene constructs were purchased from 
GenScript USA Inc. (Piscataway, NJ, USA). 
 
 
 
 
 
Figure 2D: Plasmid cloning vector pUC57 with utilised restriction enzyme cut  
                   sites 
 
 
Restriction enzyme digests were set up (see sections 2.3.1 and 2.3.2 for protocols) 
using 0.5-1 µg of each purified DNA sample to cut the DNA inserts from the 
pUC57 vector.  
The restriction enzymes used to digest both the mBmp15 and mGdf9 miniprep 
DNA samples were XhoI and XbaI, because both inserts have XhoI and XbaI cut 
sites at the 5’ and 3’ ends respectively. The digests were carried out at 37°C for 2 
h and then the reaction was stopped by incubation at 65°C for 5 min. The DNA 
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digests were mixed with SYBRE Green dye and run on a 1% agarose gel at 100V 
for 1 h. 
The correct size bands were excised under a UV lamp, followed by gel extraction 
using QIAquick® Gel Extraction kit (QIAGEN, Cat. No. 28704). An aliquot of 
pEFIRES cloning vector was linearised by digestion using the same two 
restriction enzymes described above, XbaI and XhoI. A ligation mix was prepared 
for each gene by mixing 5 µl of 2x ligase buffer (10X), 1 µl of linearised 
pEFIRES plasmid vector, 3 µl of linearised DNA insert and 1 µl of T4 DNA 
ligase. The ligation mix was incubated for 2 h at room temperature and then used 
to transfect the DH5α cells in order to amplify the pEFIRES plasmids containing 
the target DNA inserts. The transformation, colony selection, miniprep 
purification and linearization of the DNA inserts were carried out as before. 
 
2.6.3  HEK 293 cell transfection 
 
The HEK 293 cell line was chosen for this experiment because of its 
known ability to produce biologically active, correctly folded proteins, as opposed 
to E. coli. HEK 293 cells were transfected with the non-cleavable mBmp15 and 
mGdf9 gene constructs, using Fugene 6 transfection reagent (Roche, Cat. No. 04 
709 705 001), as described previously (McNatty, Juengel et al. 2005b). To prepare 
293 HEK cells for transfection, the cells were cultured in 6-well tissue culture 
plates (BD Falcon™, Cat. No. 353934) to 60-80% confluence in Dulbecco 
modified Eagle medium (DMEM, Invitrogen), supplemented with 10% fetal calf 
serum (Invitrogen), 2mM L-glutamine (Glutamax, Invitrogen) and 100 unit/ml 
penicillin, 100 mg/ml streptomycin. Pre-warmed Fugene 6 reagent (4 µl) was 
mixed with 2 µg DNA construct in pEFIRES plasmid vector and 100 µl serum 
free medium (DMEM/L-glutamine). The transfection mix was incubated for 15 
min at room temperature, to allow lipid complexes to form, then added to the cells 
in a drop wise manner. The plates were mixed gently and placed in a 37C° tissue 
culture incubator under 5% CO2, 95% humidity for 24 hours. 
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2.6.4  Selection 
 
After 24 h incubation, successfully transfected 293 HEK cells were 
selected by their resistance to puromycin (Invitrogen). The spent/conditioned 
culture media was replaced with fresh media containing 1 µg /ml of puromycin. 
Every 3-4 days the cells were trypsinised from the plates by removing the spent 
media and dead cells, washing the cell layers with PBS, followed by incubation 
with 1 ml of trypsin for 3 minutes at 37°C. After the incubation, fresh culture 
medium (without Puromycin) was added to the wells to neutralise the trypsin. The 
cells were pooled into a 15 ml Falcon tube and pelleted by centrifugation at 150g 
for 5 min at room temperature. After one further wash with warm cell culture 
medium, the cells were re-plated in fresh 293 cell culture medium, containing 
increased amounts of puromycin, up to 100 µg/ml.  
 
2.6.5  Protein production 
 
When the HEK 293 cells were growing steadily in culture media 
containing 100 µg/ml puromycin, ten 75 cm2 cell culture flasks (BD Falcon™, 
Cat. No. 353136) were seeded at 1:5 dilution with the transfected 293 cells for 
each gene to prepare the cells for exogenous protein production. At 90% 
confluence, the culture medium was replaced with protein production medium, 
prepared with DMEM:Hams F12  at 1:1 ratio (both from Invitrogen), 0.01% BSA 
(Sigma), 2 mM L-glutamine (Glutamax, Invitrogen), 100 unit/ml penicillin, 100 
mg/ml streptomycin and 100 µg /ml heparin (Sigma). The 293 HEK cell layer was 
washed once with PBS, then 15 ml of protein production media was added to each 
tissue culture flask. The 293 cells were incubated with the protein production 
medium at 37C°, under 5% CO2 and 95% humidity for 3.5 days.  
The conditioned media containing the proteins of interest was harvested after 3.5 
days and stored frozen at -80°C until used in methyl-3H-thymidine uptake assays. 
The HEK 293 cells were also harvested and frozen in RIPA lysis buffer (see 
Appendix I) for subsequent analysis by Western blotting to confirm that the cells 
produced the non-cleavable forms of mBMP15 and mGDF9. In addition, an 
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aliquot from each of the transfected HEK 293 cell preparations were subjected to 
RNA extraction and cDNA synthesis, using the ArrayPure™ Nano-scale RNA 
purification kit (EPICENTRE Biotechnologies, MPS04050, Wisconsin, USA) and 
the Superscript® VILO™ cDNA synthesis kit (Cat. No. 11754-050, Invitrogen, 
CA, USA) as described in section 2.4.1. Full length mouse Bmp15 and Gdf9 were 
amplified using primers described in Table 2G. Following gel extraction and 
miniprep purification, the DNA samples were sent to the Waikato DNA 
sequencing facility to confirm that the HEK 293 cells contained the modified, 
non-cleavable mouse BMP15 and GDF9 coding sequences. Aliquots of non-
cleavable mBMP15 and mGDF9 conditioned media were used to quantify the 
non-cleavable protein content by Western blotting and densitometry. 
 
 
Table 2G: Primers used to amplify full-length mBmp15 and mGdf9 from  
                  transfected 293 HEK cell lysates 
 
Gene Primers Nucleotide 
Position 
mBmp15 Fwd:  CCGCTCGAGCTTTGCAAGATGGCCCTTCTC 
Rev:  GCTCTAGATTATCTACATGTACAGGACTG 
225 - 255 
1402-1428 
mGdf9 Fwd:  CCGCTCGAGTCCCAAGTCATGGCACTTC 
Rev:  GGAATTCCTAACGACAGGTGCACCTCGTAG 
106 - 130 
1424-1451 
 
 
2.7  Methyl-3H-thymidine uptake assay 
 
The rat granulosa cells (GC) and denuded oocytes (DO) were collected 
and prepared as described in section 2.1.2.5.   
Care was taken to keep the GC and DO as close as possible to 37°C during the 
culture set up, since this was shown to be essential for maintaining cell viability. 
The growth factor combinations tested in a series of methyl-3H-thymidine uptake 
assays (n=5 assays on n=5 individual pools of cells) were combinations of wild-
type and non-cleavable mouse BMP15 and ovine GDF9. The method for 
generating the non-cleavable form of BMP15 is described in section 2.6.  
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Master mixes containing the treatments and GC suspension at 1000 cells/µl were 
prepared and aliquoted into 96 well plates with 5 wells/treatment (NUNC, Cat. 
No. 167008). The final cell concentration was 20,000 cells/well in a total volume 
of 55 µl. The growth factor treatments were kept at 8% of the total volume per 
well to avoid the HEK 293 cell culture media effecting GC proliferation, as 
described elsewhere (Edwards, Reader et al. 2008; McIntosh, Lun et al. 2008). 
Where the treatment volume did not amount to 8% of the total volume per well, 
‘empty’ HEK 293 cell culture media (harvested from cells transfected with 
pEFIRES plasmid vector only) was used to standardise the treatment volume to 
8%. 
The negative control for each assay was 20,000 rat GC, treated with 8% ’empty’ 
HEK 293 cell culture media. Three sets of positive controls were used. The 
addition of 32 DO to GC cultures is known to dramatically increase granulosa cell 
culture proliferation (Lin, Pitman-Crawford et al. 2012), as well as the 
combination of wild-type mouse BMP15 and ovine GDF9 conditioned media 
(6ng/ml and 60ng/ml respectively), shown to increase rat GC proliferation 3-7 
fold (McNatty, Juengel et al. 2005b; McIntosh, Lun et al. 2008). The third 
positive control, namely recombinant human (rh) activin A treatment at 100 ng/ml 
(R&D Systems, Cat. No. 338-AC-010), has also been shown to produce 2-7 fold 
increase in rat GC proliferation (Miro and Hillier 1996); this latter effect is 
comparable to the synergistic effects of the mouse BMP15 and ovine GDF9 
combined treatment as measured by 3H-thymidine uptake. 
 
The plate with all controls and test treatments was incubated for 16-18 h at 37°C, 
95% humidity under 5% CO2. Following the incubation period each well was 
treated with 10 µl of methyl-3H-thymidine (Perkin Elmer, cat. No. 
NET355001MC, 1mCi) diluted 1:24 with the cell culture media. The plate was 
carefully mixed by tapping on the sides and placed back in the incubator for 6 h. 
At the end of the 6 h incubation, the cells from each plate were harvested onto a 
90 x 120 mm glass fibre mat (Perkin Elmer, printed Filtemat A, Cat. No. 1450-
421), using a cell harvester (TOMTEC, mod. No. MACH 3-FM series). The filter 
mat was dried and heat sealed (Wallac heat sealer, mod. No. 1295-012) in a 
plastic sleeve (Perkin Elmer sample bag, Cat. No. 1450-432) with 5 ml of 
scintillation fluid (Beta Scint, Perkin Elmer, Cat. No. SC/9200.21). The 3H-
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thymidine uptake was measured using a beta counter (Perkin Elmer, 1450-SLC 
MicroBetaTriLux) and reported as cpm (count per minute) per well, accumulated 
over a 2 min interval. 
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Chapter 3:  BMP15 and GDF9 expression in the mouse 
ovary %
3.1  Introduction and Aim 
 
As outlined in Chapter 1, BMP15 and GDF9 are important regulators of 
follicular development in mammals (McGrath, Esquela et al. 1995; Dong, 
Albertini et al. 1996; Dube, Wang et al. 1998; Laitinen, Vuojolainen et al. 1998; 
Aaltonen, Laitinen et al. 1999; Elvin, Clark et al. 1999; Galloway, McNatty et al. 
2000; Eppig, Wigglesworth et al. 2002; Juengel and McNatty 2005). These 
proteins are known to act synergistically (Yan, Wang et al. 2001; Liao, Moore et 
al. 2003; Su, Wu et al. 2004; McNatty, Juengel et al. 2005a; McNatty, Juengel et 
al. 2005b; McIntosh, Lun et al. 2008; Reader, Heath et al. 2011; Mottershead, 
Ritter et al. 2012) and in a species-specific manner (Moore, Erickson et al. 2004; 
McNatty, Juengel et al. 2005a; McNatty, Juengel et al. 2005b; Reader, Heath et al. 
2011; Lin, Pitman-Crawford et al. 2012) to affect a number of intrafollicular 
events throughout follicular development.  
The species specificity of BMP15 and GDF9 has been partially attributed to the 
differences of their expression patterns in different mammalian species. In some 
species, such as the sheep, cow (Bodensteiner, Clay et al. 1999; Crawford and 
McNatty 2012), pig, deer (Crawford and McNatty 2012), hamster (Wang and Roy 
2004), possum (Eckery, Whale et al. 2002) and human (Aaltonen, Laitinen et al. 
1999), these proteins are reportedly produced only by the oocyte in the developing 
follicle. However, BMP15 and GDF9 expression has also been detected in 
somatic follicular cells in goats (Silva, van den Hurk et al. 2005) and cows 
(Hosoe, Kaneyama et al. 2011), whilst BMP15 alone was shown to be expressed 
by porcine somatic follicular cells (Paradis, Novak et al. 2009) and GDF9 was 
detected in somatic follicular cells of some primates (Duffy 2003).  
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In the mouse, there are also conflicting reports in the literature regarding the 
localisation and levels of expression for both BMP15 and GDF9 mRNA and 
protein, most noticeably around the time of the preovulatory LH surge. A number 
of studies show Bmp15 and Gdf9 mRNA expression exclusively in the mouse 
oocyte (McGrath, Esquela et al. 1995; Dong, Albertini et al. 1996; Dube, Wang et 
al. 1998; Laitinen, Vuojolainen et al. 1998; Crawford and McNatty 2012), but 
there is no consensus as to the timing of protein production and localisation of the 
different protein forms.  
The biologically active mature BMP15 protein was detected throughout follicular 
development in the mouse oocyte, as well as in the follicular fluid and the 
expanded cumulus mass in the preovulatory follicle (Gueripel, Brun et al. 2006). 
This was contradicted by reports that mouse BMP15 protein production was only 
up-regulated to a detectable level just before ovulation (Yoshino, McMahon et al. 
2006). The non-cleaved promature precursor proteins and the proregions of mouse 
BMP15 and GDF9 have not yet been characterised in the mouse ovary. However, 
there is evidence for the proregion to play an important role in follicular 
development. Immunisation against the BMP15 proregion resulted in decreased 
ovulation rate while immunisation against the GDF9 proregion resulted in an 
increase in ovulation rate (McIntosh, Lawrence et al. 2012). However, both 
immunisations led to a smaller litter size in mice and therefore lowered fertility 
(McIntosh, Lawrence et al. 2012). 
 
The aims of the experiments in this chapter were to: 
 i) determine if Bmp15 and Gdf9 mRNA and protein are produced exclusively by 
the oocyte in mice  
ii) investigate if BMP15 and GDF9 mRNA expression and protein production 
levels change during follicular development 
 iii) map (characterise) the localisation patterns of different BMP15 and GDF9 
protein forms in the mouse follicle. 
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3.2  Method Optimisation 
 
The application of several different techniques were utilised to characterise 
the expression patterns of Bmp15 and Gdf9 mRNA (in situ hybridisation, qPCR) 
as well as the protein forms (Western blotting) in the mouse follicle. All protocols 
for these techniques are described in detail in Chapter 2, whilst the aim here is to 
describe the optimisation and troubleshooting of the above-mentioned methods. 
 
3.2.1  In situ hybridisation (ISH) 
 
ISH allowed the localisation of expression of genes responsible for the 
production of BMP15 and GDF9 proteins, using radio-labelled riboprobes to 
pinpoint the cellular location, thus answering the question of whether granulosa 
cells and/or cumulus cells are capable of producing these proteins or whether they 
are produced exclusively by the oocyte. 
By using prepubertal mice primed with PMSG, PMSG + hCG or saline as a 
control, expression patterns were analysed in follicles at different stages of 
development: during the early (control) and late (PMSG only) follicular phases 
and after the preovulatory LH surge (PMSG + hCG).  
The ISH method employed was modified from a previously published method 
(Tisdall, Hudson et al. 1994). The 33P labelled riboprobes were designed to 
recognise the mature region of Bmp15 and Gdf9 on 5 µm pre-treated, paraffin 
embedded mouse ovarian sections. The original protocol called for overnight 
hybridisation of the tissue sections with 45000 cpm radio-labelled probes per µm2 
section, followed by 3 weeks of incubation of the slides in the darkroom after 
coating with autoradiographic silver emulsion. When using the original protocol, 
following development and haematoxylin staining, an overflow of silver grains, as 
visualised by both light field and dark field microscopy, was observed in the 
oocytes for both Bmp15 and Gdf9 in all follicles of all three treatment groups. The 
overflow signal made it impossible to determine whether the somatic follicular 
cells directly adjacent to the oocyte had specific riboprobe binding or if the signal 
was from over exposure. The somatic follicular cells further away from the oocyte 
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and the rest of the ovarian tissue showed no signal above the background, neither 
did the sections hybridised with sense probes to serve as negative controls.  
To reduce signal strength, two modifications were trialled successfully. In one set 
of experiments, the slides were hybridised with reduced-strength Bmp15 and Gdf9 
riboprobes. These were prepared by changing the ratio of [33P]-UTP compared to 
‘cold’ UTP in the riboprobes, but when this was not enough to sufficiently reduce 
the probe strength, the probes used in the overnight hybridisation step were 
diluted to 30,000 cpm/µm2, rather than the 45,000 cpm/µm2 described in the 
original protocol. The hybridisation step was followed by the usual 3 weeks of 
incubation and development. 
In another experiment series, the tissue sections were hybridised with normal 
strength (45,000 cpm/µm2) riboprobes overnight, but the silver emulsion coated 
slides were incubated for only 1 week before developing. 
Both measures yielded the expected results in reducing the signal strength in the 
oocytes, making it possible to determine if any cell type other than the oocyte 
showed radioactive Bmp15 or Gdf9 riboprobe binding in the mouse ovary. 
In further ISH experiments (n=3), the modified protocol requiring normal strength 
probe and only 1 week incubation time was used. 
 
3.2.2  Quantitative PCR (qPCR) 
 
It was considered that the sensitivity of the ISH method might not be 
sufficient to measure Bmp15 and Gdf9 expression below a certain threshold, thus 
leading to false negative results in cases where mRNA expression levels might be 
too low to distinguish from the background. Quantitative PCR (qPCR) - or real-
time polymerase chain reaction - is a technique used to amplify and 
simultaneously quantify the expression level of a targeted DNA molecule. It 
enables both detection and quantification of a specific sequence in a DNA sample 
with high sensitivity. The use of the Superscript® VILO™ cDNA synthesis kit 
(Invitrogen, CA, USA) to transcribe the extracted mRNA to cDNA, ensured that 
the mRNA to cDNA ratio was 1:1 and enabled the quantification of the initial 
target mRNA content in the samples.  Multiplex qPCR analysis was used to 
quantify both target genes and a reference gene in the same sample, minimizing 
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the sample mRNA required, thus enabling the detection and quantification of 
multiple genes in a single oocyte. The highly sensitive qPCR technique was 
suitable as a confirmation method for the gene expression data obtained using 
ISH. It was also used to quantify the expression levels of mouse Bmp15 and Gdf9 
mRNA at different stages of ovarian follicular development, determining whether 
the expression levels of the target genes change during follicular growth. 
The multiplex qPCR template, primer and probe optimization is explained in 
detail in Chapter 2, sections 2.5.2.1 and 2.5.2.2. The importance of using the 
purest possible sample preparation for qPCR analysis was highlighted during the 
sample collection method optimization. Somatic follicular cell and denuded 
oocyte (DO) samples were collected from the same three treatment groups of 
prepubertal mice as used in ISH and described in Chapter 2, section 2.1.2. A 
number of sample collection methods were trialled to ensure that following RNA 
extraction and cDNA synthesis, the concentration of the target genes was at a 
sufficient level to be measured by qPCR and at the same time to avoid cross 
contamination between cumulus cells and oocytes. 
The use of the ArrayPure™ Nano-scale RNA purification kit from EPICENTRE 
Biotechnologies for RNA extraction ensured that a suitable amount of RNA was 
extracted from individual DO recovered from a range of small antral to large 
preovulatory follicles, or cumulus cells extracted from a single cumulus-oocyte 
complex (COC). The inclusion of mouse ribosomal protein L19 (Rpl19) in the 
multiplex qPCR reaction as reference gene ensured that samples with undetectable 
levels of mRNA were not included in any subsequent statistical analyses. MIQE 
guidelines recommend the use of a minimum of two reference genes in qPCR 
studies. However, it allows the use of only one reference gene if the expression 
level of the gene in question is proven to be stable under the experimental 
conditions (Bustin, Benes et al. 2009). Since the average Rpl19 CT values 
remained constant between the three treatment groups (mean CT values were 26.5, 
27 and 25.6 in Control, PMSG and PMSG + hCG treatment groups respectively), 
Rpl19 proved to be an ideal reference gene in the present experimental series. It is 
also difficult to find ovarian reference genes that are not affected by treatments 
such as the superovulation treatment used in this study, which is another reason a 
single reference gene was used. Moreover, Rpl19 mRNA expression levels were 
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also shown to correlate to cell number as well as total mRNA concentration in the 
samples (Ekart, McNatty et al. 2013). 
 The biggest challenge in this study was avoiding cross contamination between the 
oocyte and the corresponding cumulus cells during sample collection. It was not 
possible to collect pure mural granulosa cell (GC) populations as damage to any 
oocyte during collection of the COC resulted in oocyte contamination of the 
sample.  Therefore, the primary focus was on collection of individual COC from 
all 3 treatment groups for qPCR analysis, following the method described by 
Crawford and McNatty (2012). The COC were separated into DO and cumulus 
cell (CC) fractions and analysed as individual samples. Photographic evidence 
was taken at each step of the sample collection process and used to determine 
false positive or false negative results caused by damage to the oocyte in the 
denuding process. It was observed that even the slightest damage to the oocyte 
resulted in false positive mRNA expression results in the corresponding cumulus 
cell samples, therefore photographs of the oocytes were carefully examined and 
any visible damage resulted in the qPCR data being excluded from further 
analysis for both the DO and corresponding CC sample. Being able to link the 
Bmp15 and Gdf9 gene expression in some CC samples to proven damage to the 
oocyte at sample collection highlighted the importance of the purity of samples 
when using highly sensitive detection methods such as qPCR.  
 
3.2.3. Western blotting 
 
Western blot analysis was used to assist in localising the presence of BMP15 
and GDF9 protein within the mouse ovary during follicular development and also 
to visualise the different forms, such as the full-length precursor promature 
proteins, the proregions and the cleaved mature forms of BMP15 and GDF9. The 
same three treatment groups of mice as used for ISH and qPCR were established 
for sample collection to enable a protein comparison with the mRNA expression 
data obtained through ISH and qPCR. For sample collection details see Chapter 2, 
section 2.1.2.3. 
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To detect BMP15 and GDF9 in mouse follicular cell samples, a number of 
commercially available or in-house antibodies (Figure 3A) were tested for 
specificity and sensitivity. 
 
3.2.3.1 Antibody selection 
 
Two in-house antibodies for GDF9 were tested, namely mab37A and 
mab47b (produced under contract to AgResearch by Prof Nigel Groome, Oxford 
Brookes University, UK). Both monoclonal antibodies were designed to recognise 
the mature forms of ovine GDF9. Mab37a was generated against E. coli expressed 
mature ovine GDF9 (Reproduction Laboratory, AgResearch Ltd, Wallaceville 
Animal Research Centre, Upper Hutt, NZ) and was shown to be successful in 
recognising mouse mature GDF9 protein in 293 HEK cell expressed GDF9 
conditioned media (McIntosh, Lun et al. 2008). Mab47b was generated against the 
mature GDF9 protein sequence SEYFKQFLFPQNEC, fully conserved between 
mouse and sheep. It has also been shown to immunoneutralise 293 HEK cell 
derived mouse GDF9 (McIntosh, Lun et al. 2008). Insufficient quantities of 
antisera validated previously for the proregion and promature form of mouse 
GDF9 (McIntosh, Lun et al. 2008) were available for this study. Therefore, 
another polyclonal mouse antisera 4e, produced against the same mouse GDF9 
peptide (PVDGTDRSGLLPPLFKVL) and at the same time as the antisera 
previously validated (McIntosh, Lun et al. 2008) (Reproduction Laboratory, 
Victoria University of Wellington, Wellington NZ), was trialled for its ability to 
recognise the proregion and the non-cleaved promature form of mouse GDF9.  
The two commercially available BMP15 antibodies tested in this study for their 
ability to recognise the mature form of the mouse BMP15 protein were sc-28911 
(H-83) and sc-18337 (A-20) from Santa Cruz Biotechnology, Inc., Dallas, Texas, 
USA. 
H-83 is a rabbit polyclonal IgG, raised against the human BMP15 sequence 
QADGISAEVTASSSKHSGPENNQCSLHPFQISFRQLGWDHWIIAPPFYTPN
YCKGTCLRVLRDGLNSPNHAIIQNLINQLVDQ, near the C-terminus of the 
protein. According to the manufacturer, it is able to recognize mouse, rat, and 
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human mature BMP15 protein. A blocking peptide for this antibody was not 
supplied by the manufacturer. 
A-20 is a goat polyclonal IgG, raised against an undisclosed internal region of 
human BMP15, but was used to recognize mouse mature BMP15 protein by Dr 
Robert Gilchrist’s laboratory at the Research Centre for Reproductive Health, 
University of Adelaide, Australia (Mester et al 2013, submitted manuscript). A-20 
is supplied with a blocking peptide (Santa Cruz, Cat. No. sc-18337P) by the 
manufacturer. To visualize the proregion form of mouse BMP15, a polyclonal 
mouse antisera 8f was used. This antibody was raised against the mouse BMP15 
proregion sequence ADDPTLPSILDLAKEAPG at the same time as another 
antisera was generated against the same sequence in a different mouse, as used 
and described by McIntosh, et al (2008). 
 
In pilot experiments for the present study, mab37a was successful in recognising 
293 HEK cell-expressed mouse GDF9 mature protein in conditioned media, 
therefore this media was used in the Western blot assays as a positive control 
(Figure 3B). The antibody also identified a protein band corresponding in size to 
the uncleaved promature form of mouse GDF9 (60 kDa) when DO lysates from 
the control, PMSG or PMSG+hCG treatment groups (n=100 DO/treatment group) 
were loaded onto the SDS PAGE gel. The same protein band was also observed in 
granulosa cell lysates (5x105 cells) from the PMSG+hCG treatment group. 
However, when the immunoblot detection was repeated using preadsorbed 
mab37a to test the specificity of these protein bands, the background was too high 
to determine if the protein bands in question were still present following detection 
with the preadsorbed antibody.  
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Figure 3A: Wild-type mouse BMP15 (accession number: NP_033887.1 and 
GDF9 (accession number: NP_032136.2) precursor (promature) protein amino 
acid sequences and the known primary antibody target regions  
  
Figure 3B: Characterisation of mab37a. Protein bands detected in saline, PMSG 
and PMSG+hCG treated mouse ovarian follicular samples by Western blot 
analysis using mab37a as primary antibody. Protein molecule sizes in kDa are 
specified on the right and the protein forms described on the left side of the image. 
The positive control was HEK 293 cell derived wild-type mouse GDF9 
conditioned media. The specificity of the bands could not be determined due to 
high background when the primary antibody was preadsorbed before 
immunoblotting. 
 
 
 
Mab47b was also successful in recognising the positive control in the preliminary 
experiments and protein bands corresponding in size to known forms of mouse 
GDF9 in some of the cell lysate samples (i.e. DO from PMSG+hCG treated mice). 
Using preadsorbed mab47b antibody also resulted in high background after ECL 
development, but not to the extent that would make it impossible to recognise if 
the protein bands in question were still present after using the blocked antibody 
for immuno-detection (Figure 3C). For this reason, the rest of the Western blot 
studies were performed using mab47b for the detection of mouse GDF9. 
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Figure 3C: Characterisation of mab47b. Protein bands detected in 50-300 mouse 
DO lysate series by Western blot analysis using mab47b as primary antibody. The 
positive control was HEK 293 cell derived wild-type (wt) mouse GDF9 
conditioned media, while the negative control was wt mouse BMP15 conditioned 
media. Antibody preadsorption, carried out using the peptide that the antibody 
was raised against, resulted in the mature band in the positive control, and the 
promature bands in the DO lysate (n=300 oocytes) being blocked. Molecular sizes 
in kDa are specified in the centre with the protein forms described on the left side 
of the image. 
 
 
 
Neither BMP15 antibodies tested (A-20 or H-83) were able to unequivocally 
recognise the 293 HEK cell derived mature mouse BMP15 protein in conditioned 
media, therefore a different positive control was required. No suitable positive 
control was found for H-83, but A-20 recognised the 293 HEK cell expressed 
human mature and promature BMP15 protein in conditioned media (Figure 3D).  
Considering that A-20 was raised against the human BMP15 protein, it is likely 
that it could recognise the human BMP15 protein with greater sensitivity than the 
mouse protein and that the amount of mouse BMP15 in the conditioned media 
was insufficient for detection. As the A-20 antibody also came with a blocking 
peptide, suitable for antibody preadsorption to validate the specificity of any 
protein bands detected, it was more suitable for use in Western blot experiments.  
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Figure 3D: Characterisation of BMP15 mature region antibodies H-83 and A-20. 
Protein bands detected in mouse COC lysates and HEK 293 cell expressed wt 
mouse BMP15 or GDF9 conditioned media aliquots by Western blot analysis 
using the A-20 (panels a-d) and H-83 (panels c-d) human BMP15 mature region 
primary antibodies. The positive control was HEK 293 cell derived wild type (wt) 
mouse or human BMP15 conditioned media (panels a and d), while the negative 
control was wt mouse GDF9 conditioned media for all immunoblots.  A-20 
antibody preadsorption  (panels c and d) was carried out using the supplied 
blocking peptide, while H-83 was preadsorbed (panel f) with recombinant mouse 
BMP15 produced in E. coli. A-20 antibody specifically recognised mature and 
promature size BMP15 bands in human BMP15 conditioned media (panel a), but 
not in mouse BMP15 conditioned media. However A-20 was able to detect mouse 
BMP15 mature protein in 400 COC lysates (panel b). Immunoblotting with H-83 
antibody resulted in faint mature and promature BMP15 size bands in the wt 
mouse BMP15 conditioned media, but also a non-specific protein band of similar 
size to the target proteins (panel e), which were also present when the antibody 
was preadsorbed with mouse BMP15 peptide (panel f). This made it impossible to 
determine with any certainty if the bands were specific. Molecular sizes in kDa 
are specified in the centre, with the protein forms described on the left side of the 
image. 
 
 
 
The A-20 antibody recognised a 37 kDa sized specific BMP15 band, which does 
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mature BMP15 dimer, but under reducing conditions, a dimer should not have 
been detected. Experiments aimed at testing whether the 37 kDa band might be an 
authentic mature dimer were undertaken by adding additional reducing reagent 
(an extra 10% of ß-mercaptoethanol) to the cell lysates during Western blot 
sample preparation.  Under these conditions, the mature BMP15 band became 
more pronounced in the developed immunoblots. However, as the 37 kDa size 
bands remained and it was not possible to establish if the signal strength of these 
bands were reduced, identification of the 37 kDa band as a mature protein dimer 
could not be confirmed unequivocally.  
 
It was determined during the preliminary stages of this project that mouse antisera 
8f was able to recognise the proregion and promature forms of mouse BMP15 
with high sensitivity in both the positive control and cell lysate samples. Therefore 
8f was considered suitable for use in the present protein mapping study (Figure 
3E). The mouse GDF9 proregion antisera 4e was excluded from the final antibody 
panel, due to its lack of sensitivity (results not shown). 
 
 
 
 
Figure 3E: Characterisation of BMP15 proregion antisera 8f. Protein bands 
detected in a mouse DO lysate series by Western blot analysis using mouse 
proregion antisera 8f as the primary antibody. The positive control was HEK 293 
cell derived wild-type (wt) mouse BMP15 conditioned media, while the negative 
control was wt mouse GDF9 conditioned media. Antibody preadsorption was 
carried out using the mouse BMP15 proregion peptide: this resulted in the 
proregion positive control band and promature bands in the 100-300 DO lysate 
samples being blocked. Molecular sizes in kDa are specified in the centre, with 
the protein forms described on the left side of the image. 
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3.2.3.2 Experimental design 
 
When planning the Western blot studies, several factors had to be taken 
into account: these included the limited amount of sample available, the maximum 
sample volume able to be loaded onto the SDS PAGE gels and the necessity of 
visualising both the BMP15 and GDF9 protein bands on the same immunoblot 
after repeated stripping and reanalysing the membranes with the risk of causing 
potential signal loss.   
Furthermore, it was considered important for the sample concentrations to be kept 
similar from the different treatment groups and for the repeat experiments to be 
reproducible. After testing the selected antibodies for their sensitivity in 
recognising the target protein during repeated stripping and reanalysing the same 
membrane, it was decided that the first immunoblot assay carried out would be for 
the mature BMP15 protein using the goat polyclonal antibody A-20 (Santa Cruz), 
followed by stripping and reanalysis of the membrane with the preadsorbed A-20 
antibody for validating specificity of the protein bands detected. 
After another stripping of the membrane, it was to be reanalysed with the 
monoclonal GDF9 mature region antibody 47B followed by stripping and blotting 
with the preadsorbed 47B antibody. The last protein form to be visualised was the 
proregion and the uncleaved promature form of mouse BMP15, using the mouse 
polyclonal antisera 8f, followed by stripping the membrane one last time and 
reanalysing with the preadsorbed 8f antibody. In this way, the expression pattern 
of the different forms of both mouse BMP15 and GDF9 could be evaluated in the 
same samples.  
 
3.2.3.3 Sample preparation 
 
The samples analysed for protein localisation using Western blotting were 
pooled mouse DO and mixed GC/CC lysates from the three established treatment 
groups: control, PMSG, PMSG + hCG; representing different stages in follicular 
development. Two sets of samples of the three established treatments groups were 
collected.  The DO samples had to be pooled within treatment groups at each 
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collection because the number of DO collected from individual animals contained 
protein levels below the sensitivity of the Western blot assay. The number of 
GC/CC collected from individual animals contained high enough levels of the 
target proteins in some samples to be detected by Western blotting.  Thus, two 
independent pools of DO and eight independent pools of GC/CC cells were 
generated for each of the three treatment groups. These samples were run in the 
first set of Western blot experiments as six separate immunoblots. For the DO 
samples, ~ 400 DO were pooled per treatment group, but the somatic cell samples, 
containing both GC and CC, were analysed separately from individual animals 
after the amount of protein was determined in each sample by BCA protein assay. 
This experiment was used to collect BMP15 and GDF9 protein localisation data 
during different stages of follicular development that corresponded to the mouse 
Bmp15 and Gdf9 mRNA expression results obtained during the ISH and qPCR 
studies.  
 
In a second set of Western blot experiments (n=2 independent pools of samples), 
the expression patterns of mouse BMP15 and GDF9 were compared in COC 
before and after the oocyte underwent GVBD following the preovulatory LH 
surge (simulated using hCG treatment). The pooled, expanded CC (from 100 
COC) and pooled GVBD DO (n=100) were compared to cell lysates of intact GV 
COC (n=100) and intact GVBD COC (n=100). GC collected from follicles 9 
hours post hCG treatment were also tested. 
 
3.3  Results and conclusions 
 
3.3.1  Bmp15 and Gdf9 mRNA expression 
 
As assessed by ISH, Bmp15 and Gdf9 mRNA expression was restricted to 
the oocytes of follicles at all developmental stages in all three treatment groups 
(Table 3A, Figure 3E). The follicular types identified on the hybridised tissue 
sections ranged from type 3 primary follicles to type 8 preovulatory follicles with 
expanded cumulus mass occurring immediately before ovulation (Table 3A). With 
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the exception of Bmp15 expression in type 3 primary follicles, all other follicular 
types showed strong silver staining emitting from the oocyte. No staining was 
observed in any somatic follicular cell types when hybridised with either Bmp15 
or Gdf9 antisense probes (Table 3A, Figure 3F). Tissue sections hybridised with 
either Bmp15 or Gdf9 sense probes also had no signal above background in any of 
the three treatment groups, providing evidence that all signals observed on 
sections labelled with antisense probes were specific for either mouse Bmp15 or 
Gdf9 mRNA (Figure 3F). Large illustrative ISH images can be found in Appendix 
III. 
 
 
 
Table 3A: In situ hybridisation summary 
 
‘√’ indicates positive gene expression, while ‘x’ indicates no expression 
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Oocytes 
Bmp15 X √ √ √ √ √ 
Gdf9 √ √ √ √ √ √ 
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Bmp15 X X X X X X 
Gdf9 X X X X X X 
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Figure 3F: In situ hybridisation images detecting Bmp15 and Gdf9 in ovarian 
sections from mice treated with saline, PMSG and PMSG + hCG. The treatment 
groups are described on the left side of the images, with the radio-labelled probes 
specified on top. The enlarged antisense images (second column) represent the 
areas highlighted on the original antisense images (first column).  
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Multiplex qPCR analysis of individual DO (n=97) and corresponding CC 
also confirmed that mouse Bmp15 and Gdf9 mRNA expression is confined to the 
oocyte of the developing follicle. No expression of these genes was detected in 
CC except when the oocyte was damaged during the denudation process, as 
evidenced from the photographs taken at that time. Images of COC and DO 
collected for qPCR analysis from all three treatment groups (n=3 animals/group) 
are shown in Figure 3G. All oocytes collected from control (saline treated) and 
PMSG treated animals had an intact germinal vesicle (GV), while oocytes from 
PMSG+hCG treated animals often underwent germinal vesicle breakdown 
(GVBD) by the time of collection. COC with oocytes in GVBD could be 
identified by the expanded cumulus mass, and required enzymatic digestion, using 
hyaluronidase solution (described in detail in chapter 2, section 2.1.2.4.), before 
the oocyte could be denuded without damage. 
Examples of images where oocytes were damaged during collection, leading to 
false positive mRNA expression results, can be seen in Figure 3H. 
 
 
 
Figure 3G: Images of intact mouse COC and DO samples collected for qPCR. 
Control (saline treated) and PMSG treated COC were mechanically denuded. 
Some COC from PMSG+hCG treated animals had undergone germinal vesicle 
breakdown (GVBD) at the time of collection, recognisable by an expanded 
cumulus mass. The outer expanded cumulus layers (panel a.) were enzymatically 
removed first before the inner cumulus layer (i.e. corona radiata; panel b.) was 
removed mechanically. COC from the PMSG+hCG treated group with intact 
germinal vesicles (GV) were mechanically denuded without prior enzyme 
treatment.  
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       Black arrows point to areas of damage e.g. tear in oocyte zona pellucida, cytoplasm shrinkage 
etc. 
Figure 3H: Examples of mouse DO samples damaged at sample collection from 
each treatment group. The top panel shows the COC before denuding; the bottom 
panel shows the damaged oocyte following denuding. The denuding process, 
which includes vigorous pipetting up and down and also enzymatic digestion for 
COC with expanded cumulus mass (GVBD stage) often resulted in some level of 
damage to the zona pellucida, leading to leakage of cytoplasm and contamination 
of the cumulus cells. Even minor damage to the oocyte caused false positive 
mRNA expression results in the corresponding cumulus cells.  
 
 
Expression levels of Bmp15 and Gdf9 mRNA (Figure 3H, a) remained constant 
between DO collected from the control (n=23) and PMSG (n=28) treated groups. 
DO samples from the PMSG+hCG treated group (n=46) had significantly lower 
levels of both Bmp15 (P<0.001) and Gdf9 (P<0.05) mRNA, compared to DO from 
the control and PMSG treated groups (Figure 3I a). Once the oocyte underwent 
GVBD (n=22) following the preovulatory LH surge simulated by hCG treatment 
in the present study (Figure 3I b), Bmp15 and Gdf9 mRNA levels decreased 
further compared to oocytes with intact GV (n=24).  
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Figure 3I: Mean relative Bmp15 and Gdf9 mRNA expression levels in DO 
collected from control, PMSG and PMSG+hCG treated mice. Graph a) presents 
the overall differences in expression levels between the three treatment groups. 
Graph b) compares the expression levels of PMSG+hCG treated mice, when 
analyses were grouped based on the presence (GV), or absence (GVBD) of a 
germinal vesicle. Within each graph, different letters denote significant 
differences between groups as determined by ANOVA. Y-axis shows the fold 
change in mRNA expression levels relative to control on both graphs. Note that 
the black boxes appearing on the oocyte images are part of the fluorescent 
imaging component of the software used and are not relevant to the images 
themselves. 
 
 
 
When mRNA expression levels in oocytes of PMSG+hCG treated mice were 
corrected against control values, mean expression levels in oocytes that had a GV 
present were lower than GV stage oocytes in the PMSG-treated group. 
  
The ratio of Bmp15:Gdf9 mRNA (Table 3B) remained constant throughout 
follicular development, both before and after the LH surge. The tight correlation 
between Bmp15 and Gdf9 mRNA expression levels reported in other species not 
treated with gonadotrophins (Crawford and McNatty 2012) was observed here as 
well, as evidenced by the coefficient of variation (R2) values given in Table 3B.  
The statistical analysis was performed by one-way analysis of variance 
(ANOVA), using the IBM SPSS statistical package. P values <0.05 were 
considered to be significant. Each sample was analysed twice to ensure 
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repeatability of the qPCR assays. The inter- and intraassay coefficiences for 
Bmp15, Gdf9 and Rpl19 were calculated form the CT values of the calibrator 
samples included in each qPCR run at the beginning and the end of the runs. The 
interassay CVs for Bmp15, Gdf9 and Rpl19 were 2.1%, 4.2% and 1.8% 
respectively. The intra assay CVs were <1% for Bmp15 and Rpl19, and 2.1% for 
Gdf9. 
 
 
 
Table 3B: Ratio of Bmp15:Gdf9 mRNA levels between treatment groups 
 
                               Bmp15:Gdf9 mean ratio ± SEM            correlation coeff. (R2)  
Control        1 : 4.56 ± 0.43    0.92 
PMSG                            1 : 3.81 ± 0.16    0.98 
PMSG+hCG (total)        1 : 4.09 ± 0.16    0.97 
PMSG+hCG (GV)         1 : 3.86 ± 0.23    0.96 
PMSG+hCG (GVBD)    1 : 4.35 ± 0.22    0.97 
 
(Bmp15:Gdf9 mRNA ratios between treatment groups were not significantly different by linear 
regression and ANOVA of ratio values.) 
 
 
3.3.2  BMP15 and GDF9 protein localisation 
 
Pooled DO lysates and individual follicular somatic cell lysates from each 
of the 3 treatment groups (control, hCG and/or PMSG treated animals) were 
analysed for BMP15 and GDF9 protein localisation using Western blot analysis. 
Protein localisation results were accepted if the appropriate signals for positive 
and negative controls were observed on the immunoblots with both the primary 
antibody and preadsorbed primary antibody. 
Mature mouse BMP15 protein bands (17-20 kDa) were detected in both 
the oocyte and somatic cell lysates from all 3 treatment groups, when A-20 
polyclonal human BMP15 mature region antibody (Santa Cruz) was used for 
detection (Figure 3J). A protein band between 28-37 kDa in size (Figure 3J a), 
which was absent or greatly reduced when analysed with the antigen-preadsorbed 
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primary antibody (Figure 3J b), was detected in all of the samples. This did not 
correspond to the size of known forms of the BMP15 protein. The non-cleaved 
precursor/promature protein was detected in the positive control (293 HEK cell 
expressed human BPM15 conditioned media), but not in any of the follicular cell 
lysates. However, another unknown large protein band between 118-211 kDa was 
detected in the DO lysates in all three treatment groups, which was also blocked 
when the membrane was reanalysed with preadsorbed A-20 antibody, using the 
supplied blocking peptide (Santa Cruz). The proregion of BMP15 (40-42 kDa) 
was also detected in both the DO and somatic cell lysates in all 3 treatment groups 
when using the mouse polyclonal antisera 8f (Figure 3J c). The non-cleaved 
promature protein or any larger protein bands could not be visualised using 8f as 
primary antibody due to non-specific signals above the 50 kDa mark (Figure 3J 
d).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 94%
 
Note: Images c.) and d.) are edited images of two Western blot membranes cut together to show 
the best representation of both the DO and somatic cell BMP15 proregion expression. The original 
images can be found in Appendix II. 
 
Figure 3J: BMP15 protein localisation in saline (control), PMSG and 
PMSG+hCG treated mouse ovarian follicular samples, as detected by Western 
blot analysis. Somatic follicular cell (GC/CC) lysates of known protein 
concentration and oocyte lysates of around 400 denuded oocytes (DO) were 
analysed from each of the 3 treatment groups to compare the detectable BMP15 
protein forms in follicular samples representing different developmental stages.  
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 The mature form of GDF9 (19-22 kDa) was detected in somatic cell 
lysates in all 3 treatment groups and these could be blocked, Figure 3K b). 
However, no mature form was found in the DO samples (Figure 3K a). No other 
forms of GDF9 could be visualised in these experiments. 
 
 
 
 
Figure 3K: GDF9 protein expression in saline, PMSG and PMSG+hCG treated 
mouse ovarian follicular samples, as detected by Western blot analysis. Molecular 
sizes in kDa are specified on the left, with the protein forms described in between 
the images.  
 
 
 
 
To characterise BMP15 and GDF9 protein localisation after the 
preovulatory LH surge, intact GVBD COC (with expanded cumulus mass and 
oocytes in GVBD), GV COC and GC samples were collected from mice 9 hours 
post hCG treatment. They were analysed either as lysates of GC and intact GVBD 
COC (n=100), or as isolated GVBD DO (n=100) and their corresponding CC 
(n=100). Protein levels of these fractions were compared to those of GV COC 
lysates (n=100).  
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Figure 3L: Mouse BMP15 protein localisation in ovarian follicular samples 
before and after the preovulatory LH surge. Intact COC [‘pre- (GV COC) and 
post-germinal vesicle breakdown (GVBD COC)], denuded GVBD stage oocytes 
(GVBD DO), the corresponding cumulus mass (CC), and preovulatory post-LH 
surge granulosa cells (PMSG+hCG GC) from PMSG+hCG treated animals were 
analysed for the presence of different BMP15 protein forms, using BMP15 mature 
region (A-20; panels a and b) and proregion (8f; panels c and d) antibodies. 
Preadsorbed primary antibody detection (right side images) was used to confirm 
the specificity of the detected protein bands. Molecular sizes are given in kDa on 
the right side of the images with the protein forms with confirmed specificity 
indicated between the original and preadsorbed antibody immunoblot images. 
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The mature form of BMP15 could not be detected in any of the COC 
samples (Figure L a). The unknown form of BMP15 at the 28-37 kDa mark was 
present in the GC lysates. The uncleaved promature BMP15 form was detected in 
the positive control and possibly in the GC sample, although this was obscured by 
some non-specific signal. A large 118-211 kDa band, absent in preadsorbed-
antibody analysis (Figure 3L b), was visualised in the GVBD COC and the CC 
lysates.  
 
The proregion of BMP15 was detected in GVBD COC, and the analysis of 
DO versus CC, both extracted from GVBD COC, showed the location of the 
protein to be mainly the CC rather than the oocytes (see Figure 3L c).  
GV COC also contained BMP15 proregion protein, as did the GC lysate, but the 
signals were less intense in these samples compared to GVBD COC or the 
cumulus lysate extracted from GVBD COC. A specific protein band, absent when 
analysed with preadsorbed antibody, and corresponding in size to the uncleaved 
precursor promature BMP15 protein (45-52 kDa), was detected in the GVBD DO 
and CC samples but not in intact GV or GVBD COC lysates or in GC samples 
(Figure 3L c, d). This surprising lack of detectable promature BMP15 protein in 
GVBD COC was possibly due to incomplete reduction of the sample, preventing 
antibody recognition of this form of BMP15 in the intact COC. 
 
GDF9 mature protein could only be detected in the expanded CC samples, 
isolated from the GVBD COC (Figure 3M a). A GDF9 precursor protein size 
band (45-54 kDa), which was not observed when the antibody was blocked 
(Figure 3M b), was present in both the GVBD COC and the CC samples. 
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Figure 3M: Mouse GDF9 protein expression in ovarian follicular samples before 
and after the preovulatory LH surge. Molecular sizes given on the left in kDa, the 
detected protein forms indicated in the centre of the figure. Size difference in the 
detected GDF9 mature region protein bands between conditioned media and cell 
lysates is most likely due to differences in phosphorylation between the different 
sample types. The preadsorbed antibody immunoblot on the right shows non-
specific protein bands in the GVBD COC and CC samples, which were not 
present in the original blot. These bands are a slightly different size to the mature 
protein bands detected in the original blot on the left side. 
 
 
Table 3C: Summary table of BMP15 protein localisation and mRNA 
expression in mouse follicular cells 
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Table 3D: Summary table of GDF9 protein localisation and mRNA 
expression in mouse follicular cells. 
 
 
 
3.3.3  Conclusions 
 
This study confirmed other reports that the sole source of BMP15 and 
GDF9 mRNA expression and protein production within the mouse ovary is the 
oocyte (McGrath, Esquela et al. 1995; Dong, Albertini et al. 1996; Dube, Wang et 
al. 1998; Laitinen, Vuojolainen et al. 1998; Crawford and McNatty 2012). 
Additionally, Bmp15 and Gdf9 mRNA expression was detected exclusively in the 
oocytes of the growing follicles at all developmental stages, including after the 
preovulatory LH surge. 
 
Bmp15 mRNA expression was visualised by ISH in oocytes of type 4 to 
type 8 preovulatory follicles. Other studies also reported Bmp15 to be first 
expressed in mouse oocytes at the late primary, early secondary stage (type 3b-
type 4 follicles) (Dube, Wang et al. 1998).  The lack of Bmp15 mRNA expression 
in small type 3 follicles could mean that BMP15 has no role in early primary 
stages of mouse follicular growth. However, it cannot be ruled out that Bmp15 
mRNA expression is too low in early primary stage mouse follicles to be detected 
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by ISH. In contrast, Gdf9 mRNA expression was detected throughout all 
developmental stages in the oocytes of follicles from type 3 to type 8. Even 
though densitometry analysis was not carried out on the hybridised mouse ovarian 
sections to quantify gene expression, it appeared evident, from studying the tissue 
slides, that Gdf9 is expressed at higher levels than Bmp15 in the mouse ovary 
throughout follicular development. This observation was confirmed by multiplex 
qPCR results, where Gdf9 was on average 4.12 times more abundant than Bmp15 
(Bmp15:Gdf9 mRNA expression level ratio 1:4.12 ± 0.14) at all antral stages of 
follicular growth. The quantitative PCR data points to a tight co-regulation of 
Bmp15 and Gdf9 expression in antral follicles regardless of developmental level, 
but the mechanism behind the co-regulation remains to be elucidated. Both genes 
were expressed at constant levels throughout follicular development until the 
preovulatory LH surge, after which expression of Bmp15 and Gdf9 mRNA was 
down-regulated, with a further drop in expression levels once the oocyte 
underwent GVBD prior to ovulation.  
In the present study, oocyte maturation was achieved by hCG treatment, 
simulating the preovulatory LH surge. In response to the superovulation 
treatment, at 9 h post-hCG some oocytes in each animal had undergone GVBD, 
while others remained at the GV stage. This shows that the microenvironments of 
follicles are not fully synchronised by the superovulation treatment. Furthermore 
the decreased expression observed in the GVBD oocytes compared to the GV 
stage oocytes following hCG treatment suggests that Bmp15 and Gdf9 mRNA 
levels continue to decrease as the oocyte progresses through maturation. 
 
The observed Bmp15 and Gdf9 mRNA expression timeline fits into known 
physiological events taking place in the ovary during follicular development and 
around the time of ovulation. During follicular growth, BMP15 and GDF9 regulate 
follicular somatic cell function (Dong, Albertini et al. 1996; Galloway, McNatty et 
al. 2000; Juengel, Hudson et al. 2002; McNatty, Lawrence et al. 2006) by 
promoting GC proliferation (Hayashi, McGee et al. 1999; Otsuka, Yao et al. 2000; 
Vitt, Hayashi et al. 2000; Vitt, McGee et al. 2000; Hreinsson, Scott et al. 2002; 
Nilsson and Skinner 2002; Di Pasquale, Beck-Peccoz et al. 2004; McNatty, 
Juengel et al. 2005a; McNatty, Juengel et al. 2005b), preventing premature 
luteinisation (Otsuka, Yao et al. 2000; Vitt, Hayashi et al. 2000; Yamamoto, 
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Christenson et al. 2002)  and maintaining CC and GC phenotype (Elvin, Clark et 
al. 1999; Matzuk 2000; Dragovic, Ritter et al. 2005). Once the follicle reaches the 
preovulatory stage and the oocyte achieves developmental competence, the anti-
luteinisation and mitogenic effects of BMP15 and GDF9 are no longer required.  
Following the preovulatory LH surge, Bmp15 and Gdf9 mRNA expression is 
down-regulated in the oocyte. At this time the cumulus mass undergoes GDF9-
facilitated expansion (Elvin, Clark et al. 1999; Matzuk 2000), leading to the 
termination of the gap junction communication between the oocyte and the 
somatic follicular cells (Granot and Dekel 1994; Larsen, Chen et al. 1996; Kalma, 
Granot et al. 2004; Sela-Abramovich, Chorev et al. 2005). Following cumulus cell 
expansion, the GC switch from oestradiol to progesterone production and the 
oocyte is ready for ovulation and subsequent fertilisation (Eppig 2001). 
 
In the present study, 400 denuded oocytes and 17-25 µg somatic follicular 
cell lysate were analysed from each treatment group to achieve the detection of 
the BMP15 protein, a sample amount based on results obtained from pilot 
experiments. The detection of both the mature and proregion forms of the BMP15 
protein in all three treatment groups indicates that BMP15 was being actively 
translated and processed throughout follicular development in the mouse follicles. 
Mature BMP15 expression was detected in somatic follicular cells in small antral 
follicles and the proregion of BMP15 was also detected in these follicles.  
 
The findings that both the mature and the proregion protein were localised within 
the oocytes as well as outside in the GC/CC lysates indicates that posttranslational 
processing of BMP15 occurs within the oocyte, but doesn’t rule out the possibility 
of processing also occurring outside the oocyte.  
 
Following the preovulatory LH surge, the loss of oocyte-cumulus communication, 
with decreased expression levels of Bmp15 and Gdf9 mRNA, is likely to remove 
the inhibitory effect of BMP15 and GDF9 protein on the luteinisation of somatic 
follicular cells. However, the presence of the various protein forms of BMP15 and 
GDF9 observed in GC and CC following the preovulatory LH surge seems to 
contradict a loss of inhibition by these growth factors, and will be discussed 
further in Chapter 5.  
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A specific ~37 kDa size protein band, detected in all oocyte and somatic cell 
samples, does not correspond to known forms of mouse BMP15. It is slightly 
larger than the light chain of mouse IgG (25 kDa) and thus is unlikely to be a 
technical artefact related to the presence of IgG in the samples.  A mature dimer 
of BMP15 would be similar in size to this band but since the experiment was 
performed under reducing conditions, mature BMP15 dimers should not have 
been present. It is possible the reduction was incomplete, perhaps due to a large 
amount of BMP15 dimer protein present. This possibility is supported by 
improved BMP15 mature protein detection when an extra 10% of reducing agent 
(ß-mercaptoethanol) was added to the cell lysates during Western blot sample 
preparation. Increasing the reducing agent however did not result in observable 
decrease in the putative dimer. Further experiments with cellular samples 
subjected to a stronger reduction protocol and compared with native samples, and 
with samples subjected to chemical cross-linking, would clarify any interactions 
between the monomers of BMP15, and similarly for GDF9.  
Alternatively, it is possible that this BMP15 band is some form of the mature 
BMP15 protein, strongly bound to other proteins that failed to undergo reduction. 
The large 118-211 kDa protein band present in all oocyte lysates, which was also 
absent when using a preadsorbed primary antibody for detection, could also be a 
form of mouse BMP15, potentially part of a large multimeric complex that was 
not reduced by sample treatment.  
The mature form of GDF9 protein was detected in somatic follicular cells 
at all stages of follicular development in the mouse ovary. The finding that 
denuded oocyte samples did not show mature GDF9 protein expression, despite 
the high levels of Gdf9 mRNA expression in DO throughout follicular growth, is 
consistent with the hypothesis that the promature form of the GDF9 is rapidly 
secreted outside of the oocyte and is processed in the cumulus cell matrix. 
Alternatively, GDF9 within the oocyte might have been associated with proteins 
or folded in such a way to be resistant to the reducing agents used in sample 
treatment, and therefore not recognisable by the antibodies used. The protein 
could also be captured specifically or non-specifically by the extracellular matrix 
of the somatic follicular cells, preventing the loss during sample preparation.  The 
presence or absence of the non-cleaved precursor protein could not be determined 
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due to non-specific signalling above 40 kDa when using mab47b primary 
antibody for detection. The source of the non-specific signal is most likely the 
heavy chain of mouse IgG, which is about 55 kDa in size, the same size as the 
precursor GDF9 promature protein. The available polyclonal mouse proregion 
antisera was not sensitive enough to detect the GDF9 proregion in the follicular 
cell lysates. 
 
Analysis of BMP15 and GDF9 localisation post-hCG treatment in GVBD 
COC lysates, prepared from COC with expanded CC and oocytes in GVBD, 
helped to determine if there is a difference in protein expression by mouse 
follicles following the pre-ovulatory LH surge. 
GVBD COC showed strong BMP15 proregion localisation, as did the expanded 
CC extracted from GVBD COC, but not the corresponding DO GVBD. The 
precursor promature BMP15 protein however was detected in both the GVBD DO 
and CC lysates, pointing to enzymatic processing of BMP15 potentially occurring 
outside of the oocyte following the secretion of the full-length promature protein 
by the oocyte. The BMP15 proregion protein was also detected in GV COC post 
hCG treatment with non-expanded cumulus mass and oocytes with intact germinal 
vesicle, but to a lesser extent then in GVBD COC, which indicates that protein 
translation and/or the posttranslational processing is up-regulated after the oocyte 
undergoes germinal vesicle breakdown. Granulosa cells collected following hCG 
treatment also showed evidence of the BMP15 proregion, but not the precursor 
protein, which potentially means that even though GC are not capable of 
producing BMP15, they could be capable of processing precursor BMP15. The 
lack of detection of the mature form of BMP15 in COC and DO collected from 
PMSG+hCG treated animals in this set of experiments is most likely due to the 
lower amounts of samples analysed (lysate of 100 DO or 100 COC), compared to 
the previous experiment, where the mature form of BMP15 was detected when 
analysed the lysate of 400 DO from each of the three treatment groups were 
analysed. 
 
GVBD COC, and to a lesser extent extracted CC lysates, showed 
promature mouse GDF9 protein localisation, with the CC samples also showing 
mature GDF9 localisation. This suggests that GDF9 is produced by the oocyte as 
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the promature precursor protein, and is able to be secreted outside the oocyte 
either with or without processing, potentially to the extracellular matrix of the 
expanded CC. In the earlier experiments, mature GDF9 protein was detected in 
somatic follicular cells in all three treatment groups, including following hCG 
treatment. However, when CC and GC lysates were analysed separately post hCG 
treatment in this second set of Western blot experiments, GDF9 was not detected 
in GC, only in CC, which could mean that the GDF9 protein is primarily 
associated with CC following the preovulatory LH surge. GDF9 protein was not 
detected in GV COC post-hCG treatment, which could also be explained by up-
regulation of protein production and/or processing in the mouse follicle only after 
GVBD following the preovulatory LH surge. 
 
In summary, tight co-regulation of Bmp15 and Gdf9 mRNA expression was 
observed at all antral stages of follicular development with a mean Bmp15:Gdf9 
ratio of 1:4.12. Expression was localised to the oocytes of the developing follicle 
at all stages of follicular growth, with steady expression levels until following the 
preovulatory LH surge. After the LH surge (simulated by hCG administration), 
mRNA expression levels of both Bmp15 and Gdf9 decreased, with further 
reductions observed once the oocyte underwent GVBD directly before ovulation.  
Thus, continued maturation of the oocyte was associated with continued reduction 
of Bmp15 and Gdf9 mRNA. The finding that both cleaved and uncleaved protein 
forms were detected in somatic follicular cell samples, despite these cells not 
being capable of producing these growth factors, could mean that following 
transcription and translation of BMP15 and GDF9 by the oocyte, the 
posttranslational modification of these proteins might also take place outside the 
oocyte. However, detection of the target proteins in CC but not in DO, could also 
have been made possible by the extracellular matrix of the expanded cumulus 
mass capturing the rapidly secreted and processed oocyte derived proteins. The 
presence of the target proteins mostly in GVBD COC points to an up-regulation of 
BMP15 and GDF9 protein production and/or processing in the mouse follicle after 
GVBD following the preovulatory LH surge. Alternatively, an up-regulated 
recruitment of BMP15 and GDF9 to the ECM by other proteins or compounds, or 
by the proregion of these growth factors, could also result in the apparent 
increased localisation observed following GVBD.  
 105%
 
It is important to note that further studies are necessary to confirm the timing of 
production and localisation of BMP15 and GDF9 protein forms in the mouse 
ovary, since currently the lack of highly sensitive, specific antibodies presents 
challenges when analysing protein localisation by Western blotting. The presence 
of non-specific protein bands of similar size to the target proteins on the 
immunoblots, and the high background signal generated by either the antibodies 
or their blocking peptides make data interpretation difficult. More sensitive mouse 
BMP15 and GDF9 antibodies would also aid the visualisation of these proteins by 
other techniques such as confocal immunohistochemistry. 
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Chapter 4:  Biological activity of the non-cleaved 
precursor proteins of mouse BMP15 and GDF9  
 
4.1  Introduction  
 
BMP15 and GDF9 belong to a unique subgroup of the TGF-ß protein 
superfamily, characterised by having only six of the seven conserved cysteine 
molecules normally forming the mature region of TGF-ß proteins. The missing 
fourth cysteine residue, found in most other TGF-ß superfamily proteins, is 
responsible for covalent dimerisation by forming a disulphide bond between two 
proprotein molecules, before enzymatic processing at the RXXR cutting site 
releases a biologically active mature dimer (McPherron and Lee 1993; Dube, 
Wang et al. 1998; Laitinen, Vuojolainen et al. 1998); (reviewed in (Juengel and 
McNatty 2005). Despite BMP15 and GDF9 being unable to form covalently bound 
dimers, it has been shown that they can form non-covalently bound homo- and 
heterodimers, or exist as monomers in vitro (Liao, Moore et al. 2003; McIntosh, 
Lun et al. 2008). As with several other TGF-ß proteins, there is evidence for non-
covalent interactions between the BMP15 proregion and mature region protein 
after enzymatic processing, and similarly between the GDF9 proregion and mature 
region protein (McIntosh, Lun et al. 2008). Co-immunoprecipitation experiments 
using 293 HEK cell expressed mouse BMP15 and GDF9 proteins show that the 
proregion of mouse BMP15 can also form heteromeric complexes with the mature 
region of mouse GDF9, as well as with the mature mouse BMP15 dimer or 
monomer, whilst mouse GDF9 can be detected mostly as a mature homodimer 
(McIntosh, Lun et al. 2008). 
It has also been reported that in some species, such as mice (McIntosh, Lun et al. 
2008), sheep (McNatty, Lawrence et al. 2006) and humans (Saito, Yano et al. 
2008), BMP15 and GDF9 are secreted in vitro not only as a mature protein but 
also as cleaved proregion and uncleaved promature proteins.  
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The importance of the proregions and precursor proteins in regulating the 
biological activity of TGF-ß superfamily proteins has been highlighted in several 
studies. The non-covalent interaction between the cleaved proregion and the 
mature dimer keeps some TGF-ß superfamily members inactive, while in others it 
is necessary to store the protein in the extracellular matrix (ECM) (Annes, Chen et 
al. 2004; Anderson, Goldberg et al. 2008; Ramirez and Sakai 2010). TGF-ß 
monomers reportedly are able to form complexes with ECM linked binding 
proteins, preventing disulphide bridge formation between the TGF-ß molecules 
and therefore keeping them inactive (Shi, Zhu et al. 2011). The mitogenic activities 
of mouse TGF-ß1, TGF-ß2 and TGF-ß3 proteins were inhibited by interaction 
between the mature region and proregion forms of these proteins both in vitro and 
in vivo (Bottinger, Factor et al. 1996). The uncleaved precursor forms of TGF-ß 
proteins belonging to the nodal family were shown to have different bioactivities 
and stabilities than the cleaved mature protein forms (Le Good, Joubin et al. 2005). 
The uncleaved Nodal precursor protein was also reported to maintain proprotein 
convertase enzyme (furin and PACE4) activity to facilitate its own processing and 
by promoting Bmp4 expression to activate a positive feedback loop enhancing 
nodal expression in mouse embryos (Ben-Haim, Lu et al. 2006). Intact proregion-
mature region interaction has also been shown to enhance the bioactivity of anti-
Mullerian hormone (Wilson, di Clemente et al. 1993).  
 
Each of the proregions of BMP15 and GDF9 has physiological importance within 
and outside the oocyte of the ovarian follicle. In rat granulosa cell cultures treated 
with mouse BMP15 and GDF9 together, immunoneutralisation using antibodies 
raised against the proregion of mouse BMP15 resulted in diminished synergistic 
bioactivity of BMP15 and GDF9, as measured by reduced proliferation of 
granulosa cells (McIntosh, Lun et al. 2008). Mutations identified causing amino 
acid substitutions in the proregions of human BMP15 and GDF9 were linked to 
hypergonadotrophic ovarian failure (Di Pasquale, Beck-Peccoz et al. 2004; Dixit, 
Rao et al. 2006). Immunisation against the proregion of BMP15 or GDF9 in mice 
(McIntosh, Lawrence et al. 2012) resulted in different ovulation rates and reduced 
litter sizes, emphasising the importance of the GDF9 and BMP15 proregion in vivo 
in regulating fertility in mammals. However, the biological activity and potential 
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role of most other secreted forms of BMP15 and GDF9, including the uncleaved 
precursor protein, are unknown. 
 
The overall aim of this study was to investigate the potential bioactivity of 
the uncleaved promature forms of mouse BMP15 and GDF9 by assessing the 
abilities of these precursor proteins to increase granulosa cell proliferation in vitro. 
The aim was firstly to design and produce, in 293 HEK mammalian cells, non-
cleavable mouse BMP15 and GDF9 precursor proteins with the proregion to 
mature region cleavage sites mutated so that processing of the precursors by furin-
like enzymatic activities was prevented. The biological activities of the uncleaved 
promature precursor proteins were then to be compared, using the 3H-thymidine 
incorporation bioassays, to the known active mature forms of BMP15 and GDF9, 
also produced in 293 HEK cells (McNatty, Lawrence et al. 2006; McIntosh, Lun 
et al. 2008; Saito, Yano et al. 2008). However, due to unexpected cleavage of the 
GDF9 protein, experiments to test the biological activity of the uncleaved GDF9 
were not undertaken.   
 
4.2  Method Optimisation 
 
4.2.1  Designing and generating non-cleavable mouse Bmp15 and Gdf9 gene 
constructs   
 
When designing the altered cleavage site between the proregions and the 
mature regions of mouse BMP15 and GDF9, both PAM and Blosum amino acid 
substitution matrices (Dayhoff 1978; Altschul 1991; Henikoff and Henikoff 1993; 
Johnson and Overington 1993) were consulted to ensure that the chosen mutations 
would have minimal alteration to protein charge and polarity, and therefore 
folding of the protein. It was hoped that the altered cleavage site would not be 
recognised by the proprotein convertase enzymes such as furin, thus preventing 
proteolytic cleavage so that the biological activity of the intact precursor protein 
could be assessed.  
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Details of the design and generation of the non-cleavable proteins can be found in 
Chapter 2, section 2.6.  
 
Briefly, constructs to produce non-cleavable Bmp15 and Gdf9 were designed 
(Chapter 2, Table 2F) and then purchased from GenScript USA Inc. (Piscataway, 
NJ, USA). The DNA constructs were then subcloned into pEFIRES and 
transfected into HEK 293 cells for the production of non-cleavable protein.   
To check that the cells were producing RNA (and thus protein) with the correct 
sequences, after collection of the conditioned media, RNA from the transfected 
HEK 293 cell cultures was extracted using the ArrayPure™ Nano-scale RNA 
purification kit from EPICENTRE Biotechnologies. The messenger RNA was 
reverse transcribed to cDNA using the Superscript® VILO™ cDNA synthesis kit 
from Invitrogen, as described in Chapter 2, section 2.5.1. Full-length mouse 
Bmp15 and Gdf9 were amplified using primers described in Chapter 2, Table 2A. 
The resulting products were verified to contain the altered furin cleavage site by 
automated sequence analysis at the Waikato DNA Sequencing Facility (University 
of Waikato, Hamilton, New Zealand).   
Aliquots of the harvested, non-cleavable mouse BMP15 and GDF9 conditioned 
(serum-free) media were evaluated, and non-cleavable protein content was 
quantified by Western blot detection and densitometry analysis using Image J 
software. 
 
4.2.2  Detection and quantification of the non-cleavable mouse BMP15 and GDF9 
protein forms  
 
The Western blot protocol that was used is detailed in Chapter 2, section 2.4. The 
antibodies used for evaluation of the non-cleavable proteins were mouse BMP15 
proregion polyclonal antisera 8f and ovine/mouse mature GDF9 monoclonal 
antibody 47b. Both antibodies had been validated to recognise the non-cleaved 
promature form of the target proteins. The protein separation on SDS-PAGE gel 
by electrophoresis had to be optimised for the detection of the non-cleavable 
mouse BMP15. The mouse proregion antisera 8f has been shown to recognise a 
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large non-specific band similar in size to the promature (precursor) BMP15 
protein (see Figure 4A).  
 
 
 
Figure 4A: Serial dilution of wild-type mouse BMP15 (dilution range: 10ng - 
0.2ng) and aliquots of non-cleavable promature mouse BMP15 conditioned media 
as detected on 13.5% SDS PAGE gel by immunoblotting with BMP15 proregion 
antisera 8f.  
 
 
To be able to separate the promature BMP15 protein band from the non-specific 
band above it, different SDS PAGE gel concentrations were trialled ranging from 
13.5% to 7.5%. The 10% and 7.5% gels (Figures 4D-F) were successful in 
separating the two proteins to allow quantification of the non-cleaved mouse 
BMP15 promature protein band using Image J densitometry software, without 
signal interference from the non-specific protein band above. Three technical 
repeats (same samples analysed in three different assays) utilizing 7.5% SDS 
PAGE gel for Western blot analysis were used for quantification of the non-
cleavable mouse BMP15 protein.  
The reference sample for quantifying the non-cleavable content of the freshly 
harvested conditioned media was quantified wild–type mouse BMP15 conditioned 
HEK 293 cell expressed media (McIntosh, Lun et al. 2008). Known 
concentrations of wild-type mouse protein standards, and respective non-cleavable 
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promature protein conditioned media series, were generated by diluting the 
conditioned media with distilled water, and analysed by electrophoresis on SDS 
PAGE gels to separate the proteins, followed by Western blotting.  
 
4.2.3  Methyl-3H-thymidine uptake assay optimisation 
 
The biological activity of the non-cleavable form of mouse BMP15 in 
comparison with the wild type protein was evaluated by the ability to promote rat 
granulosa cell proliferation in methyl-3H-thymidine uptake assays. 
The rat granulosa cell (GC) culture system was used since the effects of 
combinations of GDF9 and BMP15 on rat GC proliferation are well known 
(McNatty, Juengel et al. 2005b; McIntosh, Lun et al. 2008), and the collection of 
sufficient numbers of rat GC for all required treatment replicates could be 
achieved quickly and efficiently. 
An established rat GC culture protocol (Lin, Pitman-Crawford et al. 2012) was 
modified slightly to suit the current study. Rat GC were cultured in serum-free 
media for 16-18 h in 96 well flat-bottom plates at 20000 total cells in 55 µl 
M199/1% PenStrep media per well at 37°C, 95% humidity under 5% CO2. In 
preliminary experiments, suitable positive controls for the 3H-thymidine uptake 
assays were identified. It was established in dose response studies that a 
combination of 6 ng/ml wild-type mouse BMP15 and 60 ng/ml ovine GDF9 
conditioned media increases rat GC proliferation, as reported earlier (McNatty, 
Juengel et al. 2005b; McIntosh, Lun et al. 2008), while neither growth factor had 
any effect when administered alone, thereby providing suitable controls when 
testing the biological activity of the non-cleavable promature protein forms. 
Mouse GDF9 had shown biological activity on its own in the rat GC culture 
system; therefore it was deemed unsuitable to test the synergistic biological 
activity of the various mouse BMP15 and GDF9 protein forms, since the 
interpretation of the results would have been equivocal (Figure 4B).  
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Figure 4B: Example of a validation 3H-thymidine uptake assay, testing the 
biological activity of mouse (m), ovine (o) wild-type (wt) GDF9 and wt mBMP15 
alone and in combination to select a suitable positive control for testing the 
biological activity of the non-cleavable mBMP15 and mGDF9. 
 
 
Two more assay controls were tested and adopted for the 3H-thymidine uptake 
assays. These included 100 ng/ml recombinant human activin A and 32 denuded 
rat oocytes (DO). Assays in which the activin A positive control failed to 
stimulate 3H-thymidine uptake ≥1.5-fold and where the DO failed to stimulate 3H-
thymidine uptake ≥10-fold were excluded from analysis. It was established 
previously that components present in the HEK 293 conditioned media interfere 
with the proliferative activity of granulosa cells, regardless of species of origin 
(McIntosh, Lun et al. 2008). Therefore, the amount of HEK 293 cell conditioned 
media was standardised between all treatments and controls at 8% of the total 
volume per well. Where the treatment did not amount to 8%, the deficit was made 
up with HEK 293 conditioned media collected from HEK 293 cells transfected 
with empty pEFIRES vector. 
 
The 3H-thymidine incorporation data were analysed by REML using the 
GenStat Release 15.1 statistical programme. Counts were log-transformed to 
stabilise variance. The structure of the model included the technical replicates 
(n=5 wells/treatment) nested within the biological replicates (n=5 independent GC 
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pools). The predicted means were compared by two-tailed t test using the 
approximate average standard error of difference, with p<0.05 considered 
significant. Tests were limited to pre-planned comparisons. To facilitate 
interpretation, data are presented as fold changes compared to the negative 
control.  
 
4.3  Results  
 
4.3.1  Generation of non-cleavable mouse promature BMP15 and GDF9  
 
Immunoblot detection carried out on conditioned media harvested from 
HEK 293 cells transfected with the non-cleavable mouse Gdf9 gene construct 
showed that, even though non-cleaved promature protein was produced by the 
transfected HEK 293 cells, most of the proprotein was processed and could be 
detected as the mature GDF9 protein form (Figure 4C). 
 
 
Figure 4C: Non-cleavable mouse GDF9 protein and wild-type mouse GDF9 
protein conditioned media Western blot analysis, using mouse/ovine GDF9 
mature region mab 47b.  
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Despite the mutated GDF9 conditioned media containing relatively large amounts 
of the promature protein form compared to the wild-type (wt) GDF9 conditioned 
media, it also contained the mature region of the protein in larger quantities.  
Therefore, further evaluation of this conditioned media, and investigation of 
mouse GDF9 precursor activity, was not undertaken. 
 
Western blot analysis of the conditioned media collected from HEK 293 cell 
cultures transfected with the mouse Bmp15 gene construct containing an altered 
furin cut site, showed that production of the non-cleavable mouse BMP15 
promature protein was successful, as shown in Figures 4D and 4E.   
 
 
 
 
Figure 4D: Mouse BMP15 protein forms in non-cleavable (estimated 
concentration range: 3ng - 0.75 ng) and wild type (dilution range 9.6 ng - 4.8 ng) 
mouse BMP15 protein conditioned media, detected on 10% SDS PAGE gel, using  
a) mouse proregion antisera 8f and b) mouse proregion antisera 8f preadsorbed 
with the immunisation proregion antigen.  
 
 
To quantify the non-cleavable mouse BMP15 protein content of the HEK 293 cell 
expressed conditioned media, the wt mouse BMP15 conditioned media was used 
as a reference sample. The mature protein content of the wt mouse BMP15 
conditioned media was quantified to be 0.8 ng/µl by McIntosh, et al (2008), using 
E. coli expressed recombinant mouse BMP15 mature protein as a primary 
reference sample (McIntosh, Lun et al. 2008), but the BMP15 proregion content 
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was not quantified due to the lack of recombinant proregion protein as a reference 
sample.  
To estimate the amount of wt mouse BMP15 proregion in the standards, the 
assumption was made that the proregion protein content of the wt BMP15 
conditioned media is 2.17 times of the mature protein content, giving the wt 
BMP15 proregion concentration of 1.7 ng/µl. This assumption was based on the 
molecular weights of the different mouse BMP15 protein forms (MW of wt full 
length form = 44897.8 g/mole; MW of wt mature region = 13996.9 g/mole; MW 
of wt proregion = 30330.26 g/mole), and presuming that for every 1 mature 
BMP15 protein molecule there is a proregion molecule in the conditioned media, 
which has 2.17 x the molecular weight of the mature protein. Using this estimated 
value, the wt mouse BMP15 proregion standard curve was created as shown in 
Figure 4E. A standard (15.6 ng) was chosen from the linear part of the curve to 
normalise all non-quantified protein band density values to this density signal 
value. The unknown BMP15 protein concentrations were estimated by comparing 
the signal density values of the serial dilutions of the non-cleavable BMP15 
conditioned media protein bands to the signal density values of the chosen 
quantified protein band of the wild type standard. The Western blot analysis was 
repeated three times and the concentration was calculated as the average of the 
three technical replicates.  
 
 
 
Figure 4E: Quantification of protein forms in non-cleavable mouse BMP15 
protein conditioned media, using 7.5% SDS PAGE gel. Estimated concentration 
range: 1.5 ng - 3 ng, detected by mouse proregion antisera 8f and compared to a 
wild type mouse BMP15 conditioned media dilution series (10.4ng - 20.8 ng), 
n=3. The wild-type standard chosen for calculating concentrations based on signal 
density is highlighted in bold (15.6 ng/well wt BMP15 proregion protein). 
promature mouse BMP15 protein 
mouse BMP15 proregion protein 
Non-cleavable mouse 
BMP15 conditioned media 
dilution series 
37 kDa 
53 kDa 
79 kDa 
Wild type mouse BMP15 proregion protein conditioned media dilution series 
10.4 ng 13 ng 15.6 ng 18.2 ng 20.8 ng 
Non-specific protein band 
 116%
The non-cleavable BMP15 promature protein content in the conditioned media 
was calculated to be 1.73 ng/µl. For comparison, the full-length promature protein 
concentration of the wt mouse BMP15 conditioned media was 0.85 ng/µl. The wt 
conditioned media also contained 1.74 ng/µl BMP15 proregion protein, while the 
non-cleavable BMP15 conditioned media had negligible amounts (< 5%) of 
proregion protein. The weak band of mouse BMP15 proregion size in the non-
cleavable mouse BMP15 conditioned media was only detected on overexposed 
and overloaded immunoblots (Figure 4F). Moreover, when using preadsorbed 
primary antibody for detection, only partial removal of the wt BMP15 proregion 
size band was achieved (Figure 4D). This raises the question as to whether this 
was incomplete preadsorption, or whether there is a non-specific band of the same 
size as the mouse BMP15 proregion protein (40 kDa) present in the conditioned 
media samples, which can be detected when large volumes of the non-cleavable 
BMP15 conditioned media samples are loaded onto the SDS PAGE gels. 
 
 
 
 
Figure 4F: Overexposed Western immunoblot showing mouse BMP15 proregion-
sized protein in both wild-type (dilution range 9.6 ng - 4.8 ng) and mutated 
(estimated concentration range 12 ng - 0.75 ng) BMP15 conditioned media on a 
7.5% SDS PAGE gel, detected by the mouse BMP15 proregion antisera 8f.  
 
 
 
When the wild-type and the mutated protein standard curves were created by 
plotting the density of the detected protein bands against the volume of standards, 
the two standard curves were shown to be approximately parallel to each other 
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with high correlation (as assessed by regression analysis in GenStat Release 15.1), 
providing evidence that the antibody was recognising both the wild-type and the 
mutated protein forms with the same sensitivity and specificity (Figure 4G).  
 
 
 
 
 
 
Figure 4G: Parallelism between standard curves of the non-cleavable and wild-
type mouse BMP15 promature proteins, when using the mouse proregion antisera 
8f. 
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4.3.2  Biological activity of the non-cleavable mouse BMP15 promature protein  
  
The biological activity of the non-cleavable promature BMP15 protein was 
assessed with rat GC methyl-3H-thymidine uptake assays (n=5 independent pools 
of GC). The activity of the promature protein was compared to the activity of 
wild-type mature mouse BMP15 and ovine GDF9 protein forms both in 
combination and individually. Conditioned media containing wt mouse BMP15 
and wt ovine GDF9 mature protein were tested at concentrations of 6 ng/ml and at 
60 ng/ml respectively, either individually or in combination. The above 
concentrations were chosen as they were shown to have a positive effect on the 
proliferation of rat GC when combined (McNatty, Lawrence et al. 2006; 
McIntosh, Lun et al. 2008). At the concentrations examined, neither the wt mouse 
BMP15 nor the wt ovine GDF9 had any effect on the proliferation of rat GC when 
administered alone. However, a synergistic effect of the combined treatment was 
observed with respect to thymidine uptake by rat GC.  
In order to compare treatment effects between wt and non-cleavable protein 
treatments, the amount of mature region protein present in the non-cleavable 
BMP15 protein treatment was also calculated. The molecular weight of the full-
length promature mouse BMP15 protein is 44897.8 g/mole. The molecular weight 
of the wt mouse BMP15 mature region is 13996.9 g/mole and the proregion is 
30330.26 g/mole. It follows then that if the concentration of the non-cleavable 
BMP15 conditioned media is 1.73 ng/µl promature BMP15 protein, than the 
mature portion of this is 0.54 ng/µl. Using this concentration value, the tested non-
cleavable protein treatments were administered as either 3, 6, or 12 ng/ml mature 
BMP15 protein portion of the non-cleavable promature protein, and were used 
either as individual treatments, or combined with 60 ng/ml wt ovine GDF9 mature 
protein. A range of 3, 6 and 12 ng/ml mature portion of the non-cleavable BMP15 
conditioned media was chosen, given the semi-quantitative nature of the 
estimation of concentration due to the number of assumptions required for the 
methodology.  
 
Proliferation results are presented as fold changes, normalised to the negative 
control, which was rat GC treated with 8% (v/v) 293 cell culture media, harvested 
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from HEK 293 cells transfected with pEFIRES plasmid only. The combined wt 
mouse BMP15 and wt ovine GDF9 treatments showed a mean increase (p<0.001) 
in rat GC 3H-thymidine uptake by 3 fold (range: 2.2-3.8). In comparison, no 
significant increase in proliferation was observed when individual wt ovine GDF9 
or wt mouse BMP15 treatment was used [1.1 fold (0.9-1.2) and 0.9 fold (0.8-1.2) 
respectively].  
 
Combining 3, 6 or 12 ng/ml mature portion of the non-cleavable mouse BMP15 
promature protein with 60 ng/ml wt ovine GDF9 mature protein caused a 
significant increase (p<0.001) in rat GC proliferation at 1.3, 1.5 and 1.9 fold, 
ranging between 1.0-1.6, 1.4-1.9 and 1.7-2.5 respectively. However, the 
magnitude of the simulation was significantly less (p<0.001) than observed with 
the wt mouse BMP15 comparing the combined ovine GDF9 and wt mouse 
BMP15 to any of the combined non-cleavable mouse BMP15 and ovine GDF9 
treatments.  When administering the non-cleavable mouse BMP15 protein 
treatments alone, 3 ng/ml and 6 ng/ml non-cleavable BMP15 treatments caused a 
non-significant increase of 1.1 fold (0.9-1.4 and 1.0-1.4 respectively), and the 12 
ng/ml treatment a significant (p<0.05) 1.2 fold (1.0-1.3) increase in thymidine 
incorporation in rat GC.  Direct comparison of the 6 ng/ml non-cleavable mouse 
BMP15 treatment to the 6 ng/ml wt mouse BMP15 treatment also indicated a 
significant difference (p<0.05) in mitogenic activity of these two forms (Figure 
4H). 
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Figure 4H: Methyl-3H-thymidine uptake by rat granulosa cells in response to 
treatment with wt or non-cleavable mBMP15 conditioned media, alone or in 
combination with wt oGDF9. The error bars represent SEM. Preplanned 
comparisons included determining if treatments affected 3H-thymidine uptake 
compared to the negative control, and whether the effects of the non-cleavable 
mBMP15 in combination with wt oGDF9 were similar to the effects of the 
combined effects of the wt oGDF9 and wt mBMP15. The effect of the 6 ng/ml wt 
mBMP15 was also compared to the individual non-cleavable mBMP15 treatment.  
Abbreviations: o – ovine; m – mouse; wt – wild-type; rh – recombinant human 
 
4.4  Conclusions  
 
It has been hypothesised that in most species tested so far, the biologically 
active forms of both BMP15 and GDF9 are the non-covalently bound, cleaved 
mature dimers, but the biological activities of other protein forms such as the 
uncleaved full-length mouse BMP15 protein have not been evaluated.  Given that 
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mouse BMP15 and GDF9 have been detected as both cleaved and uncleaved 
protein at different stages of follicular development in vivo (Chapter 3), the aim of 
this study was to identify any potential biological activity of the unprocessed 
promature form of these proteins.   
 
The finding that, in conditioned media samples collected from the altered 
Gdf9 transfected HEK 293 cells, posttranslational processing of GDF9 did not 
completely stop indicates that either there are other enzymes capable of 
successfully cleaving the human kidney cell derived mouse GDF9 precursor 
protein at another cleavage site, or that the furin proprotein convertase enzyme is 
able to recognise an alternative cleavage site to the native RRRR sequence. The 
general motif established for a possible furin cleavage site is an arginine residue 
located in position 1 of the cut site and at least two more basic residues at either 
position 2, 4 or 6 for cleavage by furin to occur (Nakayama 1997). It has been 
shown that, although the RXXR sequence represents the preferential furin 
cleavage site, under certain circumstances furin can recognise the RXXXRR 
sequence as a cut site (Krysan, Rockwell et al. 1999; Thomas 2002). 
 Such a possible alternative cleavage site (RXXXRR) was introduced by 
the mutations (RRRR altered to QRRQ) upstream from the native cut site, as 
shown on Figure 4I. It is likely that this alternative cut site was used in the 
processing of the mutated GDF9 sequence, preventing the generation of non-
cleavable mGDF9, and instead producing cleaved protein forms similar in size to 
those produced by cleavage at the furin cut site.  
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Altered furin cleavage site highlighted in bold letters, with the mutations in red. Proposed 
alternative cutsite boxed. p1; p2 and p6 shows the positions of the necessary basic amino acids in a 
successful furin cut site, with blue arrow pointing to the cleavage. 
 
Figure 4I: Potential alternative furin cleavage site generated in the altered mouse 
GDF9 amino acid sequence. 
 
 
 
Testing of the non-cleavable BMP15 conditioned media, which was 
produced by HEK 293 cells transfected with the Bmp15 gene construct containing 
an altered furin cleavage site, showed that enzymatic processing of the BMP15 
precursor protein was successfully halted when the cleavage site was altered from 
RSVR to QSVQ. In comparison, analysis of the wt BMP15 conditioned media 
showed unimpaired proteolytic cleavage of the precursor protein with both the 
p1 p2 p6 
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cleaved and uncleaved protein forms detected. Western blot experiments carried 
out as part of the present study confirmed that in vitro, as for human and ovine 
BMP15, mouse BMP15 is secreted both as cleaved and uncleaved proteins 
(McIntosh, Lun et al. 2008; McMahon, Sharma et al. 2008; Reader, Heath et al. 
2011).  The wild-type BMP15 conditioned media contained on average less than 
20% of the uncleaved promature protein, while 95% of the non-cleavable BMP15 
conditioned media was the full-length BMP15 protein, making it suitable as a 
reference sample to test the biological activity of the promature form of the mouse 
BMP15 protein. Hashimoto, et al (2005) reported that mouse BMP15 is only 
secreted as the uncleaved promature form in vitro and proposed that the mature 
form of the protein is not secreted in mice until just before ovulation (Hashimoto, 
Moore et al. 2005). In contrast, it has been shown by McIntosh, et al (2008), that 
mouse BMP15 is indeed processed in vitro and the cleaved mature and proregion 
forms are present in significant quantities in transfected 293 HEK cell conditioned 
media. 
 
It is likely that the promature form of mouse BMP15 has a stimulatory 
activity on rat GC thymidine incorporation, since treating rat GC with 3, 6 or 12 
ng/ml mature portion of non-cleavable mouse BMP15 conditioned media in 
combination with 60 ng/ml ovine GDF9 caused a modest, but significant increase 
in GC proliferation in a dose-dependent manner, which was also observed when 
administering 12 ng/ml mature portion of the non-cleavable BMP15 treatments 
alone.   
If, as discussed in section 4.3.1, a small amount (<5%) of the BMP15 protein is 
processed and the cleaved protein forms are secreted together with the non-
cleavable promature BMP15 into conditioned media, these processed forms could 
potentially account for some of the bioactivity observed in the 3H-thymidine 
uptake assays. However, it is more likely that it is the non-cleavable form of the 
mouse promature BMP15 protein which stimulates rat GC thymidine uptake, 
since when comparing the effects of the same dose (6 ng/ml) of wt and non-
cleavable mouse BMP15 individually, the latter stimulated rat GC proliferation 
significantly (p<0.05) more than wt mBMP15. To assess the bioactivity of the 
uncleaved promature form of mouse BMP15 further, its affinity for binding to the 
membrane bound type I and type II BMP receptors would need to be evaluated. 
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Interestingly, the wt BMP15 conditioned media contained protein bands of large 
molecular weight (117-203 kDa), which seem to be recognised by the mouse 
BMP15 proregion antibody 8f, but were not present in the non-cleavable BMP15 
conditioned media (Figure 4B). This could mean that in vitro, the proregion of 
BMP15 is involved in the formation of large protein complexes, as reported by 
McIntosh et al, (2008), which does not happen, or not to the same extent, when 
the proregion is not released from the proprotein by enzymatic cleavage.  
 
In summary, the present study provides evidence that the full-length, uncleaved 
promature form of mouse BMP15 is biologically active. The proregion of mouse 
BMP15 may also be important for the formation of large BMP15 protein 
complexes, as these were not observed when cleavage of the proregion was 
prevented by mutation of the cut site recognised by members of the proprotein 
convertase family.  
Unimpaired mouse GDF9 protein processing, despite the native RRRR furin 
cleavage site being altered to QRRQ, indicates that either proprotein convertases 
or other enzymes with affinity for cut sites other than the furin RXXR site may be 
capable of processing the GDF9 precursor protein in mice.  
 
Increasing evidence is available to support the hypothesis that it is not just the 
mature forms of the BMP15 and GDF9 proteins that are biologically active (Di 
Pasquale, Beck-Peccoz et al. 2004; Dixit, Rao et al. 2005; Dixit, Rao et al. 2006; 
McIntosh, Lun et al. 2008; McIntosh, Lawrence et al. 2012). The proregions of 
TGF-ß protein superfamily members have the potential to play multiple direct and 
indirect roles (Wilson, di Clemente et al. 1993; Bottinger, Factor et al. 1996; 
Thies, Chen et al. 2001; Yang, Ratovitski et al. 2001; Annes, Chen et al. 2004; Le 
Good, Joubin et al. 2005; Ramirez and Sakai 2010; Shi, Zhu et al. 2011) in 
regulating the biological activity of these growth factors.  Similarly, evidence that 
the uncleaved precursors of several TGF-ß family proteins play diverse regulatory 
roles is also increasing (Ben-Haim, Lu et al. 2006; Anderson, Goldberg et al. 
2008), including that of the results presented here. 
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Chapter 5: General Discussion 
5.1  The sole source of Bmp15 and Gdf9 is the oocyte in the mouse ovary  
 
  From the results of the ISH and qPCR studies, the location of Bmp15 and 
Gdf9 mRNA expression was found to be exclusively within oocytes of the mouse 
ovary. From the three treatment groups of prepubertal female mice primed with 
PMSG, PMSG+hCG or saline as a control, which were used to represent the 
developmental stages of follicular growth before and after the preovulatory LH 
surge, ISH indicated that Bmp15 was first expressed at the early secondary stage 
(type 4 follicles) whereas the first Gdf9 expression was observed at the primary 
stage (type 3 follicles). This confirms other reports in regards to the timing of 
Gdf9 expression in the mouse ovary (McGrath, Esquela et al. 1995), although the 
timing of Bmp15 expression in the mouse follicle was reported to be slightly 
earlier at late primary (type 3b) stage (Dube, Wang et al. 1998). This discrepancy 
between the reported timing of first Bmp15 expression in mouse oocytes could be 
caused by differences in sensitivity of the different ISH methods used. Both 
results however suggest that BMP15 has a minimal, if any, role in early primary 
follicular development in mice.   
 
The results from the qPCR studies were crucial in confirming that the sole source 
of Bmp15 and Gdf9 mRNA expression is the oocyte in the mouse ovary. In rats, a 
similar pattern for Bmp15 mRNA was reported, with expression localised to the 
oocyte, and increasing during the preantral stages and then constant through to 
ovulation (Erickson and Shimasaki 2003). GDF9 is also reported to be oocyte-
derived for most species studied (for review, see(Mazerbourg and Hsueh 2003). In 
the present study, the ISH results alone might infer that sensitivity may have been 
an issue in detecting Bmp15 and Gdf9 mRNA but it is not an issue when qPCR is 
used. A number of qPCR sample collection methods were tested to minimise the 
possibility of cross contamination between the different ovarian cell types. The 
optimisation of the sample collection highlighted the importance of sample purity 
and provided a potential cause for the contradicting reports in various species 
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(Duffy 2003; Silva, van den Hurk et al. 2005; Paradis, Novak et al. 2009; 
Celestino, Lima-Verde et al. 2011; Hosoe, Kaneyama et al. 2011) regarding the 
location of BMP15 and GDF9 mRNA expression.  
The tight correlation between mouse Bmp15 and Gdf9 mRNA expression 
previously reported (Crawford and McNatty 2012) was confirmed in the present 
study. Moreover, it has been shown for the first time that this tight correlation 
between Bmp15 and Gdf9 remains constant at all stages of antral follicular 
development in the mouse. This finding is consistent with the hypothesis that 
BMP15 and GDF9 cooperate to regulate follicular growth and oocyte maturation 
throughout all stages of antral follicular development (McNatty, Juengel et al. 
2005a; McNatty, Juengel et al. 2005b; McNatty, Lawrence et al. 2006). 
 
It was also demonstrated in mice that, throughout all stages of antral follicular 
development, Gdf9 is expressed in greater abundance relative to Bmp15 with the 
mean Bmp15:Gdf9 mRNA ratio remaining constant at 1:4.12. In contrast it has 
been shown in monovular species (e.g. sheep, cow and red deer) that the mean 
BMP15:GDF9 mRNA ratio is much lower (Crawford and McNatty 2012), 
suggesting that a low BMP15:GDF9 ratio might be associated with low ovulation 
quota, while a higher BMP15:GDF9 ratio such as observed in rats (Crawford and 
McNatty 2012), as well as in mice, is indicative of high ovulation rate. One 
exception to this notion was found for the polyovular pig where the 
BMP15:GDF9 ratio was 1:0.5 (Crawford and McNatty 2012). Nevertheless, the 
species-specific relative mRNA expression levels of Bmp15 and Gdf9, and the 
tight correlation observed between the expression levels of these genes in all 
species studied, points to these being important and highly regulated elements in 
the molecular actions of BMP15 and GDF9. 
The results reported in this thesis indicated that while the Bmp15: Gdf9 expression 
ratio in mouse oocytes remained unchanged throughout follicular growth, the 
Bmp15 and Gdf9 message levels after the LH surge declined in GV oocytes and 
decreased still further in those undergoing GVBD. This decrease in gene 
expression coincides with the breakdown of gap junctions between the oocyte and 
the surrounding cumulus cells during cumulus expansion (Granot and Dekel 1994; 
Larsen, Chen et al. 1996; Kalma, Granot et al. 2004; Sela-Abramovich, Chorev et 
al. 2005) and could be a physiological effect of the breakdown in the bidirectional 
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communication between the oocyte and somatic follicular cells. The down-
regulation of these genes is likely to remove the inhibitory effects of the oocyte on 
certain somatic cell functions (Otsuka, Yao et al. 2000; Vitt, Hayashi et al. 2000; 
Yamamoto, Christenson et al. 2002). For example this would remove an 
inhibitory effect on granulosa cells to undergo luteinisation and increase 
progesterone production (Eppig 2001).  
 
5.2  BMP15 and GDF9 protein is localised primarily to cumulus/granulosa 
cells in the mouse ovary following the preovulatory LH surge 
 
 
Western blot analyses of mouse follicular cell samples collected from the three 
established treatment groups determined that both BMP15 and GDF9 are 
produced in a number of forms during the different stages of follicular 
development in mouse follicles. The cleaved mature and proregion forms of 
mouse BMP15 were detected in both oocyte and somatic cell lysates collected 
from all three treatment groups. Uncleaved promature (precursor) BMP15 protein 
as well as large, potentially multimeric complexes, were detected only in the 
oocytes both before and after hCG treatment, until the oocyte underwent LH 
induced GVBD, when the large complexes were observed exclusively in the 
expanded cumulus cell lysate. After GVBD, the only BMP15 protein form 
detected in the oocyte was the uncleaved promature protein. The detection of the 
different GDF9 protein forms was hindered by the lack of specific antibodies and 
non-specific signalling. Therefore, prior to the LH induced GVBD in oocytes, 
only the cleaved mature region protein was identified and only in somatic 
follicular cells. Following GVBD, both the cleaved mature and uncleaved 
promature GDF9 protein was observed in the expanded cumulus mass. The fact 
that GDF9 was detected in somatic cells only, and only as mature protein, could 
mean that the protein is secreted rapidly from the oocyte at this time, and 
processed immediately. However, GDF9 has been observed in mouse oocytes by 
immunocytochemistry (Elvin, Clark et al. 1999), supporting the notion that the 
inability to detect GDF9 in mouse oocytes in the present study may have been an 
assay sensitivity issue. The protein content in oocyte lysates compared to somatic 
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cell samples used in the Western blot assays was not standardised, therefore it is 
possible that there were larger pools of somatic cells analysed compared to 
oocytes. 
 
The detected BMP15 and GDF9 protein forms at different stages of mouse 
follicular development are summarized in Figures 5A and 5B.  The diagram also 
includes an additional hypothesis, which proposes a posttranslational processing 
and secretion profile of BMP15 and GDF9 from the mouse oocyte.  %%
A previous study by Gueripel, et al (2006), also reported BMP15, as well as 
GDF9, protein expression in mouse oocytes throughout follicular development, 
and BMP15 expression in the expanded cumulus mass after the preovulatory LH 
surge and in follicular fluid of atretic follicles. Another report however indicated 
that BMP15 is only present in the mouse follicle after the preovulatory LH surge, 
immediately before ovulation (Yoshino, McMahon et al. 2006). This study had 
the same experimental design and model animal as the present work, but analysed 
only 6 µg of follicular cell lysate (less than half of what was tested in this thesis), 
and used a different, potentially less sensitive antibody for detection. The findings 
of this thesis study are contradictory to another report, that in vitro, mouse BMP15 
protein is produced by transfected HEK 293 and CHO cells as the uncleaved 
promature protein only, suggesting that during posttranslational processing the 
full-length protein undergoes degradation, rather than enzymatic cleavage and 
secretion (Hashimoto, Moore et al. 2005).  
 
The results presented here are in agreement with findings by McIntosh, et al 
(2008), reporting that mouse BMP15 and GDF9 are indeed produced in vitro as 
both cleaved and uncleaved proteins, as well as in large, potentially multimeric 
complexes.%%
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Protein forms detected by Western blot analysis in the present study are labelled with black letters. 
Protein forms labelled with red letters are forms that are hypothetical. * denotes non-covalent 
interaction between monomers; yellow boxes represent the BMP15 mature region, green boxes the 
GDF9 mature region, while clear boxes represent either BMP15 or GDF9 proregion  forms. 
 
Figure 5A: BMP15 and GDF9 protein expression in the mouse follicle before 
the LH surge. Prior to the preovulatory LH surge, which triggers GVBD in the 
preovulatory oocytes, BMP15 was detected in DO at all stages of follicular 
development as both the cleaved mature and proregions, uncleaved promature 
form, and large, potentially multimeric complexes and although there was 
evidence for a homodimeric form this was not unequivocally proven. This 
indicates that the oocyte is producing and secreting both processed and 
unprocessed proteins, as well as assembling large, potentially latent complexes, 
most likely for storage in the ECM for possible further processing. The cleaved 
pro- and mature regions and the mature dimer were detected in somatic follicular 
cells at the same developmental stages. This could either mean that these are the 
forms capable of binding to the cell membrane-associated receptor complexes, or 
that the somatic cells, as well as the DO, are also able to process the large 
complexes and/or the promature form of BMP15. 
       GDF9 protein expression was not detected in the DO but only in CC as 
processed mature protein. The lack of available antibodies prevented collection of 
required data to determine whether GDF9 expression was similar to that of 
BMP15, as in the figure, or if it differed. 
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Protein forms detected by Western blot analysis in the present study are labelled with black letters. 
Protein forms labelled with red letters are forms that are hypothetical. * denotes non-covalent 
interaction between monomers; yellow boxes represent the BMP15 mature region, green boxes the 
GDF9 mature region, while clear boxes represent either BMP15 or GDF9 proregion forms. 
 
 
Figure 5B: BMP15 and GDF9 protein expression in the mouse follicle after 
the LH surge. Following the preovulatory LH surge, only the uncleaved 
promature BMP15 protein was detected in the GVBD DO, suggesting that 
processing of the protein slowed in the DO. The large protein complexes, the 
promature BMP15 and the cleaved proregion were detected in the expanded 
cumulus mass, giving further weight to the notion that the large complexes serve 
as a latent stored form, awaiting further enzymatic and other processing in the 
ECM. Further out in the granulosa cell compartment of the follicle, cleaved and 
uncleaved forms of the protein, but not the large complexes, were also detected. 
This could either mean that the GC is not capable of storing and processing the 
large complexes, or that the detection of the target proteins in CC but not in DO 
has been made easier by the extracellular matrix of the expanded cumulus mass 
capturing the rapidly secreted and processed oocyte-derived proteins. 
       GDF9 protein expression potentially follows the same pattern as BMP15 with 
both cleaved and uncleaved GDF9 detected in the CC compartment after the LH 
surge. This supports the idea that posttranslational processing of the secreted 
proproteins could take place inside or outside of the oocyte. 
 
 
 
 However, it is important to note, that proteins in biochemical solutions may differ 
from those in biological fluids where they are associated proteoglycans and 
binding proteins (Russell and Robker 2007). The same report by McIntosh et al, 
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(2008) also showed that immunoneutralization of the proregion of mouse BMP15 
inhibits the synergistic bioactivity of mouse BMP15 and GDF9 in vitro, providing 
further evidence of the importance of the mouse BMP15 proregion in regulating 
bioactivity of these proteins. A more recent study reported that immunising mice 
with BMP15 or GDF9 proregion peptides leads to altered ovulation rates and 
smaller litter sizes (McIntosh, Lawrence et al. 2012). In co-immunoprecipitation 
experiments, the proregions of mouse BMP15 and GDF9 individually associated 
with mouse granulosa cells, providing evidence that the proregion forms of these 
proteins are able to directly interact with somatic follicular cells in vitro (Mester, 
et al 2013; submitted manuscript). The presence of the BMP15 proregion 
throughout follicular development in mice, as detected in the present study, also 
supports the proregion having important functions in the regulation of follicular 
development. 
The uncleaved promature form of BMP15 was detected in oocytes and somatic 
cells following GVBD, induced by hCG treatment, but was not observed in less 
mature follicles in oocytes or in the surrounding somatic follicular cells. One 
explanation is that with an up-regulation of BMP15 protein expression after the 
LH surge, the promature BMP15 is at a level that is able to be visualised by 
Western blot. However, it is also possible that posttranslational processing of 
BMP15 is down-regulated in the mouse follicles just before ovulation, but does 
not cease completely since the cleaved proregion of BMP15 was also detected in 
cumulus cells collected from follicles with GVBD oocytes. Since the proregion 
was no longer present in GVBD DO, but only in the corresponding cumulus mass 
and to a lesser extent GC, postranslational processing could potentially be taking 
place outside of the oocyte as well, as reported in the case of other TGF-ß 
superfamily members, such as nodal (Beck, Le Good et al. 2002) and myostatin 
(Anderson, Goldberg et al. 2008).  Another possibility is that the proregion protein 
could have been secreted from the oocyte throughout follicular development but 
only sequestered in the expanded cumulus mass by binding proteins, proteoglycan 
or other molecules whose expression was up-regulated after the LH surge (Russell 
and Robker 2007). Similar roles and expression patterns are likely to apply for the 
GDF9 protein forms as indicated in Figures 5A and 5B, but this was not 
confirmed due to lack of specific antibodies able to recognise the different mouse 
GDF9 forms.  
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Both the DO and the somatic cell lysates also showed the expression of an 
unidentified 37 kDa protein specifically recognised by the BMP15 mature region 
antibody. This might be a dimeric form of BMP15 protein or a monomeric form 
associated with another protein (potentially an ECM binding protein), even though 
the Western blot was run under reducing conditions. Despite the reducing 
conditions, evidence that this 37 kDa protein was an authentic non-covalently 
bound mature BMP15 dimer is indicated from the blocking experiment, where the 
BMP15 mature region antibody (A-20) was preadsorbed with the blocking peptide 
supplied by the manufacturer, showing a significant decline in the 37 kDa signal 
intensity.  
The inability to detect a GDF9 mature homodimer in the present Western blot 
series however raises doubts about the authenticity of the 37 kDa BMP15 band. 
The possibility of inadequate reduction of Western blot samples was raised 
earlier, since the addition of an extra 10% of reducing agent (ß-mercaptoethanol) 
improved the detection of the BMP15 mature protein in all sample types. 
Therefore a GDF9 homodimer, if present, should have been detected. A potential 
mouse GDF9 mature dimer however would be slightly larger than the BMP15 
dimer, above the 40 kDa mark, where non-specific signalling was often observed 
on immunoblots, masking the possible detection of a GDF9 dimer. It is also 
possible, that in vivo, mouse GDF9 does not form mature homodimers, despite it 
being one of the protein forms detected previously in vitro (McIntosh, Lun et al. 
2008). Under the present experimental conditions no heterodimers of BMP15 and 
GDF9 were detected either. To confirm the presence or absence of homodimers 
and/or heterodimers the experiments would have to be repeated using non-
reducing and/or cross-linking reagents as described by Edwards et al (2008). A 
recent report by Peng, et al (2013) described the presence of GDF9 and BMP15 
homodimers and heterodimers in rodents and humans although these finding has 
been disputed (see(Mottershead, Harrison et al. 2013). 
 
Another unidentified BMP15 protein form detected was a large 118-211 kDa band 
in the DO lysates at all developmental stages and also in the cumulus mass 
collected from GVBD COC following hCG treatment. This band could represent 
large multimeric complexes, involving both the mature and the proregions of 
BMP15, since it was recognised by both the proregion (8f) and the mature region 
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(A-20) antibodies. Again, these bands could have been the products of incomplete 
reduction, or an artefact of the conditions of the Western blotting technique. 
Similar high molecular weight complexes, containing the pro- and mature regions 
of recombinant mouse BMP15 and GDF9 proteins after chemical cross-linking, 
have been observed previously (McIntosh, Lun et al. 2008). Other TGF-ß 
proteins, such as myostatin (Thies, Chen et al. 2001; Anderson, Goldberg et al. 
2008) and TGF-ß1, 2 and 3 are also known to be held in association with latency-
associated peptides (LAP), bound to latent TGF-ß binding proteins in the ECM, 
forming large inactive complexes, before the biologically active TGF-ß ligand is 
released for signalling (Miyazono, Hellman et al. 1988; Kanzaki, Olofsson et al. 
1990; Moren, Olofsson et al. 1994; Saharinen, Taipale et al. 1998; Koli, Saharinen 
et al. 2001; Rifkin 2005). The BMP15, and potentially the GDF9, mature proteins 
may also be stored in a similar fashion, bound non-covalently to the proregion and 
potentially to other binding proteins for transport, recruitment and sequestration 
before becoming biologically active, as suggested previously (Simpson, Stanton et 
al. 2012; Watson, Mottershead et al. 2012). Two TGF-ß monomers were shown to 
create a complex with an ECM- linked binding protein, preventing disulphide 
bridge formation between the TGF-ß molecules thereby keeping them inactive, 
until integrin molecules released and activated the growth factors by applying 
tactile forces (Shi, Zhu et al. 2011). Similar mechanisms could play a role in the 
storage and activation of mouse BMP15, and potentially GDF9, involving 
components of the cumulus cell matrix. 
 
When COC, GC and CC lysates were tested separately following hCG treatment, 
only the CC contained detectable levels of GDF9 in the form of uncleaved 
promature protein. This, together with the presence of the uncleaved BMP15 and 
large potentially latent complexes in CC, supports the hypothesis that together 
with the down-regulation of Bmp15 and Gdf9 mRNA expression in the oocytes, 
proteolytic processing of both BMP15 and GDF9 may also be reduced after the 
preovulatory LH surge. However, the inability to detect GDF9 in other ovarian 
cell samples could also have been due to insufficient sample concentrations. 
Similarly, not being able to detect other forms of the protein could be attributed to 
the lack of specific antibodies. To overcome these technical difficulties, previous 
studies characterising BMP15 and/or GDF9 used his- or FLAG taged recombinant 
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proteins and employed antibodies raised against the tags for detection of the 
various forms of BMP15 and GDF9 protein. The generation of more specific 
monoclonal antibodies for mouse BMP15 and GDF9 mature regions and 
proregions would be highly valuable, in order to clarify changes in the expression 
levels, changes in location and changes in protein form occurring during follicular 
development.  
 
In summary, oocyte-derived mouse BMP15 and GDF9 are produced at all stages 
of follicular development and possibly enzymatically processed by both the 
oocyte and within the extracellular matrix surrounding somatic follicular cell 
compartment.  The proregion of BMP15 might be involved in assembling large 
multimeric complexes, but the function and biological activity of these complexes 
are unknown, although they could also be a consequence of the in vitro 
conditions. It could not be determined if similar complexes of GDF9 were present 
as there was no suitable GDF9 proregion antibody available and the mature region 
antibody used often produced non-specific signalling above the 40 kDa mark, 
making it impossible to detect any protein forms larger than the 40 kDa proregion. 
Following the preovulatory LH surge, the expression of both genes are down-
regulated in the oocyte and the posttranslational processing of the proteins are 
reduced, just as the gap-junction communication between the oocyte and the 
somatic follicular cells is disabled, removing the inhibitory effects of oocyte 
produced growth factors from the somatic cells, and enabling luteinisation of GC 
and ovulation of the COC. 
 
  5.3  The uncleaved promature form of mouse BMP15 is biologically active   
 
The present results showed that the full-length, uncleaved promature forms 
of mouse BMP15 and GDF9 are present in follicular cell lysates from the mouse 
ovary. This raises the possibility that the promature proteins have a biological or 
regulatory activity. To establish whether secreted promature forms of BMP15 and 
GDF9 have biological activity, molecular constructs were designed in order to 
produce non-cleavable promature forms of these proteins where the RXXR furin 
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cleavage sites between the pro- and mature domains of each of BMP15 and GDF9 
proteins were modified to QXXQ.  
 
In the case of mouse GDF9 protein, where the original amino acid motif was 
RRRR, the modification to QRRQ lead to the creation of a six amino acid long 
sequence (RSPQRR) that fulfilled the requirement for a potential secondary, less 
efficient furin cleavage site (Nakayama 1997; Krysan, Rockwell et al. 1999; 
Thomas 2002) (see Chapter 4, Figure 4H). This secondary cut site could explain 
why enzymatic processing of the modified mouse GDF9 occurred, yet was 
incomplete. When compared to the wild-type protein, where close to 100% of the 
GDF9 protein was cleaved, processing of the modified GDF9 was less efficient, 
as evidenced by the presence of a relatively large amount of non-cleaved 
promature protein in the modified GDF9 conditioned media. Since enzymatic 
processing of GDF9 was not fully blocked, the biological activity of the full-
length promature mouse GDF9 was not investigated further. Purification of the 
promature form of GDF9 protein, or repeated transfection of 293 HEK cells with 
a Gdf9 construct containing a different mutation was not attempted due to time 
constraints. 
 
A promature form of mouse BMP15 was successfully produced by transfected 
293 HEK cells and quantified in a series of Western blot experiments. To 
determine the biological activity of the promature mouse BMP15, a rat GC culture 
system was established and treated with different concentrations of the modified 
full-length promature mouse BMP15 either alone, or together with ovine GDF9. 
As has been shown previously (McNatty, Juengel et al. 2005b; McIntosh, Lun et 
al. 2008), the combination of wt mouse BMP15 and wt ovine GDF9 had a 
synergistic effect in up-regulating rat GC thymidine incorporation as a marker for 
cell proliferation: this stimulatory effect was not observed when administering 
either growth factor alone. In a series of 3H-thymidine uptake assays, it was 
shown, in this thesis, that the full-length promature mouse BMP15 was 
biologically active, albeit being less potent then the wild-type protein. A point of 
caution in interpreting the bioassay results is noted, due to the possibility that the 
non-cleavable mouse BMP15 conditioned media may have contained a very small 
amount of cleaved mature region protein. However, while the concentration of the 
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mature region present in the final assay was potentially at the threshold of 
biological activity of BMP15 (McNatty, Juengel et al. 2005b), it seems unlikely 
that the activity observed could be attributed solely to a mature region 
contaminant. The bioactivity of the wild-type mouse BMP15 conditioned media, 
containing mostly the cleaved mature form that was present at significantly higher 
levels than the non-cleavable form, suggesting that defective posttranslational 
processing negatively affects both the bioactivity of BMP15 and its ability to 
interact with GDF9. This interpretation is consistent with previous findings by 
others (Liao, Moore et al. 2003; Liao, Moore et al. 2004; Hashimoto, Moore et al. 
2005). Although the wild-type mouse BMP15 had a positive effect on rat GC 
proliferation only when administered together with ovine GDF9, the promature 
form of BMP15 showed some limited stimulatory effect on thymidine 
incorporation alone but not at the levels observed when present with ovine GDF9. 
 
In conclusion, the present study provides evidence that the unprocessed promature 
form of BMP15 is bioactive either alone or together with GDF9. However, given 
that the activity of the promature form of BMP15 is lower than when there is 
greater abundancy of mature BMP15, it is suggested that the higher molecular 
weight forms are less able to have significant effects on follicular somatic cell 
functions. Moreover, the present findings suggest that the proregion of mouse 
BMP15 may well be involved in contributing to the formation of large multimeric 
complexes in follicular fluid. This interpretation is based on the fact that in non-
cleavable mouse BMP15 conditioned media, these multimeric complexes were 
absent, most likely because the uncleaved BMP15 proregion was unavailable for 
binding to other moieties. 
 
5.4  Future Directions 
 
One question the present study did not address is that concerning the issue 
of Bmp15 and Gdf9 mRNA expression levels, and their expression ratios, in 
oocytes during the preantral stages of follicular development. The sample 
collection method used for qPCR was only suitable for collecting COC from 
antral follicles. Collection of COC by laser dissection would be a possible 
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approach to collect specific cell samples at the preantral developmental stages. 
Studying mRNA expression levels and the correlation between the expressions of 
these genes at these earlier stages of follicular development, as well as the relative 
expression level of GDF9 before that of BMP15, would enhance our 
understanding of the molecular actions of Gdf9 as well as Bmp15. Moreover, 
application of the same rigorous sample collection method described in this study 
for other species such as goats, pigs and primates would help clarify the disparate 
reports of species differences in ovarian expression patterns of BMP15 and GDF9.  
 
The characterisation of BMP15 and GDF9 protein expression in the mouse 
ovary was hindered by the lack of specific antibodies to recognise the various 
forms of mouse BMP15 and GDF9. The non-specific binding of the available 
antibodies often made it difficult to interpret some of the protein expression data. 
Generation of highly sensitive and specific monoclonal antibodies, especially to 
recognise the proregion of mouse GDF9, the mature region of mouse BMP15 and 
the uncleaved promature form of the proteins, potentially by using peptides 
incorporating the cleavage site, would provide further information on the location 
and posttranslational processing of BMP15 and GDF9 within the mouse follicle. 
Indeed, one of the most pressing rate-limiting steps in elucidating the molecular 
forms and actions of BMP15 and GDF9 protein is the lack of specific antibodies 
with well-characterized reference standards. It would have also been informative, 
if the present Western blot studies were undertaken under non-reducing conditions 
and further investigations using cross-linking reagents. The current controversies 
concerning the existence of homodimers and possible heterodimers where 
modified proteins with pull-down tags were analysed, is testimony to this issue 
(see(Mottershead, Harrison et al. 2013; Peng, Li et al. 2013). 
 
A study on IVF patients reported that in human follicles, a higher GDF9 
mature protein concentration in the follicular fluid was associated with higher 
embryo quality, while there was no correlation between the levels of follicular 
fluid BMP15 mature protein, or either of the precursor protein concentration and 
embryo quality (Gode, Gulekli et al. 2011). Another report comparing BMP15 
levels in human follicular fluid also obtained from IVF patients showed that high 
BMP15 concentrations in follicular fluid was associated with better oocyte quality 
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(Wu, Tang et al. 2007). The BMP15 precursor protein, as well as the cleaved 
mature and proregion, were detected in abundance in porcine follicular fluid in 
follicles both before and after the preovulatory LH surge, suggesting a role for 
BMP15 around the time of ovulation (Paradis, Novak et al. 2009). However, the 
results from these studies are questionable as the reports did not include 
appropriate reference standards (positive ligand or antibody controls, molecular 
ladders etc.) nor evidence for GDF9 or BMP15 specificity. 
In mice, immunohistochemical analysis showed follicular fluid BMP15 
expression but only in atretic follicles (Gueripel, Brun et al. 2006). Again 
questions can be raised about the specificity of antibodies used for these studies. 
Further analyses of follicular fluid samples from mouse follicles to determine 
which BMP15 and GDF9 protein forms are present during the periovulatory stage 
of follicular development, compared to what is known about molecular forms in 
mono-ovulatory species such as humans, could provide information on how these 
growth factors affect ovulation quota. However, as discussed earlier, the key issue 
of quality antibodies and reference standards remains as the key limiting factor. 
 
Subtilisin-like proprotein convertases (SPCs), including furin and PACE4 have 
been shown to process TGF-ß superfamily proteins (Dubois, Laprise et al. 1995; 
Gueripel, Brun et al. 2006), such as Nodal and BMP4 (Constam and Robertson 
2000). Furin was also reported to increase the processing of TGF-ß1 (Dubois, 
Laprise et al. 1995). The fact that some SPC and BMP protein expression overlaps 
in mouse embryos also suggests that enzymes belonging to the SPC family are 
responsible for enzymatic processing of BMP proteins (Constam, Calfon et al. 
1996; Constam and Robertson 1999). The specific SPCs capable of processing 
BMP15 and GDF9 however have not yet been identified. Identification of the 
enzymes capable of processing BMP15 and GDF9 within the follicle, and whether 
their activities are regulated by gonadotrophins would provide important 
information to further our understanding of how the actions of these growth 
factors are regulated. 
 
The antibodies used for Western blot analysis were also evaluated in these studies 
using immunohistochemistry with confocal microscopy, aiming to visualise the 
cellular localisation of BMP15 and GDF9 protein expression within the mouse 
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ovary. However, the sensitivity and specificity of these antibodies were unable to 
distinguish the fluorescent signal of the target proteins from the background signal 
created by auto-fluorescence of contaminating red blood cells and the fixative 
used. By using more specific monoclonal mouse antibodies for 
immunohistochemical and/or Western blotting techniques, enhanced visualisation 
of the proregion and mature regions of mouse BMP15 and GDF9, and any co-
localisation of these different protein forms, is more likely to be achieved. 
Visualisation of the co-expression of the different protein forms in vivo, together 
with immunoneutralisation of the different protein forms in bioassays, would also 
help to determine the role of the proregions and precursor proteins. It was 
proposed that in vivo, BMP15 and GDF9 might operate as promature complexes, 
despite the synergistic effects of these growth factors being observed even in the 
absence of the proregion forms of the proteins in vitro (Mottershead, Ritter et al. 
2012). Further characterisation of the potential multimeric complexes by co-
immunoprecipitaion with specific antibodies or 2D Western blot analysis, could 
shed some light to the molecular basis of the synergistic action of BMP15 and 
GDF9. This would be aided by determining whether the promature forms of 
BMP15 and GDF9 are able to bind to the type I and type II BMP receptors, or if 
they could initiate signalling through the Smad pathway and if they would activate 
the Smad1/5/8 or the Smad 2/3 pathway. A better understanding of the molecular 
forms and actions of BMP15 and GDF9 will enable future technologies to 
improve the maturation-rates of oocytes during IVM and IVF in vitro, thereby 
leading to new and improved fertility treatments for livestock, endangered species 
and humans. 
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Appendix I.  Reagents and Solutions 
 
Histology 
 
4% Paraformaldehyde fixative (250 ml) 
Paraformaldehyde solution: 
Dissolve 10 g paraformaldehyde (Sigma Aldrich, Cat. No: P6148-500G) in 125 
ml distilled water with continuous stirring on a hotplate (working in the 
fumehood). Monitor the temperature of the solution. When the temperature 
reaches 65°C, add a few drops of 1M NaOH, until the solution clears. Let the 
solution cool down, and then filter through Whatman filter paper No1. 
Double strength PBS solution: 
Dissolve 2.5 g of NaH2PO4 (Sigma Aldrich, Cat No: S3139) and 4 g of Na2HPO4 
(Sigma Aldrich, Cat No: S3264) in 125 ml distilled water.  
Combined the filtered paraformaldehyde solution and the double strength PBS 
solution in a 1:1 ratio. Adjust pH to 7.4, if necessary. Store refrigerated, use for a 
maximum of 1 week.  
 
Phosphate buffered saline (PBS) 
Dissolve 5 PBS tablets (Sigma-Aldrich, Cat. No: P4417-100TAB) in 1 L distilled 
water. Sterilise the solution by autoclaving. 
 
70%; 80% or 95% ethanol solution 
Absolute ethanol (PureScience, Wellington, New Zealand, Cat. No: 200-
9985.2500) was diluted to the required concentration with distilled water. 
 
Acid alcohol 
Prepare 1 L of 70% ethanol as described above and then add 10 ml of 
concentrated Hydrochloric acid (1%) (HCl, AR grade, UNIVAR, Seven Hills, 
Australia, Cat No: 1367-2.5L). 
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In Situ Hybridisation Solutions 
 
Diethylpyrocarbonate (DEPC) treated water 
Add 1ml of DEPC (Sigma-Aldrich, Cat. No. 40718) to 1 L of distilled water. Stir 
overnight in the fume hood with the lid loose on the bottle. Autoclave the DEPC 
treated water to break down the chemical to carbon dioxide and water. 
20x SSC 
3 M NaCl, 0.3 M Na citrate x 2H20 
Dissolve 175.3 g NaCl (reagent grade, Scharlau, Cat. No: SO02270500) and 88.2 
g Na citrate x 2H20  (Sigma Aldrich, Cat. No: W302600) in 1 L of un-autoclaved 
DEPC water. Adjust the pH to 7.0 and autoclave. 5x SSC, 2x SSC and 0.2x SSC 
solutions were diluted from the 20x SSC stock solution using either DEPC treated 
water or distilled water. 
 
2x SSC/50% Formamide solution 
To get 100 ml of the solution, mix 10 ml 20x SSC stock solution, 50 ml 
formamide (Sigma Aldrich, Cat No: F9037) and 40 ml DEPC treated water or 
distilled water (as required). 
 
Proteinase K (10 mg/ml) 
Resuspend lyophilized Proteinase K powder to a final concentration of 10 mg/ml 
in 50 mM Tris-HCl pH 8.0 (made in DEPC treated water) on ice. Filter sterilise 
through 0.22 µm filter. Store in aliquots at –20 °C. 
 
Proteinase K Digestion buffer was prepared by adding 20 µl of Proteinase K (10 
mg/ml) to a solution of 0.2 M Tris HCl pH: 7.2 and 50 mM EDTA pH 8.0. 
 
Acetic anhydride 
Purchased from Sigma Aldrich, Cat No: 242845. 
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Hybridisation Mix 
For 1 ml Hybridisation Mix combine: 
60 µl 5 M NaCl, 10 µl 1 M Tris HCl pH 6.8, 20 µl 0.5 M NaP pH 6.8, 10 µl 0.5 M 
EDTA pH 8.0, 20 µl Denhards solution (50x stock), 50 µl 1 M DTT, 100 µl tRNA 
(10 mg/ml) and 20 µl DEPC treated water. Add 200 µl dextran sulphate (50% 
(w/v) Pharmica). Vortex well. Add 500 µl deionised formamide. Vortex and 
incubate on ice for 10 minutes. Centrifuge at 13,000 g for 10 min. Use supernatant 
to dilute the radiolabeled riboprobe. 
 
7.5 M Ammonium Acetate pH 7.0 
Dissolve 57.81 g ammonium acetate (Sigma Aldrich, Cat No: A1542) in 100 ml 
of un-autoclaved DEPC treated water, adjust the pH to 7.0. 
Autoclave the solution to break down the DEPC content to carbon dioxide and 
water. 
 
1 M Tris 
Dissolve 60.55 g Tris (Invitrogen, Cat. No: 15504-020, MW: 121.14 g/mol) in 
400 ml autoclaved DEPC treated water; adjust the pH to 6.8, 7.2 or 7.5 as 
required. Dilute to 500 ml with autoclaved DEPC treated water. Sterilise solution 
by autoclaving. 
 
500 mM EDTA pH 8.0 
Dissolve 73.06 g EDTA (ethylenediaminetetraacetic acid, BDH, Poole, England, 
Cat No: 100935V) in 400 ml of un-autoclaved DEPC water. Adjust the pH to 8.0 
with 5 M NaOH. Make volume up to 500 ml with autoclaved DEPC treated water. 
Sterilise solution by autoclaving. 
 
2 M Triethanolamine pH 8.0 
Dissolve 53 ml of triethanolamine (Sigma Aldrich, Cat. No: 90279) in un-
autoclaved DEPC treated water. Adjust the pH to 8.0 with concentrated HCl 
(37%), dilute to 200 ml with un-autoclaved DEPC treated water. Wrap bottle in 
tin foil and autoclave. Store at room temperature. Dilute to the required 
concentration with DEPC treated water. 
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5 M NaCl 
Dissolve 146.1 g NaCl in 500 ml un-autoclaved DEPC water. Autoclave the 
solution to break down the DEPC content to carbon dioxide and water. 
 
0.5 M NaPO4 pH 6.8 
Dissolve 7.09 g Na2HPO4 in 100 ml of un-autoclaved DEPC water to make 0.5 M 
Na2HPO4. 
Dissolve 7.8 g NaH2PO4 in 100 ml of un-autoclaved DEPC water and autoclave to 
make 0.5 M NaH2PO4. Use 0.5 M NaH2PO4  to adjust the pH of 0.5 M Na2HPO4 to 
6.8. Heat to 68°C to break down DEPC, then filter sterilise the solution. Note that 
the finished solution should not be autoclaved as precipitation occurs. 
 
Denhardts 50x 
Dissolve 0.2 g polyvinylpyrrolidone (PVP, Sigma Aldrich), 0.2 g BSA (bovine 
serum albumin, ICPbio, Cat. No. ABRE-010) and 0.2 g Ficoll 400 (Sigma 
Aldrich, Cat No: F2637) in 20 ml DEPC treated water. Filter sterilise through 0.22 
µm filter. Store in aliquots at –20°C. 
 
1.0 M Dithiothreitol (DTT) 
Dissolve 1.54 g DTT (BDH, Cat. No: 443852A) in 10 ml of autoclaved DEPC 
water. Filter sterilise through 0.22 µm filter. Store in aliquots at –20°C. 
 
tRNA (10 mg/ml) 
Make up the vial of tRNA to the required concentration with autoclaved DEPC 
water. Filter sterilise through 0.22 µm filter. Store in aliquots at –20°C. 
 
50% Dextran Sulphate 
Dissolve 10 g Dextran sulphate (Pharmacia brand) in 20 ml of autoclaved DEPC 
water. Heat to help dissolve the dextran sulphate (Note that it is a very viscous 
solution). Filter through 0.22 µm filter. Store in aliquots at –20°C 
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RNAse A (20 mg/ml) 
Add 5 ml of autoclaved (sterile) DEPC treated water to the vial of unopened 
Rnase A (100 mg, Sigma Aldrich, Cat. No: R4875). Vortex, filter sterilise through 
a 0.22 µm filter and aliquot. Incubate the aliquots for 2 minutes in boiling water 
bath. Cool to room temperature, then store at –20°C. 
 
0.3 M Ammonium acetate / Ethanol solutions 
30% Ethanol solution: Mix 20 ml of 7.5 M ammonium Acetate with 150 ml of 
ethanol, make up to 500 ml with autoclaved DEPC treated water. 
60% Ethanol solution: Mix 20 ml of 7.5 M ammonium Acetate with 300 ml of 
ethanol, make up to 500 ml with autoclaved DEPC treated water. 
80% Ethanol solution: Mix 20 ml of 7.5 M ammonium Acetate with 400 ml of 
ethanol, make up to 500 ml with autoclaved DEPC treated water. 
95% Ethanol: Mix 20 ml of 7.5 M ammonium Acetate with 475 ml of ethanol, 
make up to 500 ml with autoclaved DEPC treated water. 
 
1% Acetic Acid 
Mix 10 ml of glacial acetic acid (Scharlau, Cat No: AC03522500) with 990 ml of 
distilled water. 
 
Scott’s Tap Water 
Weigh out 2.0 g potassium bicarbonate (potassium hydrogen carbonate) and 20.0 
g magnesium sulphate (MgSO4 x7H20, Sigma-Aldrich, Cat No: M1880). Dissolve 
in distilled water and add 1 ml formalin (Scharlau, Cat No: FO00102500) as a 
preservative. Make up to 1 L with distilled water. 
 
Ilford Fixer - 5L 
Dissolve contents of Ilford Ilfofix II in 3750 ml un-autoclaved distilled water and 
stir to mix. 
Make up to 5 L. Filter through 2 pieces of Whatman filter paper No 1 into 2 x  
2.5 L dark glass bottles.  Store at 4oC. 
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Western blot solutions 
 
1 M Tris buffer pH 7.5 
Disolve 60.7 g Tris (Invitrogen, Cat. No: 15504-020, MW: 121.14 g/mol) in 
distilled water, adjust the pH to 7.5 with concentrated HCl, make up to 500 ml 
with distilled water. 
 
1.5 M Tris-HCl pH 8.8 
Dissolve 36.34 g of Tris in 160 ml distilled water and adjust the pH to 8.8 with 
concentrated HCl. Make up to 200 ml with distilled water, store at 4 °C. 
 
0.5 M Tris-HCl pH 6.8 
Dissolve 6.06 g of Tris in 80 ml distilled water and adjust the pH to 6.8 with 
concentrated HCl. Make up to 100 ml with distilled water, store at 4°C. 
 
10 % (w/v) Sodium Dodecyl Sulphate (SDS) 
Dissolve 20 g of SDS (BDH, Cat. No: 444464T) in 200 ml distilled water. Store at 
room temperature. 
 
10 % (w/v) Ammonium persulphate 
Dissolve 1 g of ammonium persulphate (Sigma Aldrich, Cat No:215589) in 10 ml 
distilled water. Store in aliquots at 4 oC. 
 
Bis-acrylamide (30%) 
Bis-acrylamide (30%) was purchased from BioRad (Cat. No: 161-0158). 
 
TEMED 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) was purchased from BioRad 
(Cat. No: 161-0800). 
 
Low salt Tris wash buffer (TBS) 
Dissolve 9 g NaCl (Thermo Fisher Scientific NZ, Cat No: AC19409-0010) in 20 
ml 1 M Tris buffer pH 7.5. Add 1 ml Tween 20 (MW: 1227.72 g/mol); make up to 
1 L with distilled water. 
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5 % Blotto solution 
Dissolve 5 g of non-fat milk powder in 100 ml of low salt Tris wash buffer. Let 
stand for 10 minutes before use. 
 
Enhanced chemi-luminescence (ECL) reagents 
250 mM luminol (5-amino-2,3-dihydro-1,4-phthalazinedione): 
Dissolve 0.44 g of luminol (Sigma Aldrich, Cat No: 45106182) in 10 ml dimethyl 
sulphoxide (DMSO, Sigma-Aldrich, Cat No: D2650). Store aliquots at -20 oC. 
90 mM P-coumaric acid: 
Dissolve 0.15 g of P-coumaric (Sigma-Aldrich, Cat No: C9008-5G) acid in 10 ml 
DMSO. Store aliquots at -20 oC. 
Reagent A: Mix 8.85 ml distilled water, 1 ml 1 M Tris pH 8.5, 100 µl 250 mM 
luminol and 44 µl 90 mM P-coumaric acid.  
Reagent B: Mix 9 ml distilled water, 1 ml 1 M Tris pH 8.5 and 6 µl hydrogen 
peroxide (Scharlau, Cat. No: HI0136100). Make reagents A and B just before use 
and combine them directly before adding to the membrane. 
 
Ponceau stain 
Dissolve 1 g of Ponceau S (BDH Laboratory Supplies, Cat. No: 440832H) in 200 
ml distilled water, then add 2 ml Acetic acid. Store at room temperature. 
 
10x Tris-glycine transfer buffer 
Dissolve 30.3 g Tris base and 114 g Glycine (BDH, Cat. No: 101196X, MW: 
75.07 g/mol) in 1 L of distilled water. Store at room temperature. 
• 2 L of 1x transfer buffer: Mix 200 ml of 10x Tris-glycine transfer buffer, 
400 ml of methanol and 1.6 L distilled water. 
 
5x DNA loading dye 
Combine 0.8 ml distilled water (10.81%), 1 ml 0.5 M Tris-HCl pH 6.8 (13.51%), 
0.8 ml glycerol (10.81%), 4.6 ml 10% SDS (62.16%), 114 mg 100 mM DTT 
(1.08% w/v) and 0.2 ml 1% bromophenol blue sodium salt (BPB, Sigma-Aldrich, 
Cat. No: BE131-5G) (2.7%). Aliquot and store at -20 °C. 
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5x SDS PAGE running buffer 
Dissolve 72 g glycine (Sigma Aldrich, Cat No: G8898) (7.2%), 15 g Tris (1.5%) 
and 5 g SDS (0.5%) in distilled water. Adjust the pH to 8.3. Make up to 1 L with 
distilled water and store at room temperature. Before use, dilute 100 ml of 5x SDS 
PAGE running buffer with 400 ml distilled water 
 
RIPA Lysis buffer 
Dissolve 0.15 g Tris (25mM), 0.438 g NaCl (150mM), 500 mg Sodium 
deoxycholate (Sigma Aldrich, Cat No: 30970) (1%), 50 mg SDS (0.1%) and  
500 µl Tween 20 (Sigma Aldrich, Cat No: P1379) (1%) in 30 ml distilled water. 
Dilute to 48 ml with distilled water. Add 2 µl protease inhibitor (25x stock) just 
prior to use. 25x protease inhibitor stock is made up by resuspending 1 tablet 
(Roche, Cat No: 11697498001) in 2 ml distilled water. Store smaller aliquots of it 
at -20 ºC. 
 
Stripping buffer 
Dissolve 2 g of SDS in 100 ml of 62.5 mM Tris HCl pH 6.7. Warm the solution in 
a 50 °C waterbath. Add 700 µl ß-mercaptoethanol (Life Technologies, Cat No: 
21985-023) just prior to use.  
 
Other reagents and solutions 
 
6x DNA loading dye 
Mix 5 ml of autoclaved distilled water, 20 ml 0.5 M EDTA pH 8.0, 0.025 g BPB, 
and 5 ml sterile glycerol. Aliquot and store at -20 °C. 
 
Ampicilin (50 mg/ml) 
Dissolve 500 mg of Ampicillin in 10 ml autoclaved distilled water. Filter through 
a 0.22 µm filter. Aliquot and store at -20 °C. 
 
50x TAE buffer 
Dissolve 242 g of Tris in 700 ml distilled water. Add 57.1 ml of glacial acetic acid 
and 100 ml of 0.5 M EDTA pH 8.0. Dilute to 1 L with distilled water. 
 
 148%
0.5 M Ethylenediaminetetraacetic acid (EDTA) pH 8.0 
Dissolve 9.3 g of EDTA (BDH, Cat. No: 100935V) in DEPC treated water and 
adjust the pH to 8.0 with 5 M NaOH. Dilute to 50 ml with DEPC water and store 
at room temperature. 
 
5 M Sodium hydroxide (NaOH) 
Dissolve 30 g of NaOH in 150 ml DEPC water. Store at room temperature. 
 
LB broth 
Dissolve 5 g Bacto™ Yeast Extract (Becton Dickinson, Sparks, MD, Cat No: 
212750), 10 g Bacto™ Tryptone (Becton Dickinson, Sparks, MD, Cat No: 
211705) and 10 g NaCl in 1 L distilled water. Autoclave. 
 
LB agar 
Dissolve 15 g Bacto™ Agar (Becton Dickinson, Sparks, MD, Cat No: 214010) in 
1 L LB broth and autoclave. Add 1 ml of 150 mg/ml ampicillin before pouring 
plates. 
 
2% X-gal 
Add 10 ml of N, N-dimethyl formamide to a vial of 200 mg X-gal (VWR 
International, Darmstadt, Germany, Cat No: A49780001). Mix and wrap in tinfoil. 
Store at -20 °C. 
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Appendix II.  Original images for Figure 3I  
 
 
 
 
 
 
Original Western blot images used in edited images in Chapter 3, Figure 3I, 
panels c) and d), to show the best representation of BMP15 proregion expression 
in DO and somatic cell lysates collected from Control, PMSG and PMSG+hCG 
treated animals. 
Note, that the samples analysed and shown in panels a) and c) were collected in 
two separate experiments. Panel b) and d) show results of antibody preadsorption 
following stripping membranes a) and c) respectively. 
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Appendix III.  In situ hybridisation images  
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o = oocyte; GC = granulosa cells; CC= cumulus cells; T = theca cells 
 
Lightfield and darkfield images of mouse ovarian cross sections, showing silver 
grain localisation exclusively in the oocytes, denoting Bmp15 or Gdf9 mRNA 
expression following in situ hybridisation. 
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